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Abbreviation 
 
APC/C   anaphase-promoting complex or cyclosome 
ATP    Adenosine-5'-triphosphate 
BSA    bovine serum albumin 
CDK    cyclin-dependent kinase 
CLK    CDK-like kinase 
Cpm    counts per minute 
CRM1    exportin-1 
DAPI    4',6- diamidino-2-phenylindole 
DH-box   DYRK homology-box 
DMEM   Dulbecco´s modified Eagle medium 
DMSO   dimethyl sulfoxide 
dNTP    deoxynucleotide triphosphates 
Dox    doxycycline 
DS    Down syndrome 
DSCR    Down syndrome critical region 
DTT    Dithiothreitol 
DYRK    dual-specificity tyrosine-phosphorylation regulated kinase 
EDTA    ethylenediaminetetraacetic acid 
ER    endoplasmatic reticulum 
EST    expressed sequence tag 
FACS    flow cytometry 
Fig.    Figure 
FLAG    octapeptide used as a tag in molecular biology 
FLIP    fluorescence loss in photobleaching 
FRT    Flp recombinase target sequence 
GFP    green fluorescent protein 
GSK    glycogen synthase kinase 
GST    gluthathione S-transferase 
HA    Human influenza hemagglutinin  
HDAC    histone deacetylases 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP    horseradish peroxidase 
IgG    immunglobuline G 
  
 III 
IMAC    immobilized-metal affinity chromatography 
IP    immunoprecipitation 
IPTG    isopropyl-β-D-thiogalactopyranoside 
IVK    in vitro kinase  
LB    medium after Luria Bertani 
LSB    laemmli sample buffer  
M-MLV   moloney murine leukemia virus 
MAPK    mitogen-activated protein kinase 
Mnb    minibrain 
NAPA    N-terminal autophosphorylation accessory 
NiNTA   nickel-nitrilotriacetic acid  
NES    nuclear export signal 
NLS    nuclear localization signal 
OD    optical density 
uORF    upstream open reading frame 
PAGE    polyacrylamide gel electrophoresis 
PEST    proline, glutamic acid, serine, threonine-rich region 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
PMSF    phenylmethylsulphonyl fluoride 
PP    phosphoprotein phosphatase 
qRT-PCR   quantitative real-time reverse transcription-PCR 
RB    retinoblastoma protein 
ROI    region of interest 
Rpm    rounds per minute 
RT    room temperature 
RT-PCR   reverse transcription-PCR 
SDS    sodium dodecyl sulphate 
SF3B1   splicing factor 3B 1 
TBS    Tris-buffered saline 
TBS-T   TBS + 0.1% Tween-20 
Tris    2-amino-2(hydroxymethyl)-1,3-propanediol 
UPR    unfolded protein response 
XBP1    X-box binding protein-1 
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1. Introduction 
 
1.1 Protein kinases 
Protein kinases are enzymes that phosphorylate proteins, and thereby regulate 
essential processes in the eukaryotic cell. They transfer a phosphate group from a 
nucleoside triphosphate and covalently attach it to a serine, threonine or tyrosine 
residue replacing the hydroxyl group. The human genome contains about 500 protein 
kinase genes and kinases were classified by sequence comparison of their catalytic 
domains (Hanks and Hunter, 1995), which are highly conserved in closely related 
kinases. Protein kinases also can be divided into groups by the residues they 
phosphorylate. Some only phosphorylate tyrosine residues (Tyr kinases), others only 
serine or threonine residues (Ser/Thr kinases), and few kinases can phosphorylate 
both aliphatic and aromatic residues (dual-specificity kinases). Often the members of 
kinase families not only share similar amino acid sequence, but also functional 
properties. 
 
1.2 DYRK (dual-specificity tyrosine(Y)-phosphorylation regulated kinase) 
 
1.2.1 The DYRK family 
Together with cyclin-dependent kinases (CDK), mitogen-activated protein kinases 
(MAPK), glycogen synthase kinases (GSK) and CDK-like kinases (CLK), the dual-
specificity tyrosine(Y)-phosphorylation regulated kinases (DYRKs) belong to the 
CMGC group of protein kinases. This evolutionarily conserved family of protein 
kinases play key roles in the regulation of cell differentiation, proliferation and survival 
(Park et al. 2009). DYRKs share a conserved kinase domain and a adjacent            
N-terminal DYRK homology (DH)-box (DDDNXDY), although they differ in their N- 
and C-terminal extensions (Becker and Joost, 1999). From a phylogenetic point of 
view, DYRKs are divided into two subclasses (Fig. 1A) which can be distinguished by 
the presence of specific protein motifs (Aranda et al. 2010).  
Class I DYRKs harbour a functional, bipartite nuclear localization signal (NLS) 
N-terminal to the DH-box, and a C-terminal PEST-region, a motif rich in proline, 
glutamic acid, serine, and threonine which is believed to initiate a rapid degradation 
of the protein (Rogers et al. 1986). This class includes the Drosophila melanogaster 
minibrain kinase (mnb), Caenorhabditis elegans MBK-1, and mammalian DYRK1A 
Introduction 
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and DYRK1B (also called Mirk) (Tejedor et al. 1995; Raich et al. 2003; Becker et al. 
1998). Although DYRK1A and DYRK1B show 85% identity in their amino acid 
sequence within the catalytic domain, they differ in their C-terminal region (Leder et 
al. 1999). DYRK1A harbours a stretch of 13 consecutive histidine residues (His) and 
a domain containing a high portion of serine and threonine residues (Ser/Thr) 
(Fig. 1A and B). The histidine-rich region targets DYRK1A to the nuclear speckle 
compartment (Alvarez et al. 2003). An alternative splicing event in the N-terminal 
domain of DYRK1A gives rise to two protein isoforms that differ by the presence or 
absence of a 9 amino acid segment (Kentrup et al. 1996; Guimerá et al. 1999; 
Aranda et al. 2010). These splice variants seem to be expressed at similar levels and 
show no apparent functional differences. In this study, the numbering of the amino 
acids refers to the long splicing variant. Alternative splicing is observed in all human 
DYRKs (Aranda et al. 2010). 
 Class II DYRKs do not contain any known protein domain within the N- and  
C- terminal extensions, except for the N-terminal autophosphorylation accessory 
(NAPA) regions, NAPA1 and NAPA2, N-terminal to the DH-box (Kinstrie et al. 2010). 
They include mammalian DYRK2, DYRK3 (also called REDK) and DYRK4, 
Drosophila melanogaster dDYRK2 (smi35), Caenorhabditis elegans MBK-2 and 
Schizosaccharomyces pombe Pom1p (Becker et al. 1998; Raich et al. 2003; Bähler 
and Pringle, 1998; Lochhead et al. 2003).  
The mammalian class I DYRKs differ in tissue expression, with DYRK1A being 
ubiquitously expressed in adult and fetal tissues (Guimera et al. 1999; Okui et al. 
1999) and DYRK1B predominantly found in testis, but also in muscle tissue (Becker 
et al. 1998; Deng et al. 2003). Among the mammalian class II DYRKs, which are 
predominantly expressed in testis in rodents, DYRK2 and DYRK3 are most closely 
related and they are encoded by paralogous genes that originated by gene 
duplication (Zhang et al. 2005). Despite this close relationship, they have acquired 
very different functions. DYRK2 is involved in the response to DNA damage through 
p53 phosphorylation (Taira et al. 2007), whereas DYRK3 regulates erythropoiesis 
through as yet unknown molecular pathways (Geiger et al. 2001; Lord et al. 2000).  
In contrast to DYRK2 and DYRK3, very little is known about the function of the 
other mammalian class II DYRK, DYRK4, and no substrate has been identified for 
this kinase. Rat and murine DYRK4 were reported to be testis-specific kinases 
expressed only in stage VIII post-meiotic spermatids (Becker et al. 1998; 
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Sacher et al. 2007). However, Dyrk4 deficient mice are fertile (Sacher et al. 2007), 
which could possibly reflect some redundancy in function of the class II DYRKs, all of 
which are strongly expressed in the testis. Conversely, it remains unclear whether 
DYRK4 can phosphorylate the same substrates as other DYRKs and thus, substitute 
for a loss of DYRK3 or DYRK2.  
 
 
 
 
A 
 
 
B
 
 
Figure 1: Schematic representation of DYRK protein structure in mammals. 
A. Schematic representation of class I (DYRK1A/1B) and class II (DYRK2/3/4) DYRKs 
showing the different protein motifs identified. NLS, nuclear localization signal; DH, 
DYRK homology-box; Kinase, kinase domain; PEST, motif rich in proline, glutamic 
acid, serine, and threonine residues; His, polyhistidine stretch; Ser/Thr, region enriched in 
serine and threonine residues; N1 and N2, N-terminal autophosphorylation accessory 
region (NAPA). B. Schematic representation of the full-length DYRK1A protein. 
Accompanying numbers indicate the first and the last amino acids, and amino acids 
relevant in this study. K, lysine residue; Y, tyrosine residue; S, serine residue. 
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1.2.2 DYRK1A 
Mammalian DYRK1A and the orthologous gene in Drosophila, called minibrain 
(mnb), are the best characterized members of the DYRK family and are highly 
conserved from insects to humans (Galceran et al. 2003). The human DYRK1A gene 
is located within the so called Down syndrome critical region (DSCR) on 
chromosome 21, its overexpression in Down syndrome (DS) is suggested to 
contribute to developmental brain defects and the early onset neurodegeneration in 
individuals with trisomy 21. In particular, the phosphorylation of microtubule-
associated protein tau by DYRK1A suggests the involvement of DYRK1A in 
neurofibrillary degeneration in DS (Wegiel et al. 2010). Analyses of mouse models 
overexpressing DYRK1A are consistent with its proposed contribution to 
neuropathological traits of DS (Park et al. 2009). Heterozygous DYRK1A+/- mice 
show reduced body weight, brain size and total number of neurons (Fotaki et al. 
2002) and strongly indicate the importance of DYRK1A gene dosage. DYRK1A-/- 
mice embryos show a severe developmental delay, reduced body size and die 
around embryonic day 10.5 (Fotaki et al. 2002), indicating that DYRK1A plays a vital 
role in cellular mechanisms. Indeed, numerous studies have revealed that DYRK1A 
is a pleiotropic protein kinase with a broad substrate range and diverse functions in 
cellular regulation (Fig. 2).  
 
 
 
 
Figure 2: DYRK1A is a pleiotropic protein kinase.  
Examples of known substrates and putative functions of DYRK1A (reviewed in Aranda et 
al. 2010). 
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1.2.3 Autophosphorylation of DYRKs 
The dual-specificity tyrosine(Y)-phosphorylation regulated kinases (DYRKs) belong 
to the dual-specificity protein kinases, which are able to phosphorylate aliphatic 
(serine and threonine) and aromatic (tyrosine) residues. DYRK kinases contain a 
conserved Tyr-X-Tyr motif in the activation loop (Fig. 1B), and the phosphorylation of 
the second tyrosine residue (Tyr321) is essential for full catalytic activity of all DYRKs 
tested to date (reviewed in Aranda et al. 2010; Becker and Sippl, 2011). In contrast to 
e.g. the mitogen-activated protein kinase family, in DYRK kinases the 
phosphorylation of Tyr321 is not catalysed by upstream kinases, but is an 
autophosphorylation event (Fig. 3A). This event takes place during translation and is 
called “one-off autophosphorylation”. It leads to a constitutive active kinase and has 
been found using dDYRK2 as a model (Lochhead et al. 2005).  
Class I and class II DYRKs show mechanistical differences in their tyrosine 
autophosphorylation process, because class II DYRKs require the NAPA domain for 
this one-off event (Kinstrie et al. 2010), which provides a chaperone-like function. 
Mature DYRKs are incapable of phosphorylating themselves on tyrosine residues 
and phosphorylate exogenous substrates only at serine or threonine residues. Using 
a mutant version of DYRK1A, where the tyrosines of the Tyr-X-Tyr motif in the 
activation loop are mutated to phenylalanine (Y319F/Y321F), it has been shown that 
DYRK1A autophosphorylates not only its tyrosines in the activation loop, as this 
mutant is still detectable with a phosphotyrosine specific antibody (Himpel et al. 
2001).  
A second autophosphorylation site reported for mammalian DYRK1A is 
located close to the PEST domain, Ser529 (RARSDP) (Fig. 1B) (Alvarez et al. 2007). 
Autophosphorylation on Ser529 occurs via an intramolecular mechanism. Alvarez et 
al. showed that phosphorylation of this residue does not affect the intrinsic kinase 
activity on its own, but mediates the interaction of DYRK1A with 14-3-3β. Binding of 
14-3-3β increases the catalytic activity of DYRK1A (Alvarez et al. 2007).  
All protein kinases have a conserved lysine in the ATP-binding motif, which is 
involved in binding of ATP and facilitates transfer of ATP γ–phosphate to the target 
amino acid. Mutation of this lysine to arginine (in the case of DYRK1A: K188R), leads 
to a loss of phosphorylation on tyrosine residues and on Ser529 in DYRK1A. Such a 
mutant is a valuable tool for autophosphorylation analysis. 
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A 
 
B 
 
 
Figure 3: Dual-specificity of DYRK kinases.  
A. Autophosphorylation of the conserved tyrosine in the activation loop (YXY motif) is 
catalysed by a translational intermediate form of DYRK1A. B. Substrate phosphorylation 
by mature DYRK1A occurs only on serine or threonine residues. Consensus sequence for 
substrate recognition by DYRK1A is given (RX1-2S/TP). 
 
 
 
1.2.4 Substrate specificity of DYRKs 
Mature DYRKs phosphorylate substrates only at serine or threonine residues 
(Fig. 3B). The definition of a consensus phosphorylation sequence for DYRK1A, 
(RX1-2(S/T)P) (Himpel et al. 2000) has stimulated the identification of numerous 
phosphorylation sites in DYRK1A substrates (see UCSD-Nature Molecule Pages: 
Protein A000796; Aranda et al. 2010). Some DYRK1A substrates, such as eukaryotic 
initiation factor 2Bε, the microtubule associated protein tau or glycogen synthase are 
also phosphorylated by DYRK2 in vitro (Skurat and Dietrich, 2004; Woods et al. 
2001), whereas histone H2B is only phosphorylated by DYRK2 and DYRK3 but not 
by DYRK1A (Becker et al. 1998). A comparative analysis of peptide substrates has 
also revealed both similarities and differences in the substrate specificity of DYRK1A 
and DYRK2 or DYRK3 (Campbell and Proud, 2002). However, to date the substrate 
specificities of different members of the DYRK family have not been systematically 
compared. 
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1.2.5 Subcellular localization 
Since no activating kinase appears to be required, other control mechanisms may 
regulate the biological activity of DYRK kinases. Indeed, the subcellular localization 
of DYRKs has emerged as one such mechanism. DYRK1A and DYRK1B possess a 
bipartite nuclear localization signal (NLS) in their N-termini (Fig. 1A) that targets 
overexpressed GFP (green fluorescent protein)-fused DYRK1A and DYRK1B to the 
nucleus (Becker et al. 1998). Further, DYRK1A contains a histidine-rich region in the 
C-terminus that targets DYRK1A to the nuclear speckle compartment (Alvarez et al. 
2003). However, in neurons endogenous DYRK1A has been found both in the 
nucleus and the cytoplasm (Martí et al. 2003). Similar localization has been observed 
with exogenous GFP-DYRK1A when expressed at low levels in rat 
pheochromocytoma cells (PC12) cells (Fig. 4; unpublished data). Furthermore, an 
inducible re-distribution of overexpressed DYRK1A from the nucleus to the cytoplasm 
has been observed in PC12 cells (Bescond and Rahmani, 2005). Consistently, 
nuclear and cytoplasmic substrates have been identified for DYRK1A (Fig. 2). The 
yeast homolog of DYRK1A, Yak1p, translocates to the nucleus in response to 
glucose availability (Moriya et al. 2001). DYRK1B accumulates in the cytosol of cells 
from rhabdomyosarcoma tumors, whereas it is predominantly found in the nucleus of 
undifferentiated NIH-3T3 cells (Mercer et al. 2006).  
Several class II kinases have been reported to be predominately localized in 
the cytoplasm (e.g., MBK-2; Raich et al. 2003); but changes in MBK-2 localization 
from the cortex to the cytoplasm have been described during Caenorhabditis elegans 
zygote maturation (Cheng et al. 2009). DYRK2 has been shown to enter the nucleus 
upon exposure to genotoxic stress (Taira et al. 2007). DYRK3 has been found 
predominantly in nuclear protein extracts of human erythropoietin-responsive cells 
(UT7-EPO) (Lord et al. 2000) and interaction with cAMP response element (CRE)-
binding protein (CREB) predicts a nuclear localization (Li et al. 2002). The Drosophila 
homolog of DYRK4, dDYRK2, has also been suggested to translocate into the 
nucleus, because it phosphorylates the nuclear protein SNR1 (Kinstrie et al. 2006). 
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                                 GFP                        DAPI                        Merge 
 
Figure 4: GFP-DYRK1A is localized both in the nucleus and the cytoplasm in PC12 
cells.  
Expression of GFP-tagged DYRK1A was induced with doxycycline (2 µg/ml) and 
PC12_GFP-DYRK1A cells were stimulated to differentiate with NGF (nerve growth 
factor; 100 ng/ml) for 24 h (lower panel) or 72 h (upper panel). Subcellular localization 
was analyzed by fluorescence microscopy. Nuclei were stained with DAPI. Scale bars, 
10 µm. 
 
 
1.3 The cell cycle 
In a large scale phosphoproteomic screening of protein kinase, DYRK1A 
phosphorylation on serine 748 and 758 has been found to be upregulated in mitotic 
cells (Daub et al. 2008). In this study, synchronized human cervix carcinoma cells 
(HeLa) arrested in M phase were compared to cells arrested in S phase of the cell 
cycle. 
 
The cell cycle is an ordered series of events that begins with cell growth and ends 
with division into two daughter cells. The cell cycle consists of four phases: G1, S, G2 
and M phase (Fig. 5A). After cell growth, with a great amount of protein synthesis 
during G1 phase (first gap phase), cells can exit the cell cycle to enter G0 phase, 
where cells can differentiate or rest in a so called “quiescent state” and re-enter     
the cell cycle mediated by specific stimulators. At the end of the G1 phase there is     
a checkpoint called “restriction point”, where e.g. DNA damage is assessed. Once 
cells passed this restriction point, they are committed to enter S phase (synthesis 
phase) where DNA synthesis and replication occurs. In the following G2 phase 
(second gap phase), cells synthesize proteins and may continue to increase in size. 
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At the end of G2 phase, cells pass the G2 checkpoint and enter M phase (mitotic 
phase: mitosis and cytokinesis). The mitotic phase is a short period of the cell cycle, 
but nevertheless is a highly regulated process. Mitosis is divided into five stages 
(Fig. 5B). During mitosis the pairs of chromosomes condense, the mitotic spindle is 
formed and the sister chromatids are separated and driven to opposite ends of the 
cell. Finally, chromosomes unfold back into chromatin. Cytokinesis (division of the 
cytoplasm and formation of two identical daughter cells) begins during telophase and 
marks the end of M phase, but is not part of mitosis.  
 
A 
 
 
B 
 
Figure 5: The phases of the cell cycle.  
A. Scheme of the cell cycle. M, Mitosis; G0, Gap 0/Resting; G1, Gap 1; S, Synthesis; G2, 
Gap 2. Two compounds (nocodazole, thymidine) used in this study to arrest cell cycle at 
indicated phases are shown. Nocodazole inhibits spindle formation and arrests cells in M 
phase; Thymidine indirectly blocks the ribonucleoside diphosphate reductase, inhibits 
DNA synthesis and arrests cells in S phase. B. The mitotic phase which is divided into 
mitosis and cytokinesis. The five stages of mitosis are listed. 
 
 
1.3.1 The retinoblastoma protein (RB), Cyclin D1 and histone H3 
There are several ways to follow the progression through the stages of the cell cycle 
of synchronized cells. A simple method is the analysis of phosphorylation levels of 
specific proteins, such as retinoblastoma protein (RB) or histone H3, as well as the 
analysis of protein level of different cyclins, such as Cyclin D1. A summary of these 
three proteins is given that have been examined during cell cycle analysis in this 
study. 
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1.3.1.1 Phosphorylation level of the retinoblastoma protein 
The RB protein is a well studied substrate of CDKs containing over 16 consensus 
phosphorylation sites for CDKs (Tamrakar et al. 2000). Located in the nucleus,      
RB acts as a transcriptional repressor by binding transcription factors like E2F, ATF-2 
or c-ABL. Sequential phosphorylation at different sites of RB by different CDKs leads 
to the release of distinct transcription factors (Knudsen and Wang, 1996; Zarkowska 
and Mittnacht, 1997).  For instance, the release of members of the E2F family 
regulates several genes required for DNA replication (Fig. 6A) as well as Cyclin D1 
and Cyclin E (Ohtani et al. 1995) that must be expressed before the S phase of the 
cell cycle. 
In general, hyperphosphorylation of RB is present from late G1 phase up to the 
end of M phase (Fig. 6A) (reviewed in Giacinti and Giordano, 2006). In mitotic cells, 
Cyclin B/cdc2 is the principle RB kinase (Fig. 6A and B). Cyclin B level reach a 
maximum at the G2-M boundary (Evans et al. 1983; Standart et al. 1987), and in 
complex with cdc2 Cyclin B maintains the hyperphosphorylation level of RB in mitotic 
cells (Lin and Wang, 1992). At the end of mitosis Cyclin B is destroyed, what results 
in the inactivation of the cdc2 protein kinase and allows cells to leave M phase. Cells 
expressing a stable Cyclin B arrest during mitosis (Murray et al. 1989; Ghiara et al. 
1991; Luca et al. 1991).  
The release of the c-ABL tyrosine kinase occurs due to phosphorylation of RB 
on Ser807 and Ser811 by Cyclin D1/CDK4 and Cyclin E1/ CDK2 (Knudsen and 
Wang, 1996). Nuclear c-ABL tyrosine kinase activity is suppressed by RB, which 
binds to the tyrosine kinase domain of c-ABL. A number of reports have shown that 
the nuclear c-ABL tyrosine kinase plays an important role in the activation of 
apoptosis by DNA damage (Wang, 2000). As the phospho-specific anti-pRB antibody 
used in the present study recognizes phosphorylation at Ser807/811, it is possible to 
determine if the tyrosine kinase c-ABL is bound and thus inactivated 
(dephosphorylation of RB at Ser807/811) or c-ABL is released and thus active 
(phosphorylation of RB at Ser807/811).  
Dephosphorylation of RB occurs in the anaphase by phosphoprotein 
phosphatase 1 (PP1) which removes the inhibitory phosphate groups (Ludlow 
et al. 1993). Mitotic RB dephosphorylation is reported to be a sequential, temporally-
regulated event (Rubin et al. 2001) with Cyclin D/CDK4 sites, such as Ser807, being 
dephosphorylated at a rapid rate.  
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The protein p27Kip is an inhibitor of Cyclin E/CDK2 activity. Thus the 
hyperphosphorylation of RB can also be regulated by modulation of p27Kip protein 
levels directly or indirectly, since high CDK2 activity has been shown to induce the 
proteolytic destruction of p27Kip (Sheaff et al. 1997; Vlach et al. 1997).  
 
1.3.1.2 Protein level of Cyclin D1 
Cyclins exhibit distinct expression and degradation patterns to coordinate the cell 
cycle and function as regulators of CDKs together with CDK inhibitors (such as p21Cip 
or p27Kip) (Fig. 6B) (reviewed in Johnson and Walker, 1999). Cyclin D1 functions as a 
regulatory subunit of CDK4 or CDK6, whose activity is required for G1/S transition. 
The protein level of Cyclin D1 (Fig. 6B) decreases upon entry into the S phase 
(Diehl et al. 1998). Accordingly, detection of Cyclin D1 protein level can be used to 
determine cells arrested in S phase. The degradation of Cyclin D1 is essential for 
DNA replication and regulated by phosphorylation of Cyclin D1 at Thr286 by GSK-3β 
(Alt et al. 2000) or p38SAPK2 (Casanovas et al. 2000) and at Thr288 by DYRK1B 
(Zou et al. 2004).  
 
1.3.1.3 Phosphorylation level of histone H3 
Histones (H2A, H2B, H3 and H4) are components of the nucleosomes and their      
N-terminal tail domain is subjected to multiple posttranslational modifications such as 
methylation, acetylation, ubiquitination, ADP-ribosylation and phosphorylation.          
A simple method to determine mitotic cells is to detect the phosphorylation level of 
histone H3 at Ser10. Phosphorylation on Ser10 correlates with chromatin 
condensation in mitosis and upon mitotic exit a global dephosphorylation of histone 
H3 takes place (reviewed in Hans and Dimitrov, 2001). 
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A 
 
 
 
B 
 
Figure 6: Schematic of RB and Cyclin D1 in cell cycle control.  
A. Simplified regulation model of the RB phosphorylation by the indicated cyclin-
dependent kinases Cyclin/CDK complexes during the cell cycle. As example of RB 
inactivation its association with E2F is shown. Most E2F polypeptides interact with DP 
polypeptides to act as transcriptional factors. Crucial degradation of Cyclin D and B is 
indicated. RB, retinoblastoma protein; E2F, transcription factor; DP, transcription factor. 
B. Expression of cyclins through the cell cycle. The oscillations of different cyclins due to 
regulated gene expression and protein destruction by proteolysis is shown. Interaction of 
each cyclin with its specific CDK or Cdc2 is indicated. Two main CDK inhibitors are 
listed. 
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1.3.2 DYRKs and the cell cycle 
The identification, that Ser748 phosphorylation of DYRK1A is upregulated in mitotic 
cells is not the first report bringing together DYRKs and the cell cycle. The DYRK 
kinase homolog in Dictyostelium, YakA, has been reported to be essential for both a 
starvation-induced growth arrest and initiation of a developmental response, and has 
been suggested to function as a specific cell-cycle regulator to facilitate exit from the 
cell cycle and to mediate developmental events (Souza et al. 1998). The DYRK 
family members Yak1p (DYRK homolog in S. cerevisiae), Pom1 (DYRK homolog in 
S. pombe) and DYRK1B are all active G0/G1 kinases that can arrest cells in G1 phase 
of the cell cycle (Bähler and Nurse, 2001; Souza et al. 1998; Deng et al. 2003).  
MBK-2 (class II DYRK in C. elegans) kinase activity is also regulated during the cell 
cycle (Cheng et al. 2009). DYRKs have been shown to interact with cell cycle control 
genes such as SNR1 (chromatin remodelling factor) and TRX (trithorax; a chromatin 
component) (Kinstrie et al. 2006), including phosphorylation of class II histone 
deacetylases (HDACs) (Deng et al. 2005). Various other studies have identified a 
number of potential DYRK family substrates including the cell-cycle regulator, 
Cyclin D1, the cyclin-dependent inhibitor p27Kip1 and the cell-cycle inhibitor and 
survival molecule p21Cip1 (Table 1). 
Mammalian DYRK2 is reported to participate in M phase progression as 
knockdown of DYRK2 induces G2-M arrest. DYRK1B, a G0/G1-active kinase, 
stabilizes the CDK inhibitor p27Kip by phosphorylating it at Ser10 (Deng et al. 2004), 
whereas mitogen stimulation reduces DYRK1B levels and allows cells to enter G1 
(Deng et al. 2003). DYRK1B does not enhance turnover only of p27Kip but also of the 
G1 phase cyclin Cyclin D1 via phosphorylation on Thr288 (Zou et al. 2004). DYRK1A 
has been related to the cell cycle as it causes an increase in phosphorylation of the 
transcription factor Forkhead (FKHR) and high levels of Cyclin B1 in transgenic mice 
overexpressing DYRK1A (Branchi et al. 2004), which is also observed in 
hippocampal neurons of DS patients (Nagy et al. 1999; Nagy et al. 1997). 
Furthermore, overexpression of DYRK1A leads to an aberrant mitosis (Funakoshi et 
al. 2003) and thereby a disturbance of cell cycle progression through the G2-M phase 
due to alteration in Cyclin B expression. A recent study showed that overexpression 
of DYRK1A leads to the degradation of Cyclin D1 in neural progenitor cells and 
thereby facilitates exit from the cell cycle (Yabut et al. 2010). An indirect effect of 
Introduction 
 
14 
 
DYRK1A on the cell cycle is mediated by phosphorylation of the transcription factor 
p53 on Ser15 and the subsequent induction of p21Cip1 expression (Park et al. 2010). 
Taken together, all these findings strongly indicate a potential role of DYRK1A 
in the cell cycle. 
 
 
Table 1: Mammalian DYRKs and the cell cycle.  
Examples for reports that implicate DYRK family members in cell cycle control. 
Kinase Mechanism Effect Reference 
DYRK1A Degradation of Cyclin D1 Exit from the cell cycle 
 G0 , Differentiation 
Yabut et al. 
2010 
DYRK1A P  of p53 Induction of p21Cip1 
 Cells arrest in G0/G1 
Park et al. 
2010 
DYRK1B P   of Cyclin D1, D3 Degradation of Cyclin D 
 Cells arrest in G0/G1 
Zou et al. 
2004 
DYRK1B P  of p27Kip Inhibition of Cyclin/CDK 
 Cells arrest in G0/G1 
Deng et al. 
2004 
DYRK2 Knockdown of DYRK2 Stabilization of katanin 
p60 
 Cells arrest in G2/M 
Maddika and 
Chen, 2009 
Circled P, phosphorylation. 
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2. The aim of the study 
 
The members of the dual-specificity tyrosine(Y)-phosphorylation regulated kinase 
(DYRK) family play key roles in a great variety of cellular processes. The best 
characterized member is DYRK1A as its gene is located in the Down syndrome 
critical region (DSCR) on chromosome 21 in humans and it is overexpressed in 
Down syndrome individuals. DYRK1A is a candidate for drug target development. In 
contrast, DYRK4 has remained essentially uncharacterized. 
This study aimed to clarify the function, subcellular localization, substrate 
specificity and tissue distribution of DYRK4. Further, it should be answered whether 
DYRK4 is able to target the same substrates as DYRK1A.  
The second aim of the study was to elucidate the role of DYRK1A in the cell 
cycle. As a recent study revealed that DYRK1A phosphorylation at Ser748 is induced 
in mitotic HeLa cells (Daub et al. 2008), this study intended to illuminate the 
mechanism and function of Ser748 phosphorylation during the cell cycle. Finally, the 
fate of DYRK1A during the cell cycle should be followed and the effect of its 
overexpression on the cell cycle should be figured out. 
 
Material and Methods 
 
16 
 
3. Material and Methods 
 
3.1 Materials 
 
3.1.1 Chemicals  
Chemicals were obtained from Sigma-Aldrich (Munich, Germany), Merck Eurolab 
(Darmstadt, Germany), AppliChem (Darmstadt, Germany) or from companies as 
indicated. 
 
3.1.2 Frequently used buffers and chemical solutions  
Chemiluminiscence detection solution:  
Component A: 1 mL 1 M Tris-HCl (pH 8.5); 40 µL H2O2 (30% v/v); 9 mL H2O 
Component B: 1 ml 1 M Tris-HCl (pH 8.5); 100 µL 250 mM Luminol;  
                        44 µL 90 mM p-Coumaric acid; 10 ml H2O 
Glutathione elution buffer: 50 mM Tris-HCl (pH 8.0); 10 mM reduced Glutathione 
6 M GuHCL lysis buffer: 100 mM NaH2PO4; 10 mM Tris-HCl (pH 8.0);  
       6 M Guanidine-HCl; 30 mM Imidazole 
IP lysis buffer: 50 mM Tris-HCL (pH 7.5); 150 mM NaCl; 1 mM EDTA;  
   0.5% v/v Igepal;                              
                        supplemented with 100 mM NaVO4; 100 mM Phenylmethylsulphonyl  
   fluoride (PMSF); 2.5 µg/µl Aprotinin; 1 µg/µl Pepstatin;  
   10 µg/µl Leupeptin 
IP washing buffer (+Igepal): 50 mM Tris-HCl (pH 7.5); 150 mM NaCl; 2 mM EDTA;  
             (0.1% v/v Igepal) 
10x kinase buffer: 250 mM HEPES (pH 7.4); 50 mM MgCl2; 5 mM DTT 
2x LSB: 20% v/v Glycerol; 4% w/v SDS; 10 mM EDTA; 0.125 M Tris (pH 6.8);  
   0.02 % v/v Bromophenol blue 
LSB: 6 mg DTT/100 µl 2x LSB 
PBS (pH 7.4): 140 mM NaCl; 3 mM KCl; 8 mM Na2HPO4; 1.8 mM KH2PO4  
SDS lysis buffer: 20 mM Tris (pH 7.4); 1% w/v SDS 
TBS (pH 7.6): 150 mM NaCl; 20 mM Tris 
TBS-T buffer: 0.1 % v/v Tween-20 in TBS 
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8 M Urea washing buffer: 100 mM NaH2PO4; 10 mM Tris-HCl (pH 6.3); 8 M Urea;  
          60 mM Imidazole 
 
3.1.3 Microorganisms  
E. coli DH5α   [F' ProA+B+ lacIq ∆(lacZ)M15 zzf::Tn10 (tetR)/fhuA2∆ 
(argFlacZ) U169 phoA glnV44 Φ80 ∆(lacZ)m15 gyrA96 
recA1relA1 endA1 thi-l hsdR17] 
 
3.1.4 Peptides  
Peptides were obtained from JPT Peptide Technologies (Berlin, Germany), 
Deutsches Wollforschungsinstitut (DWI, RWTH Aachen University, Germany) and 
GBF (Braunschweig, Germany). Biotinylated Pep285 (1mM), biotinylated Pep3 
(1mM) and DYRKtide (2mM) were dissolved in H2O, while SAPtide (2mM) was 
dissolved in water with 5% DMSO. Aliquots were stored at -20°C. 
 
Table 2: Peptides used in this study.   
Name Sequence Mimic Supplier 
Pep285 Biotin-Ttds-VGLLKLASPELER Ser73 c-Jun protein JPT 
Pep3 Biotin-Ttds-TPGSRSRTPSLPT Thr212 tau protein JPT 
SAPtide RRARKLTATPTPLGG Thr434 SF3B1 protein DWI 
DYRKtide RRRFRPASPLRGPPK artificial GBF 
 
 
 
 
3.1.5 Antibodies  
All primary and secondary antibodies used in this study are listed in Table 3, ordered 
by name.  
Rabbit polyclonal phospho-specific antibody for DYRK1A phosphorylated at Ser748 
(anti-pS748) was generated by immunizing rabbits with the phosphopeptide 
GADREEpSPMTGVC (where pS is a phospho-Ser residue) conjugated to LPH 
(hemocyanine from Limulus polyphemus). Custom immunisation and antibody 
purification was performed by BioGenes, Berlin, Germany. 
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Table 3: Antibodies and conjugates.  
 
Target Host Specification and applicationa) Reference 
anti-β-Actin mouse monoclonal, 1:3000 WB  Sigma,  St. Louis, MO, USA 
anti-Cyclin D1 mouse monoclonal, 1:1000 WB 
Cell Signaling 
Technology, 
Danvers, MA, USA 
anti-DYRK1A mouse monoclonal, 1:1000 WB,  1µg IP 
Abnova, Taipei City, 
Taiwan 
anti-FLAG BioM2 mouse monoclonal, 2µg/ml WB Sigma, Munich, Germany 
anti-GFP goat polyclonal,  1:1000 WB 
Rockland, 
Gilbertsville, PA, 
USA 
anti-GFP rabbit polyclonal, 1µg IP 
Rockland, 
Gilbertsville, PA, 
USA 
anti-HA mouse monoclonal, 1:500 WB,  1µg IP 
Covance, 
Richmond, CA, USA 
anti-pH3 (pS10) rabbit polyclonal, 1:1000 WB 
Cell Signaling 
Technology, 
Danvers, MA, USA 
anti-pRB 
(pS807/811) rabbit polyclonal, 1:1000 WB 
Cell Signaling 
Technology, 
Danvers, MA, USA 
anti-pSer748 rabbit polyclonal, 0.38µg/ml WB this study 
anti-pThr434 rabbit polyclonal, 1:250 WB de Graaf et al. 2006 
anti-pTyr (PY99) mouse monoclonal, 1:200 WB 
Santa Cruz 
Biotechnology, 
Santa cruz, CA, 
USA 
anti-SF3B1 rabbit polyclonal, 1:500 WB custom immunizationb) 
anti-biotin goat polyclonal, HRP-linked 1:2000 WB 
Cell Signaling 
Technology, 
Danvers, MA, USA 
anti-mouse goat polyclonal, HRP-linked 1:5000 WB 
Pierce, Rockland, 
IL, USA 
anti-goat rabbit polyclonal, HRP-linked 1:3000 WB 
Dianova, Hamburg, 
Germany 
anti-rabbit goat polyclonal, HRP-linked 1:5000 WB 
Pierce, Rockland, 
IL, USA 
a)
 HRP, horseradish peroxidase; IP, immunoprecipitation; WB, Western blot. 
b)
 Polyclonal antibody raised against the N-terminal region (MAKIAKTHEDIEAQIC) of   
   SF3B1 
   
 
 
Material and Methods 
 
 19 
3.1.6 Plasmids  
The expression plasmids encoding GFP-, GST- and HA-tagged wild-type DYRK1A 
and the kinase deficient mutants K188R and Y321F have been described previously 
(Kentrup et al. 1996; Becker et al. 1998; Becker and Joost, 1999; Himpel et al. 2000). 
Point mutations of GFP-tagged DYRK1A used in the present study were generated 
by site-directed mutagenesis using corresponding oligonucleotides listed in Table 4. 
The point mutant GFP-DYRK1A S748A was generated by Simone Bamberg-Lemper. 
GFP-tagged deletion mutants of DYRK1A have been generated by Katharina 
Kolanowski under my supervision and are described in her diploma thesis1 (GFP-
DYRK1A ∆C (amino acids 1-481); GFP-DYRK1A ∆N (amino acids 135-763); GFP-
DYRK1A ∆C∆N (amino acids 135-481)). 
The pcDNA5/FRT/TetOn/GFP-DYRK1A construct was generated by cloning rat GFP-
DYRK1A cDNA into pcDNA5/FRT/TO vector (Invitrogen, Darmstadt, Germany) using 
HindIII and NotI and then by replacing the promoter with that of pTRE-d2EGFP 
(Clontech Mountain View, CA, USA) using SpeI and HindIII in order to make the 
vector compatible with the Tet-on system from Clontech. 
Plasmids pHA-hDYRK4520 and the kinase deficient mutants pHA-hDYRK4520 K133R 
and pHA-hDYRK4520 Y264F; pGFP-hDYRK4520, pGFP-hDYRK4644, pGFP-
mDYRK4594, pGFP-mDYRK4642 have been described (Papadopoulos et al. 2011). 
Generation of pGFP-hDYRK4NLGY was generated by site-directed mutagenesis using 
pGFP-hDYRK4520 and the corresponding oligonucleotides listed in Table 4. Position 
of the amino acids NLGY insertion can be seen in Figure 15A. pGFP-
mDYRK4L191A/L193A was generated by site-directed mutagenesis using pGFP-
mDYRK4642 and the corresponding oligonucleotides listed in Table 4.                       
All oligonucleotides were purchased from Eurogentec and all site-directed 
mutageneses have been performed using the QuikChange Site Directed 
Mutagenesis kit according to manufacturer’s instructions (Stratagene). All mutations 
generated were verified by DNA sequencing (GATC, Konstanz, Germany). 
GFP-SF3B1-NT (amino acids 1-492) (de Graaf et al. 2006) and GFP-SF3B1 ∆256-
382 (deletion of amino acids 256-382 of GFP-SF3B1-NT) (Becker; unpublished data) 
were available in the laboratory. FLAG-Septin4 has been previously described (Sitz 
et al. 2006). 
                                                 
1
 Kolanowski, Katharina (2011) Posttranslational Modification of the protein kinase DYRK1A,    
  diploma thesis, RWTH Aachen University 
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To express STAT5A as a yellow fluorescent fusion protein (STAT5A-YFP), mouse 
STAT5A cDNA was fused to YFP and subcloned into pcDNA5/FRT/TO (Invitrogen). 
STAT5A-YFP was a kind gift of Nicolas Chatain (Institute of Biochemistry, RWTH 
Aachen, Germany). 
 
3.2 Methods 
 
3.2.1 Preparation of bacterial expressed GST-DYRK1A variants  
180 ml of LB medium with ampicillin (100 µg/ml) were inoculated with 5 ml of over-
night culture of transformed E.coli DH5α. The cultures were left to grow till an OD     
of 0.7-0.8 at 37°C and protein expression was then induced by addition of IPTG (final 
concentration of 0.1 mM). After 2 h of induction at RT, cells were collected               
by centrifugation (10 min, 4°C, 5000 rpm) and then thoroughly resuspended in 6 ml 
phosphate buffered saline (PBS) containing 80 µl Lysozyme (10 mg/ml) and 60 µL 
PMSF (17.5 mg/ml) for 5 min at RT. Afterwards cells were sonified for 30 sec, and 
300 µL of 20% Triton X-100 were added. The mixture was incubated on ice for 
15 min, and mixed every 5 min. Next, the remaining cell debris was removed by 
centrifugation (10 min, 4°C, 10000 rpm) and the supernatant was mixed with 200 µL 
of Glutathione sepharose 4B (Amersham Bioscience, Piscataway, NJ, USA).         
For binding of the protein to the sepharose, the batch was incubated for 30 min at 
4°C, and after centrifugation (4 min, 4°C, 1600 rpm) the supernatant was discarded. 
The pellet was washed three times in 1 ml cold PBS. The protein was eluted three 
times with 150 µl Glutathione elution buffer each, the first two times for 10 min at RT 
and the last time for 20 min on ice. Eluates and aliquots were stored at -80°C. 
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Table 4: Oligonucleotides used in this study. 
Primer sequence 5’→ 3’ rest. sitec) plasmid name 
Primers for site-directed mutagenesis (only the sequence for the forward primers given) 
2009MA15 - GATAGAGAAGAGGCGCCCATGACAGGAG- KasI GFP-DYRK1A S748A 
2010JA01 
2010JA03 
-GCTGATAGAGAAGAGGAGCCCATGACAGGAG- 
- GTGTGCAACAGGAGCCTGTAGCTAGCTCG- 
- 
- 
GFP-DYRK1A 
S748E/S758E 
2010JA01 
2009SE25 
-GCTGATAGAGAAGAGGAGCCCATGACAGGAG- 
-TTTGTGTGCAACAGGCCCCTGTGGCTAGCTCGT- 
- 
BglI 
GFP-DYRK1A 
S748E/S758A 
2009SE23 
2009SE25 
- GAAGAGTCTCCCATGGCCGGCGTTTGTGTGC- 
-TTTGTGTGCAACAGGCCCCTGTGGCTAGCTCGT- 
NaeI 
BglI 
GFP-DYRK1A 
T751A/S758A 
2009SE27 - GCAAGGGGCTGACTAGTAAGAGTCTCCCATGAC- SpeI GFP-DYRK1A ∆C19 
2009DE34 -CTCAGAGCTGTGGTTCGCCGGCGCTGAAGCCA AGAAGCTCG- NaeI 
GFP-
mDYRK4642  
L191A/L193A 
2008NO21 -GCAAGACGAGTAACCTAGGCTATGATGATGAGC ATGGC- AvrII 
GFP-
hDYRK4NLGY 
RT-PCR and qRT-PCR of the long variant human DYRK4  
(primers match exons 5 and 11 as shown in Fig. 7A) 
hD4L-f -GGAAATGTGATTTGACTCCCTTCCTG- 
hD4L-r -CTGAGGCCGGCATCTGATTG- 
RT-PCR of the short variant human DYRK4  
(primers match exons 9 and 11 as shown in Fig. 7A) 
hD4S-f -GCTGTTGAAAGCCTGCAGC- 
hD4S-r -GACTTCTCCTCTGCCTTGGG- 
RT-PCR and qRT-PCR of total human DYRK4  
(primers match exons coding for the catalytic domain) 
hD4Cat-f -CGCTTCACTCTCTCTGTTTTG- 
hD4Cat-r -TCACTTCTGGGGATCGGTAG- 
RT-PCR of human GAPDH 
also used in qRT-PCR 
GAPDH-f -CGGGGCTCTCCAGAACATCATCC- 
GAPDH-r -CCAGCCCCAGCGTCAAAGGTG- 
c)
 rest., restriction;  
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3.2.2 Cell culture, transient and stable transfections  
COS-7, HEK_GFP-DYRK1A and SH-SY5Y cells were cultured in Dulbecco´s 
modified Eagle medium (DMEM) High Glucose ([4.5 g/L], with L-Glutamine and 
sodium pyruvate) (PAA) containing 10% fetal bovine serum (PAA) and supplemented 
with L-glutamine plus antibiotics (100 units/ml penicillin and 100 µg/ml streptomycin). 
SH-SY5Y cells were kindly provided and kept in culture by Ulf Soppa. HeLa cells 
were cultured in Quantum 101 for HeLa Cells with L-glutamine (PAA Laboratories 
GmbH). PC12_GFP-DYRK1A cells were cultured in DMEM High Glucose containing 
10% horse serum (PAA), 5% fetal bovine serum and 25 mM HEPES (Sigma).         
All cells were cultured at 37°C and 5% of CO2. 
Transient transfections were performed by using FUGENE HD Transfection Reagent 
(Roche Molecular Biochemicals, Mannheim, Germany), and the cells were washed 
after 24 h and processed 24 h later. For live cell imaging, COS-7 cells were 
transiently transfected and 24 h later, they were subcultured on 42-mm glass 
coverslips. After 48 h, the coverslips were placed into a thermostat-controlled (37°C) 
and CO2-controlled perfusion chamber (Pecon), and covered with DMEM culture 
medium. To block CRM1-mediated nuclear export leptomycin B (Calbiochem, San 
Diego, CA, USA) was added to the culture medium at 10 ng/ml for 4 h.  
For inducible expression of GFP-DYRK1A, PC12 Tet-on cells (Clontech) were stably 
transfected with the pFRT/lacZeo (Invitrogen) construct to introduce the Flp 
recombinase target sequence (FRT) using JetPEI (PEQLAB, Erlangen, Germany). 
Positive clones were then transfected with pcDNA5/FRT/TetOn/GFP-DYRK1A to 
stably integrate GFP-DYRK1A cDNA by Flp-mediated recombination (Invitrogen). 
Positive cells were selected in the presence of 100 µg/ml hygromycin B (PAA). 
Finally, doxycycline-induced GFP-DYRK1A expressing cells were further selected for 
GFP fluorescence using FACS Vantage SE with DIVA Software (Becton Dickinson, 
Heidelberg Germany) at the CRG/UPF FACS Unit (Barcelona, Spain).                   
The generation of stably transfected HEK293 cells expressing GFP-DYRK1A under 
the control of a tetracycline-regulated promoter (HEK_GFP-DYRK1A) has been 
described earlier (Sitz et al. 2008). Expression of GFP-DYRK1A in PC12 or HEK293 
cells was induced with 2 µg/ml doxycycline (Sigma) for two days if not stated 
otherwise. Harmine (Fluka, Buchs, Switzerland), DMAT (Calbiochem, San Diego, CA, 
USA), Calyculin A (Tocris Bioscience, Avonmoth, UK), MG132 (Sigma), nocodazole 
(Sigma) and thymidine (Sigma) were added to the cells as indicated. 
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3.2.3 Gene expression PCR analysis in tissues and cell lines 
A panel of human cDNAs normalized to the expression of housekeeping genes was 
purchased from Clontech (Human MTC Panel I). Total RNA from cell lines was 
isolated using the NucleoSpin RNA II Kit (Macherey-Nagel, Düren, Germany) 
according to the manufacturers instructions and subjected to reverse transcription 
using an oligo(dT) 12-18 primer and Superscript II Reverse Transcriptase 
(Invitrogen). The sequences of the oligonucleotides used for the specific detection of 
DYRK4 splice variants are provided in Table 4. PCR reactions were performed with 
the GoTaq DNA polymerase (Promega, Mannheim, Germany) at an annealing 
temperature of 57°C. The identity of the PCR products was verified by DNA 
sequencing (GATC, Konstanz, Germany). 
 
3.2.4 Quantitative real-time reverse transcription-PCR (qRT-PCR) 
SH-SY5Y cells were treated for 8 h with 3 µM tunicamycin (Sigma) or DMSO. 
Isolation of total RNA from SH-SY5Y was carried out on the QIAcube using the 
RNeasy Mini Kit (Qiagen, Hilden, Germany). 2x106 cells were lysed in RLT-buffer on 
ice and transferred to 2 ml reaction tubes. Tubes were placed in the QIAcube and 
automated RNA isolation was performed following the manufacturer’s instructions. 
Total RNA was eluted in 60 µl endvolume and concentration was determined by 
photometry (NanoDrop ND-1000, NanoDrop Technologies, Wilmington, USA).        
M-MLV (moloney murine leukemia virus) reverse transcriptase (Promega, Mannheim, 
Germany) was used forcDNA synthesis. Quantitative real time PCR (qRT-PCR) was 
performed using the LightCycler 480 DNA SYBR Green I Master (Roche). Details 
can be seen in Table 5 and 6. Gene expression level of DYRK4 variants were 
analyzed using the LightCycler 480-Software 1.5 and normalized to GAPDH.           
All samples were performed as triplicates. 
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Table 5: cDNA synthesis and master mix for qRT-PCR. 
RNA 1 µg  cDNA 1 µl  
Oligo(dT)-Primer [0.5 µg/µl] 1 µl   
ad 12 µl nucleasefree H2O   
SYBR Green I 
Master 
5.5 µl 
 
  10’ at 65°C, then store at 4°C   forward primer 6 µM  
5x M-MLV RT reaction buffer 4 µl  reverse primer 6 µM  
dNTP-mix [10 mM] 2 µl  ad 11 µl  H2O  
RNasin [40 U/µl] 1 µl    
M-MLV RT [2000 U/µl] 1 µl    
90’ at 37°C, 2’ at 95°C 
 
 
 
 
nucleasefree H2O 30 µl    
 
  
 
 
 
  
 
 
 
Table 6 : qRT-PCR program. 
Gene Denaturation Annealing Elongation Cycles 
DYRK4 Long 10’’  95°C 10’’  58°C 15’’  72°C 55 
DYRK4 Cat 10’’  95°C 10’’  62°C 15’’  72°C 50 
GAPDH 10’’  95°C 10’’  66°C 20’’  72°C 45 
 
 
 
3.2.5 Fluorescence microscopy and shuttling analysis  
To detect GFP-tagged proteins in the transfected cells, they were first fixed in 
4% paraformaldehyde in PBS for 15 min at RT. The coverslips were then mounted in 
Vectashield (Vector Laboratories) containing 500 ng/ml 4',6-diamidino-2-phenylindole 
(DAPI), analyzed under a Zeiss Observer.Z1 and images were acquired with an 
AxioCam MRm camera (Zeiss, Göttingen, Germany). Confocal imaging and the 
fluorescence loss in photobleaching (FLIP) assays were performed using a Zeiss 
LSM 510 Meta confocal microscope equipped with an argon laser. Cells were 
examined with a 63x1.2 NA Zeiss water immersion objective. GFP was excited at 
λ= 488 nm and detected using a 505-530 bandpass filter. YFP was excited at 
λ= 514 nm and using a 530-600 bandpass filter. In the FLIP assay, bleaching was 
performed with 14 pulses each consisting of 50 iterations in a cytoplasmic region of 
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interest (ROI) until most of the cytoplasmic fluorescent protein was bleached. Data 
were recorded after each bleach pulse and subsequently every 30 sec. Four ROIs 
were used to measure the fluorescence intensities. The first ROI was taken from the 
bleached region (ROI) and a second ROI from the nucleus (Nuc) of the bleached cell. 
A third ROI was taken from a non-bleached neighbouring cell to measure the loss of 
fluorescence during image acquisition (Con), while the fourth ROI monitored the 
background fluorescence (BG). Normalized fluorescence intensities were calculated 
from five representative FLIP measurements as follows: 1) Background subtraction: 
ROI (t) – BG (t), Nuc (t) – BG (t), Con (t) – BG (t) 2) Correction: (ROI (t) – BG (t))/ 
(Con (t) – BG (t)), (Nuc (t) – BG (t))/ (Con (t) – BG (t)) 3) Normalization: ((ROI (t) – 
BG (t))/ (Con (t) – BG (t))) * ((ROI (0) – BG (0))/ (Con (0) – BG (0))). 
 
3.2.6 Immunoprecipitation 
Transfected cells were washed twice in cold PBS and lysed in immunoprecipitation 
(IP) lysis buffer. After centrifugation the supernatant was obtained and incubated with 
1 µg/sample of rabbit anti-GFP (Rockland) or mAb anti-HA (Covance) for 1 h at 4°C. 
Equilibrated Ezview Protein G Affinity Gel (Sigma) was added to each sample and 
incubated at 4ºC overnight. Immuno-complexes were then washed twice with IP 
washing buffer containing Igepal and twice with washing buffer without Igepal.      
The samples recovered were analyzed in Western blot, in in vitro phosphorylation 
assay, in in vitro kinase assays or treated with phosphatase (as described below).  
 
3.2.7 Phosphatase treatment 
Extracts from transfected cells expressing HA-hDYRK4520 or its kinase deficient 
derivatives were subjected to anti-HA immunoprecipitation. Immuno-complexes were 
incubated for 1 h at 37°C in a total volume of 10 µl with phosphatase buffer and 2 µl 
of calf intestinal alkaline phosphatase (CIP) (10,000 U/ml, New England Biolabs, 
Schwalbach, Germany). The reaction was terminated by heating for 10 min at 65°C 
and washing twice with 50 mM Tris-HCl (pH 8) and 150 mM NaCl. Control reactions 
from the same immuno-complexes were treated similarly but in the absence of 
phosphatase. 
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3.2.8 IMAC (immobilized-metal affinity chromatography) 
Transfected cells were washed once with ice cold PBS and lysed in 6 M GuHCL 
(guanidine hydrochloride) lysis buffer. After centrifugation supernatant was obtained, 
equilibrated nickel-nitrilotriacetic acid (Ni-NTA) agarose (Qiagen) was added to each 
sample and incubated for 2 h at 4ºC, and the agarose-complexes were then washed 
three times with 8 M urea washing buffer. 
 
3.2.9 Protein purification using anti-GFPmag 
Transfected cells were washed twice in ice cold PBS and lysed in IP lysis buffer. 
After centrifugation the supernatant was obtained and incubated with equilibrated 
30µl/sample of anti-GFPmag (GFP-Trap coupled to magnetic particles; ChromoTek, 
Martinsried, Germany) for 3 h at 4°C. Proteins bound to GFP-mag were then washed 
twice with IP washing buffer with Igepal and twice with washing buffer without Igepal 
using a magnetic rack. The samples recovered were analyzed in Western blot, in     
in vitro phosphorylation assays or in in vitro kinase assays (as described below).  
 
3.2.10 In vitro phosphorylation assay 
Endogenous DYRK1A or overexpressed GFP-DYRK1A were immunoprecipitated 
with anti-DYRK1A antibody or by anti-GFPmag from HeLa, HEK_GFP-DYRK1A or 
PC12_GFP-DYRK1A cells. Immuno-complexes were split and incubated for 2 h at 
37°C in the presence or absence of 1 mM ATP in 1x kinase buffer. Where indicated 
4 µM harmine was added to the reaction. Reaction was stopped by adding LSB, 
proteins were eluted by heating at 98°C for 10 min and then analyzed in Western 
blot. 
 
3.2.11 In vitro kinase (IVK) assay 
For in vitro kinase (IVK) assays from mammalian cells, immuno-complexes were 
incubated for 30 min at 30ºC in 20 µl of 1x kinase buffer at a final concentration of 
10 µM ATP and [γ33-P]ATP (100–150 mCi/pmol) and with 100 µM of peptide. 
Incorporation of 33P into DYRKtide and SAPtide was determined in triplicate by 
dotting aliquots of the reaction mixture onto Whatman P-81 ion exchange paper 
(Whatman, Maidstone, UK), washing in 5% phosphoric acid and counting by liquid 
scintillation in LS 6000SC (Beckman, Krefeld, Germany). Incorporation of 33P into 
Pep285 and Pep3 was determined by dotting aliquots of the reaction onto a SAM² 
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biotin capture membrane (Promega, Mannheim, Germany), washing twice in 2 M 
NaCl for 2 min, twice in 2 M NaCl in 1% phosphoric acid for 3 min, twice in H2O for 
30 sec, once in 70% ethanol for 30 sec and subsequently counting by liquid 
scintillation. To ensure equal expression of the fusion proteins and 
autophosphorylation, the kinases were eluted from the beads in the presence of LSB 
by heating for 10 min at 98°C and analyzed in Western blot and subsequently by 
autoradiography using a Storage Phosphor Sreen and a Storm 820 PhosphorImager 
(Amersham Biosciences, Freiburg, Germany). The absolute counts per minute (cpm) 
obtained from unfused GFP transfected cells immuno-complexes were subtracted 
from cpm of each sample as background. Then cpms of each sample were 
normalized to the corresponding intensity of the signal obtained in the immunoblots 
(total protein). 
 
3.2.12 Whole cell lysates  
All steps were carried out on ice. Cells were washed twice with ice cold PBS and 
lysed with boiling SDS lysis buffer. The cells were then dispensed using a scraper, 
the solution was transferred to a 1.5 ml reaction tube, boiled for 5 min at 98°C and 
then sonificated for 30 sec. After centrifugation (5 min, 4°C, maximum rpm) the 
supernatant containing the proteins was stored at -20°C until further use. In the case 
of Calyculin A and nocodazole treatment, detached cells were transferred to              
a reaction tube, recovered by centrifugation (2 min, 4°C, 2000 rpm) and washed 
twice with ice cold PBS. Cell pellets were resuspended in 30 µl ice cold PBS and 
SDS lysis buffer was added. Cell lysates were then boiled, sonificated and 
centrifuged like above. 
 
3.2.13 Western blot 
Samples were resolved by SDS-PAGE using 10% SDS-polyacrylamide gels if not 
stated otherwise. The proteins were transferred to Protran Nitrocellulose membrane 
(Whatman, Dassel, Germany) that was then blocked with 5% skimmed milk in Tris-
buffered saline (TBS) plus 0.1% Tween-20 (TBS-T) or with 3% bovine serum albumin 
(BSA) in TBS-T, when a phospho-specific antibody was used as primary antibody. 
The membranes were incubated overnight at 4ºC with primary antibodies (5% BSA in 
TBS-T + 0.02% NaN3) and after washing with TBS-T  the membranes were 
incubated for 45 min at RT with corresponding secondary antibodies (5% skimmed 
Material and Methods 
 
28 
 
milk in TBS-T + anti-biotin). After washing again with TBS-T, chemiluminiscence 
detection solution was added and the membrane was incubated for 1 min at RT in 
the dark. Antibody binding was detected by enhanced chemiluminiscence using a 
LAS-3000 CCD imaging system (Fujifilm, Düsseldorf, Germany) and the data was 
quantified using AIDA Image Analyzer (v4, Fuji UK). The antibodies and conjugates 
used are listed in Table 4.  
 
3.2.14 Synchronization for cell cycle analysis 
Double thymidine block (early S phase block): HeLa or PC12_GFP-DYRK1A cells 
were treated with 2 mM thymidine for 19 h (first block), then medium was removed 
and cells were washed twice with PBS and fresh medium was added for 9 h.         
The second thymidine block was then initiated by adding 2 mM thymidine to the 
medium for 17 h. Finally, cells were washed twice with PBS and detached from the 
tissue culture dish by either treatment with trypsine (HeLa cells) or by pippeting with 
fresh medium (PC12_GFP-DYRK1A cells). Suspended cells were split to p35 Falcon 
Easy Grip tissue culture dishes (Becton Dickinson and Company, Franklin Lakes, NJ, 
USA) and harvest at different time points for Western blot (whole cell lysates) or for 
flow cytometry (FACS) analysis. Transient transfection (5 µg DNA/tissue culture dish 
100x20 mm) of HeLa cells during synchronization took place 2 h after the first 
thymidine block using FuGENE HD for 2 h. Cells were then washed and fresh 
medium was added for additional 5 h before initiating the second thymidine block 
(see Fig. 32E and F). 
Thymidine-Nocodazole block (mitotic block): HeLa or PC12_GFP-DYRK1A cells 
were treated with 2 mM thymidine for 24 h (S phase block), then washed twice with 
PBS and released in fresh medium for 3 h. Cells were arrested in prometaphase by 
adding 100 ng/ml nocodazole to the medium for 12 h. Mitotic cells in suspension 
were then collected in a reaction tube, centrifuged (2 min, RT, 2000 rpm), washed 
twice with PBS, resuspended in fresh medium and split to p35 Falcon Easy Grip 
tissue culture dishes. Cells were harvested at the indicated time points for Western 
blot (whole cell lysates) or FACS anaylsis. 
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3.2.15 FACS analysis of synchronized cells 
Cells were synchronized and released as described above. For FACS analysis, cells 
were detached from p35 Falcon Easy Grip tissue culture dishes (Becton Dickinson 
and Company, Franklin Lakes, NJ, USA) by pipetting in case of PC12_GFP-DYRK1A 
cells or by trypsinization in case of HeLa cells, washed with 1 ml PBS and 
resuspended in 100 µl PBS in a 1.5 ml reaction tube. 1.3 ml cold (< -20°C) Ethanol 
80% was added dropwise to the tube while vortexing and then tubes were kept at      
-20°C overnight. Cells were centrifuged (2 min, 4°C, 1500 rpm) and washed twice 
with 1 ml PBS. Finally, cell pellets were incubated with 200 µl RNAse (20 µg/ml in 
PBS) for 5 min at RT, then replaced in FACS tubes and 400 µl propidium iodide 
(50 µg/ml in PBS) was added for additional 30 min at RT in the dark. Cells were then 
vortexed and DNA content was measured using the BD FACS Canto II and BD 
FACS Diva Software (BD Biosciences, Franklin Lakes, NJ, USA).  
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4. Results 
 
4.1 DYRK4  
 
4.1.1 Human and murine DYRK4 are expressed as multiple 
alternative splicing variants 
 
4.1.1.1 Exon-intron organization of the N-terminal region of DYRK4  
Database mining indicates that at least two different murine Dyrk4 transcripts exist 
(Fig. 7A). One of them encodes a protein product of 594 amino acids (mDYRK4594, 
corresponding to Accession Number [Acc. Nº] NM_207210), while the other (Acc. Nº 
AK077117) has a different 5’-terminal sequence and encodes a protein of 632 amino 
acids. Similarly, two different human DYRK4 protein products can be predicted: a 520 
amino acid protein described previously (hDYRK4520, translated from Acc. Nº 
NM_003845: (Sacher et al. 2007), and a 635 amino acid protein (hDYRK4635, 
translated from Acc. Nº AK308260). The N-terminal regions of the long murine and 
human DYRK4 isoforms are encoded by orthologous exons (Fig. 7A and B). In 
contrast, the short isoform of mouse Dyrk4 starts with a 5’-exon that is not conserved 
in human DYRK4 (Fig. 7A). Thus, the longer isoform can be considered as the 
reference sequence for DYRK4, because the additional N-terminal sequence is 
conserved in mammals (Fig. 7C). By contrast, the corresponding first exon of the 
short variants appears to be species-specific, at least in human and mouse.  
In summary, both human and murine DYRK4 genes express several 
transcripts as a result of alternative splicing, with the two main protein products 
differing in their amino-terminal domain. 
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Figure 7: Exon-intron organization of DYRK4.  
A. Schematic representation of the exon–intron structure of the 5’ end of the human and 
murine DYRK4 gene. Exons are indicated by boxes and the translation start point of the 
different isoforms is marked (ATG). The length of the exons and introns (in bp) was 
determined using either the Ensembl or University of California, Santa Cruz (UCSC) 
servers. The alternatively spliced exons are shaded. The position of the PCR primers used in 
Fig. 8 is indicated. B. Alignment of the N-terminal regions of human (Hs) and murine (Mm) 
DYRK4. Translation of the different exons is shown in alternating colors (black and grey), 
and the alternatively spliced exon 6 is underlined. A predicted bipartite nuclear localization 
signal (NLS) is shown (bold underlined) and the basic amino acid residues are highlighted in 
bold. S, short; L, long. C. Conservation of the predicted protein sequence encoded by exon 5 
of the DYRK4 gene. DYRK4 genes in mammalian genome sequences were identified using 
the tblastn algorithm at http://blast.ncbi.nlm.nih.gov/Blast.cgi. Basic residues of the putative 
NLS are shown underlined in bold. Homo sapiens chromosome (chr) 12 (NC_000012.11); 
Pan troglodytes chr 12 (NC_006479.2); Macaca mulatta chr 11 (NC_007868.1); Mus 
musculus chr 6 (NC_000072.5); Rattus norvegicus chr 4 (NC_005103.2); Equus caballus 
chr 6 (NC_009149.2); Bos taurus chr 5 (NC_007303.3); Oryctolagus cuniculus chr 8 
(NC_013676.1); Canis familiaris chr 27 (NC_006609.2); Monodelphis domestica chr 8 
(NC_008808.1). 
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4.1.1.2 Differential expression of DYRK4 variants in human tissues 
When the expression of DYRK4 in different human tissues was analyzed by RT-PCR 
using oligonucleotides matching exons within the catalytic domain, the expression of 
DYRK4 mRNA was detected in all the tissues analyzed (Fig. 8A). By contrast, Dyrk4 
is predominately expressed in the testis of mouse and rat (Becker et al. 1998; Sacher 
et al. 2007). The broader tissue distribution of human DYRK4 is also evident through 
the sources of the ESTs listed in the Unigene database 
(http://www.ncbi.nlm.nih.gov/unigene), where 9 of the 10 murine ESTs but only 30 of 
150 human ESTs are from testis. Interestingly beside testis, murine Dyrk4 mRNA is 
only detected in nasopharynx. A microarray expression atlas (ref:  Su et al. 2004; 
accessible at http://genome.ucsc.edu) confirmed the broader distribution of human 
DYRK4 (GNF Expression Atlas 2 Data from U133A and GNF1H Chips) and the 
predominant detection of murine Dyrk4 (GNF Expression Atlas 2 Data from GNF1M 
Mouse Chip) in testis and olfactory epithelium. Moreover, DYRK4 mRNA is detected 
in human cell lines not derived from testis, such as A549 or HEK293 (Fig. 8B), 
NTERA-2 (Leypoldt et al. 2001) or SH-SY5Y cells (Reimertz et al. 2003) and 
fibroblasts (Kyng et al. 2003).  
PCR reactions with primer pairs specific for transcripts encoding the long or 
the short N-terminal protein variants highlighted the differentially expression of the 
corresponding transcripts, with the long isoform present in several tissues and the 
short isoform predominantly expressed in testis (Fig. 8A). The existence of human 
DYRK4 transcripts with different 5’-ends was confirmed by RT-PCR and sequencing 
of the PCR products (Fig. 8A). This analysis identified an alternative splicing event 
that involved the inclusion of an extra exon (exon 6 in humans; exon 3 in mice), 
which leads to a 9/10 amino acid inclusion in the human/murine DYRK4 proteins 
(Fig. 7B and Fig. 8A), and would give rise to a protein isoform of 644/642 amino acids 
(hDYRK4644 and mDYRK4642). In addition to the bands resulting from the 
inclusion/exclusion of exon 6, the primers also produced longer PCR products in 
several tissues. Sequencing of these products showed that they are an result of the 
inclusion of exon 7 (Fig. 8A), which would lead to an in-frame premature stop codon.  
Notably, the ratio between exon 6+/- or 7+/- isoforms was different when 
distinct tissues and cell lines were compared (Fig. 8A), suggesting that these splicing 
events are tissue specific and subject to regulation (see Discussion 5.1.1). 
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Figure 8: Differential expression of DYRK4 isoforms. 
A. A panel of cDNAs from different human tissues was used for RT-PCR with primer 
pairs specific for the two main isoforms of human DYRK4 (shown in Fig. 7A). Bands 
detected with the “long” primers correspond to the inclusion/exclusion of exon 6 and/or 
exon 7, as confirmed by sequencing of the PCR products from the testis. Total DYRK4 
expression was assessed with primers from the catalytic domain (Cat) and the expression 
of GAPDH was used as a control. B. RT-PCR with different oligonucleotide pairs specific 
for human DYRK4 and RNA from different cell lines. A549, human carcinoma alveolar 
basal epithelial cells; ECV, human bladder carcinoma cells; HEK293, human embryonic 
kidney cells; HUVEC, human umbilical vein endothelial cells. Cat refers to the PCR 
product obtained with oligonucleotides located in the exons encoding the kinase catalytic 
domain. DNA sequence of the different PCR products from a representative sample (testis, 
see Fig. 8A) revealed that they correspond to the transcripts with the indicated exon 
composition. 
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4.1.1.3 The transcript of the long human DYRK4 isoform is upregulated by 
tunicamycin in SH-SY5Y cells 
Gene expression microarray analysis of human SH-SY5Y neuroblastoma cells had 
identified DYRK4 as a tunicamycin-induced gene reaching maximal induction 8 h 
after treatment (Reimertz et al. 2003). Tunicamycin is an inhibitor of protein 
glycosylation and induces expression of target genes of the so-called “unfolded 
protein response (UPR)”. Prolonged tunicamycin treatment leads to endoplasmic 
reticulum (ER) stress and apoptosis.  
Using identical conditions, we tested if tunicamycin is able to increase mRNA 
level of the long and the short isoform of DYRK4. As tunicamycin is dissolved in 
DMSO, we used it as a negative control treatment and normalized relative mRNA 
level of tunicamycin-treated cells to the mRNA level of DMSO-treated cells. 
Quantitative real-time reverse transcription PCR (qRT-PCR) using oligonucleotides 
matching exons within the catalytic domain of DYRK4 confirmed the induction of 
DYRK4 mRNA in SH-SY5Y cells treated with tunicamycin (Table 7). Oligonucleotides 
matching the short isoform of DYRK4 failed to amplify any product, suggesting that 
the short isoform of DYRK4 is not expressed in SH-SY5Y or that this pair of 
oligonucleotides is not suitable for qRT-PCR. In contrast, oligonucleotides matching 
the long isoform revealed an up-regulation of transcript level by tunicamycin in 4 
independent mRNA samples (Table 7). In one of these amplified products the 
presence of exon 6 was verified by sequencing. 
In summary, expression of hDYRK4644 was detected in SH-SY5Y cells and, 
although to a variable extent, DYRK4 transcripts were consistently induced by 
tunicamycin treatment and thus relate DYRK4 to the UPR (see Discussion 5.1.3). 
 
Table 7: DYRK4 mRNA induction by tunicamycin in SH-SY5Y neuroblastoma cells. 
SH-SY5Y cells were treated for 8 h with 3 µM tunicamycin or vehicle (DMSO) and total 
RNA was isolated (see Material and Methods). Quantitative real-time reverse transcription 
PCR (qRT-PCR) was performed using oligonucleotides matching the catalytic domain 
(Cat) or the long isoform (Long) of DYRK4 (see Material and Methods). DYRK4 mRNA 
levels were normalized to GAPDH and arbitrarily set to 1. qRT-PCRs (1-6) were 
performed with 4 different RNA samples. nd = not done. 
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4.1.2 Alternative splicing alters the subcellular localization of 
DYRK4 
 
4.1.2.1 DYRK4 is mainly localized in the cytosol 
The 520 amino acid isoform of human DYRK4 (hDYRK4520) is located in the cytosol 
of COS-7 cells when expressed exogenously (Sacher et al. 2007). This distribution 
was confirmed in HeLa cells using wild type hDYRK4520 and two kinase deficient 
mutants* (the KR mutant where Lys133 in the ATP binding site is mutated to Arg, and 
the YF mutant where Tyr264 in the activation loop is mutated to Phe). The PSORT II 
algorithm (Nakai and Horton, 2007) predicts the presence of a putative bipartite NLS 
within the extended N-terminal region, which is conserved in the human and murine 
long protein variants of DYRK4 (Fig. 7B and C). Therefore, it has been supposed that 
the distinct protein isoforms could differ in their subcellular distribution.  
To study their subcellular localization, the long variants of human and mouse 
DYRK4 proteins (hDYRK4644 or mDYRK4642), which include the putative NLS, and 
hDYRK4520 or mDYRK4594 that do not have the N-terminal extension were fused to 
GFP. Both, the long and the short variants of human and mouse GFP-tagged DYRK4 
were mainly detected in the cytosol when overexpressed in COS-7 cells (Fig. 9C, 
untreated; shown for mouse DYRK4). In some of the cells a significant fraction of 
both isoforms (long and short, in human and mouse) was also localized in the 
nucleus.  
Experiments performed by our collaborators verified that the NLS of DYRK4 
fused to a chimeric GFP-GST protein was able to translocate this cytosolic protein to 
the nucleus and was interacting with importin α, indicating that DYRK4 contains a 
bona fide NLS. In addition they showed that in SH-SY5Y cells the long variants of 
human and mouse DYRK4 proteins fused to GFP were localized in the nucleus to a 
significant extent, whereas GFP-hDYRK4520 or GFP-mDYRK4594 were mainly 
detected in the cytosol (published in Papadopoulos et al. 2011). However, both 
isoforms (long and short, in human and mouse) behaved similarly as in COS-7 cells 
when overexpressed in HeLa cells.  
                                                 
*
 Papadopoulos, Chrisovalantis (2007) Functional Characterisation of the Protein Kinase    
   DYRK4, diploma thesis, RWTH Aachen University 
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Together, these results confirm that different DYRK4 isoforms display distinct 
subcellular localizations, in a cell type dependent manner. Moreover, these data 
further suggest that the nuclear accumulation of the long variant of DYRK4 driven by 
the NLS is partially prevented by a mechanism that remains to be identified (see 
Discussion 5.1.4). 
 
4.1.2.2 CRM1-independent distribution of GFP-mDYRK4 
For many proteins, their distribution between the cytoplasm and the nucleus is based 
on a dynamic equilibrium of nuclear import and nuclear export, with contributions 
from protein retention in either of these subcellular compartments. The preferential 
cytoplasmic localization of DYRK4 isoforms in COS-7 cells could result from a strong 
nuclear export signal (NES)-dependent and CRM1 (exportin-1)-mediated nuclear 
export that might mask the effect of the NLS in the N-terminal extensions of the long 
DYRK4 isoforms.  
Sequence analysis revealed a putative leucine-rich nuclear export sequence 
(NES; LX4LX2LXL) motif for human and murine DYRK4 present in the long and in the 
short isoform (Fig. 9A). This motif interacts with an exportin which is a member of the 
importin β family (Ohno et al. 1998). It has been reported that mutation of the two 
leucines (Fig. 9A, asterisks) to alanine destroys NES activity (Feng et al. 1999). 
Therefore we generated a mutant of GFP-mDYRK4642 in which the residues Leu191 
and Leu193 were replaced by alanine (GFP-mDYRK4642 L191A/L193A). COS-7 cells 
transiently transfected with GFP-mDYRK4642 L191A/L193A did not show any nuclear 
accumulation of the protein (Fig. 9B), indicating that this putative NES motif is not 
functional or that other NES, not matching this motif, are present in DYRK4. 
To further determine the contribution of CRM1-mediated nuclear export to the 
cytosolic accumulation of DYRK4 and to exclude additional active NES motifs, we 
exposed cells to an inhibitor of CRM1, leptomycin B. No nuclear accumulation of 
either isoform was evident after 4 h in the presence of this inhibitor (Fig. 9C). The 
effect of leptomycin B was shown using STAT5A as a positive control.  
These results suggest that subcellular localization of the long variant of 
DYRK4 is modulated due to a strong CRM1-independent NES, an inactivated NLS or 
an unknown stimulus, which could alter either nuclear export or import. 
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Figure 9: CRM1-independent distribution of GFP-mDYRK4 in COS-7 cells. 
A. Sequence and position of the putative nuclear export signal (NES) motif in full-length 
human (Hs) and murine (Mm) DYRK4 are indicated and compared to the NES consensus 
sequence. Mutated leucine residues to generate GFP-mDYRK4642 L191A/L193A are 
marked with asterisks. B.  Subcellular localization of GFP- mDYRK4642 L191A/L193A 
(LL/AA) expressed in COS-7 cells. C. Subcellular localization of GFP-mDYRK4594 and 
GFP-mDYRK4642 expressed in COS-7 cells was analyzed before (untreated) and 4 h after 
addition of leptomycin B (10 ng/ml), an inhibitor of CRM1. STAT5A fused to YFP was 
used as a positive control responding to CRM1 inhibition. Scale bars, 10 µM. 
 
 
 
4.1.2.3 Nucleocytoplasmic distribution of DYRK4 
The DYRK4 isoforms show a preferential cytoplasmic localization in COS-7 cells. 
However, low amounts of the proteins are also detectable in the nucleus by confocal 
microscopy (clearly visible after bleaching of the cytoplasm; see Fig. 10A). To answer 
the question whether the observed subcellular distribution is based on a dynamic 
equilibrium of constant nuclear export and nuclear import, we analyzed the dynamics 
of DYRK4 shuttling in single living cells using the fluorescence loss in photobleaching 
(FLIP) technique (Lippincott-Schwartz et al. 2001). A defined region of interest (ROI) 
in the cytoplasm was subjected to repeated photobleaching to wipe out the 
cytoplasmic GFP-fluorescence (Fig. 10A, post-bleach (0 min)). Subsequent reduction 
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in GFP-fluorescence in the nucleus reflects the nucleocytoplasmic shuttling of 
bleached protein into the nucleus and non-bleached protein out of the nucleus.  
The diffusible character of unfused GFP was reflected in its fast 
nucleocytoplasmic shuttling, which reached equilibrium after 7 min (Fig. 10A and B). 
The two isoforms of mDYRK4 displayed distinct nucleocytoplasmic shuttling, with the 
nucleocytoplasmic exchange of the shorter isoform (mDYRK4594) converging to 
equilibrium. In comparison with unfused GFP, shuttling of GFP-mDYRK4594 was 
more slowly (Fig. 10B, middle panel). Treatment with leptomycin B had no effect on 
mDYRK4594 nucleocytoplasmic shuttling, further supporting that nuclear export was 
independent of CRM1 (Fig. 10C). By contrast, cytoplasmic bleaching of mDYRK4642 
did not significantly reduce GFP-fluorescence in the nucleus, indicating that this 
isoform was not able to exit the nucleus (Fig. 10B, lower panel). The total loss of 
GFP-fluorescence in the bleached ROI was obtained faster than for the short variant. 
The recovery of cytoplasmic GFP-fluorescence, which is not mediated by exit from 
the nucleus (Fig. 10B, lower panel), could be due to cytoplasmic shuttling from 
cytoplasmic compartments far from the ROI during photobleaching. As expected from 
the results shown above, the NES mutant of the longer isoform 
mDYRK4642 L191A/L193A, behaved like the wild-type longer isoform (Fig. 10D). 
Similar results were obtained when the corresponding human isoforms (hDYRK4520 
and hDYRK4644) were assayed (published in Papadopoulos et al. 2011). The static 
nature of the long DYRK4 isoform could indicate that it is retained in the nucleus by 
strong interactions with nuclear proteins or chromatin. 
In conclusion, these results indicate that the alternatively spliced N-terminal 
region, common to human and mouse, confers distinct cellular properties to DYRK4. 
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Figure 10: Differences in nucleocytoplasmic shuttling of GFP-DYRK4 isoforms. 
A. Cytoplasmic FLIP analysis was performed on GFP, GFP-mDYRK4594 or GFP- 
mDYRK4642 expressed in COS-7 cells. The panels show representative images in which 
the bleached area is indicated by a white circle and the nucleus by an arrow. B. 
Fluorescence was measured in the cytoplasmic and nuclear regions of interest along the 
time period represented. C. Nucleocytoplasmic shuttling of GFP-mDYRK4594 in the 
presence of leptomycin B. The fusion protein was transiently expressed in COS-7 cells and 
analyzed by FLIP 4 h after addition of leptomycin B (10 ng/ml), an inhibitor of CRM1.    
D. Nucleocytoplasmic shuttling of the NES mutant GFP-mDYRK4642 L191A/L193A 
(LL/AA). This fusion protein was transiently expressed in COS-7 cells and analyzed by 
FLIP. The diagrams B-D show the normalized averaged fluorescence intensities of n= 4-5 
experiments as indicated. Scale bars, 10 µm. 
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4.1.3 Kinase activity of DYRK4 
 
4.1.3.1 DYRK4 is target of upstream kinases 
DYRK4 expressed in mammalian cells migrates as a doublet in SDS gels (Fig. 11). 
The appearance of the low electrophoretic mobility band does not depend on 
autophosphorylation, because the band is also present in the two kinase deficient 
mutants, hDYRK4 YF, where the second tyrosine of the YXY motif (Tyr264) is 
mutated to Phe (YF) and hDYRK4 KR, where Lys133 in the ATP binding site is 
mutated to Arg (KR) (Fig. 11). These mutants have previously been described as 
kinase deficient*. Phosphorylation is a posttranslational modification that can alter 
electrophoretic mobility. To determine if the doublet occurs due to phosphorylation, 
wild-type HA-DYRK4 and the two mutants were incubated in the presence or 
absence of a phosphatase. Treatment of DYRK4 proteins with phosphatase led to 
the disappearance of the slower migrating band (Fig. 11).  
This experiment shows that DYRK4 is phosphorylated by cellular kinases 
independently of its kinase activity (see Discussion 5.1.5). 
 
 
 
 
 
 
Figure 11: DYRK4 is phosphorylated by cellular kinases.  
HeLa cells were transiently transfected with plasmids encoding wild-type HA-hDYRK4520 
(wt) or its kinase deficient derivatives (KR or YF). HA-tagged proteins were 
immunoprecipitated with an anti-HA antibody and split in aliquots that were incubated in 
the absence or presence of calf intestinal phosphatase (CIP). The hyper- and 
hypophosphorylated forms are indicated by arrows. 
 
 
                                                 
*
 Papadopoulos, Chrisovalantis (2007) Functional Characterisation of the Protein Kinase  
   DYRK4, diploma thesis, RWTH Aachen University 
 
                                                                                                                                                                         Results 
 
 41 
4.1.3.2 Long and short isoform of DYRK4 are catalytically active in vitro 
To test if the two isoforms of DYRK4 that differ in subcellular localization are both 
catalytically active, overexpressed hDYRK4520 and hDYRK4644 were 
immunoprecipitated from HeLa or from COS-7 cell extracts and immuno-complexes 
were subjected to an in vitro kinase (IVK) assay with the peptide substrate, 
DYRKtide. DYRKtide can be used as a non-specific peptide substrate for all kinases 
of the DYRK family (Himpel et al. 2000). Both isoforms were able to phosphorylate 
the exogenous peptide (Fig. 12).  
Taken together, the alternative use of different 5’-exons does not affect the 
catalytic domain of DYRK4, and accordingly both the long and short isoforms are 
catalytically active protein kinases in vitro. 
 
 
 
 
 
Figure 12: Long and short splicing variants of human DYRK4 are catalytically active 
protein kinases. 
Extracts of HeLa cells or COS-7 cells expressing unfused GFP (-) or GFP-fusion proteins of 
DYRK1A, hDYRK4520 or hDYRK4644 were immunoprecipitated with anti-GFP antibody 
and the immuno-complexes subjected to an IVK assay with DYRKtide. Subsequently, bound 
proteins were eluted from the resin and analyzed by immunoblotting with anti-GFP 
antibody. Densitometric evaluation of expression levels and incorporation of labeled 
phosphate into the peptide (means of triplicate measurement) is indicated below the 
respective lanes. Cpm, total counts per minute; norm, total cpm normalized to protein 
expression levels. 
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4.1.3.3 DYRK4 phosphorylates SF3B1 on Thr434 
As no specific substrate for DYRK4 is known and to analyze whether DYRK4 can 
phosphorylate the same substrates as other DYRKs, one known substrate of 
DYRK1A, splicing factor 3B 1 (SF3B1) (de Graaf et al. 2006), has been tested for 
phosphorylation by DYRK4. Therefore, HeLa cells were transfected with GFP-
SF3B1-NT (amino acids 1-492) solely or in combination with wild-type HA-hDYRK4  
or with the kinase dead mutant HA-hDYRK4 KR. SF3B1 was stronger 
phosphorylated on Thr434 in cells expressing wild-type DYRK4 (Fig. 13A), compared 
to SF3B1 expressed alone. The kinase deficient mutant failed to enhance Thr434 
phosphorylation, suggesting that the active kinase DYRK4 recognizes SF3B1 as a 
substrate.  
As both the long and the short isoforms are catalytically active in vitro 
(Fig. 12), it has been tested whether this is also the case in living cells. HeLa cells 
were transiently transfected with plasmids expressing GFP-SF3B1 ∆256-382 and 
GFP-tagged DYRK1A, GFP-hDYRK4520, GFP-hDYRK4644 or unfused GFP. GFP-
SF3B1 ∆256-382 was used here, because in contrast to HA-tagged hDYRK4520, 
GFP-tagged hDYRK4520 has a similar molecular weight as GFP-SF3B1-NT. Both 
isoforms, the short and the long one, phosphorylated SF3B1 on Thr434 in HeLa cells 
(Fig. 13B). The difference in phosphorylation level of both isoforms can be explained 
by the weak expression of the long isoform in this experiment. Notably, 
phosphorylation of SF3B1 on Thr434 was less efficient than phosphorylation by 
DYRK1A (Fig. 13B). This can be explained by the nuclear subcellular localization of 
SF3B1 or SF3B1 ∆256-382 (data not shown) and the kinases. DYRK1A was co-
localized with SF3B1 in the nucleus when overexpressed, above all in splicing 
speckles (Alvarez et al. 2003), whereas both isoforms of DYRK4 were only present in 
a low amount in the nucleus (Fig. 9C). Therefore we assume that substrate 
availability is responsible for the low phosphorylation level of Thr434 by DYRK4. 
However, this is the first report showing phosphorylation of a protein by 
DYRK4 in living cells, confirming that DYRK4 is a catalytically active protein kinase in 
vivo.  
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Figure 13: Phosphorylation of SF3B1 by DYRK4.  
A. Whole cell lysates of HeLa cells co-expressing wild-type HA-hDYRK4520, the kinase 
dead mutant HA-hDYRK4 KR or vector control (-) with GFP-SF3B1-NT were analyzed in 
Western blot. Phosphorylation of SF3B1 was detected using a phosphorylation site-
specific antibody (pT434 in SF3B1). Band intensity of pSF3B1 was normalized to 
intensity of total SF3B1 and the ratio is indicated below the respective lanes. Vector 
control was arbitrarily set to 1. B. Whole cell lysates of HeLa cells co-expressing GFP-
SF3B1 ∆256-382 with unfused GFP (-), wild-type GFP-DYRK1A, GFP-hDYRK4520 or 
GFP-hDYRK4644 were analyzed in Western blot with indicated antibodies. 
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4.1.4 Substrate specificity of DYRK4 
 
4.1.4.1 Pep285 is a specific substrate for DYRK4 
When characterizing the catalytic activity of DYRK4 it has been found out that the 
phosphorylation of DYRKtide by DYRK4 was much less efficient than by DYRK1A 
(Fig. 14C). Hence, DYRKtide might not be an optimal substrate for DYRK4 and thus, 
it has been examined whether DYRK4 exhibited different substrate specificity than 
other members of the DYRK family. Accordingly, the phosphorylation specificity of 
DYRK4, or representative mammalian class I and class II DYRKs (DYRK1A and 
DYRK2, respectively), was studied in phosphosite arrays containing 720 peptides 
derived from annotated phosphorylation sites in human proteins (Becker, Zerweck, 
Schutkowski, published in Papadopoulos et al. 2011).  
To confirm that substrate specificity of DYRK4 differed from that of DYRK1A, 
we selected a peptide specifically recognized by DYRK4 for further analysis. 
Peptide 285 (Pep285) mimics Ser73 in c-Jun (Fig. 14A) and was chosen as the top 
scoring DYRK4 substrate whose phosphorylation by DYRK1A or DYRK2 was sub-
threshold in the array experiment. For comparison, DYRKtide was used as non-
specific peptide substrate for all kinases of the DYRK family (Himpel et al. 2000). 
GFP-tagged hDYRK4520 and DYRK1A were immunoprecipitated from transiently 
transfected HeLa cell extracts and immuno-complexes were subjected to an IVK 
assay with Pep285 and two other DYRK substrates, Pep3 and SAPtide (Fig. 14A) as 
peptide substrates. Pep285 was less efficiently phosphorylated by DYRK4 than 
DYRKtide, Pep3 and SAPtide (Fig. 14C). The amount of kinase used for the different 
peptides was equal, since the samples were aliquots from a common 
immunoprecipitation. However, normalization of the data to DYRKtide revealed that 
Pep285 was significantly better recognized by DYRK4 than by DYRK1A, whereas 
Pep3 and SAPtide did not show this differences (Fig. 14B). 
These results are in agreement with the results from the phosphosite array. 
Pep285 can be used as a specific substrate for DYRK4 in kinase assays. 
Furthermore, Pep285 was significantly phosphorylated by DYRK4 but not by 
DYRK1A, and thus supports the proposal that DYRK4 can phosphorylate target 
sequences not recognized by DYRK1A (see Discussion 5.1.6).  
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Figure 14: Differential peptide phosphorylation by DYRK4 and DYRK1A. 
A. Amino acid sequence of the peptides used in this study. B. Peptide selectivity of 
DYRK4. Anti-GFP immuno-complexes from HeLa cells overexpressing GFP-DYRK1A or 
GFP-hDYRK4520 were assessed in an IVK assay with different peptides as substrates (each 
at 100 µM). Incorporation of 33P into the indicated peptides was normalized to the 
phosphate incorporation into DYRKtide. The histogram represents the means ± SD from 
three independent experiments (*, p=0.0232; paired t test). Raw data corresponding to 
these experiments are shown in C. C. Selective phosphorylation of Pep285 by DYRK4. 
The diagrams show the results of the experiment illustrated in B without normalization. 
Background signal obtained in parallel samples from GFP-transfected HeLa cells was 
subtracted. Columns represent the amount of radioactive phosphate incorporated into the 
peptides (means ± SD of three independent experiments). 
 
 
4.1.4.2 Insertion of the NxGY motif does not significantly alter substrate 
selectivity of DYRK4 
To date only little is known about the structural basis of substrate specificity in the 
DYRK family of kinases. It has been suggested that the DH-box, a highly conserved 
motif upstream the kinase subdomain I in all members of the DYRK family, plays a 
role in the interaction with the substrate (Becker et al. 1999; Kinstrie et al. 2006). 
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Compared with other members of the DYRK family, mammalian DYRK4 lacks three 
amino acids (NxG) preceding the DH-box and contain a phenylalanine (F) residue 
instead of a tyrosine (Y) (Fig. 15A). This could be one reason why DYRK4 shows 
different substrate specificity than DYRK1A (Fig. 14B and C). To test this hypothesis, 
it has been determined whether the insertion of the NxGY motif altered the catalytic 
activity of DYRK4 towards exogenous substrate peptides. A mutant (GFP-
hDYRK4NLGY) was generated by inserting the amino acids NLGY into GFP-
hDYRK4520. The leucine residue has been chosen, because it is present in dDYRK2 
(Fig. 15A), which is the closest homologue of DYRK4 in D. melanogaster and has 
been characterized as a catalytically active protein kinase (Lochhead et al. 2003).  
GFP-tagged DYRK1A, hDYRK4520 or hDYRK4NLGY was immunoprecipitated 
from transiently transfected HeLa cells. Protein kinases were eluted from immuno-
complexes and analyzed by immunoblotting. GFP-hDYRK4NLGY showed no 
significant difference in tyrosine phosphorylation as detected by a phosphotyrosine-
specific antibody or autophosphorylation as detected by autoradiography (Fig. 15B). 
Furthermore, GFP-hDYRK4NLGY migrates as a doublet in SDS gels similar to wild-
type GFP-hDYRK4520, indicating that recognition by cellular kinases is not affected by 
this mutation (Fig. 15B). These results suggest that the insertion of the NxGY motif 
does not interfere with autophosphorylation on tyrosines. 
Next, we wanted to determine if the insertion mutant GFP-hDYRK4NLGY is an 
active serine/threonine kinase and if substrate specificity was altered due to this 
insertion compared to wild-type GFP-hDYRK4520. Activity was measured in IVK 
assays with a panel of peptides as substrates as described in 4.1.4.1. The 
DYRK4NLGY mutant exhibited a largely similar pattern of activity towards the different 
peptides as wild-type DYRK4 (Fig. 16A and B). We noticed however that for each 
peptide the activity of the DYRK4NLGY mutant was between that of wild-type DYRK4 
and DYRK1A, suggesting that the insertion of the NLGY motif might shift the target 
recognition of DYRK4 towards that of DYRK1A. This result may suggest that the 
absence of the NxGY motif may contribute to the different substrate specificities of 
DYRK1A and DYRK4. Nevertheless, these experiments revealed no significant 
differences between wild-type DYRK4 and the insertion mutant DYRK4NLGY. 
 
 
 
                                                                                                                                                                         Results 
 
 47 
A 
 
     
                                 B 
 
 
Figure 15: Effect of the NxGY motif on autophosphorylation of DYRK4. 
A. Conservation of the NxGY motif located directly N-terminal of the DH-box. Amino 
acids conserved in the majority of the sequences are marked in red and the integration site 
of the NxGY motif in human DYRK4520 is marked in bold. The DH-box is highlighted by 
a rectangle. Ac, Anolis carolinensis (NM_003845_anoCar1 521 scaffold_55:1366920-
1394815+); Ag, Anopheles gambiae (XP_317650); Dm, Drosophila melanogaster 
(NP_523564); Dr, Danio rerio (XP_693389); Hs, Homo sapiens (DYRK1A: AAB18639; 
DYRK1B: NP_004705; DYRK2: NP_006473; DYRK3: AAG17028; DYRK4: 
NP_003836); Mm, Mus musculus (NP_997093); Tg, Taeniopygia guttata 
(XP_002190423); Tn, Tetraodon nigroviridis (CAF98877). B. NLGY insertion does not 
affect autophosphorylation or tyrosine phosphorylation of DYRK4. Extracts of HeLa cells 
overexpressing GFP-DYRK1A, GFP-hDYRK4520, GFP-hDYRK4NLGY or unfused GFP (-) 
were immunoprecipitated with an anti-GFP antibody, and analyzed by Western blotting 
with anti-GFP and anti-phosphotyrosine antibodies as indicated. Autophosphorylation was 
assessed by autoradiography of nitrocellulose membrane. The arrowhead marks DYRK1A 
and the arrow the two DYRK4 variants. Asterisks mark unspecific bands.  
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Figure 16: Effect of the NxGY motif on DYRK4 catalytic activity and substrate 
specificity. 
A. GFP-hDYRK4520 and GFP-hDYRK4NLGY were immunoprecipitated from extracts of 
transiently transfected HeLa cells and subjected to an IVK assay with the indicated 
substrate peptides (Pep285, Pep3, SAPtide and DYRKtide, each at 100 µM). Incorporation 
of 33P into the indicated peptides was normalized to the phosphate incorporation into 
DYRKtide. B. The diagrams show the results of the experiment illustrated in A without 
normalization. Background signal obtained in parallel samples from GFP-transfected HeLa 
cells was subtracted. Columns represent the amount of 33P incorporated into the peptides 
(means ± SD of 3-4 independent experiments). 
 
 
Finally, to analyze if the DYRK4NLGY mutant can recognize and phosphorylate 
a substrate protein in living cells, both GFP-tagged proteins were co-expressed with 
GFP-SF3B1 ∆256-382 in HeLa cells. Both wild-type DYRK4 and the DYRK4NLGY 
mutant phosphorylated SF3B1 on Thr434 with similar phosphorylation levels 
(Fig. 17). Consistent with the results shown in Fig. 13, SF3B1 has been confirmed as 
a substrate for DYRK4. 
In summary, insertion of the highly conserved NxGY motif preceding the DH-
box into wild-type DYRK4 altered neither tyrosine autophosphorylation nor 
catalytically activity nor substrate specificity of DYRK4. 
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Figure 17: Phosphorylation of SF3B1 by DYRK4NLGY. 
Whole cell lysates of HeLa cells co-expressing GFP-DYRK1A, GFP-hDYRK4520 or the 
GFP-hDYRK4NLGY mutant with GFP-SF3B1 ∆256-382 were analyzed by immunoblotting. 
Phosphorylation of SF3B1 was detected using a phosphorylation site-specific antibody 
(pT434 in SF3B1). Band intensity of phosphorylated SF3B1 (pSF3B1) was normalized to 
intensity of total SF3B1 and is indicated below the respective lanes. Ratio of 
pSF3B1/SF3B1 determined for co-transfection of GFP-SF3B1 ∆256-382 with mock vector 
(-) was arbitrarily set to 1. 
 
4.2 Posttranslational modifications of DYRK1A during the cell cycle 
 
4.2.1 Harmine inhibits DYRK1A in cell culture 
 
4.2.1.1 Harmine inhibits the phosphorylation of SF3B1 
The ß-carboline alkaloid harmine has been found to inhibit DYRK1A in vitro (Bain et 
al. 2007). In this kinase selectivity screen DYRK1A together with two other kinases, 
among 69 kinases tested, was inhibited by harmine. 
Originally harmine has been isolated from Banisteriopsis caapi, a South 
American vine, and has been previously described as a potent inhibitor of 
monoamine oxidase (MAO) (Kim et al. 1997). To determine if harmine can be used to 
inhibit DYRK1A in cells, the effect of harmine on a known substrate of DYRK1A, 
SF3B1, was tested. 
SF3B1 is a subunit of the U2 snRNP-associated complex SF3B and was 
shown to be phosphorylated by DYRK1A on Thr434 (de Graaf et al. 2006).              
To examine the inhibitory effect of harmine on DYRK1A activity, the stable 
HEK_GFP-DYRK1A cells were transiently transfected with GFP-SF3B1-NT. This 
stable cell line overexpresses GFP-tagged wild-type DYRK1A under the control of a 
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doxycycline-regulatable promoter (Sitz et al. 2008). For comparison, DMAT, a cell-
permeable brominated benzimidazolo compound and a well known ATP-competitive 
inhibitor of Casein Kinase-2 (CK2), that has been reported to be a potent inhibitor of 
DYRK1A in vitro (Pagano et al. 2008), was used. Inhibitors were added 2 h after 
transfection and 15 min later GFP-DYRK1A expression was induced with doxycycline 
(2 µg/ml; +dox). As expected, expression of GFP-DYRK1A significantly enhanced the 
phosphorylation of exogenous GFP-SF3B1-NT and endogenous SF3B1 (Fig. 18, 
lane 1+5). In contrast, harmine reduced the phosphorylation on Thr434 of GFP-
SF3B1-NT in the non-induced HEK_GFP-DYRK1A cells (Fig. 18 lane 1+3+5), but 
failed to decrease the level of phospho-Thr434 in DYRK1A overexpressing cells 
(Fig. 18, lane 5+7+8). However, the strong phosphorylation signal of endogenous 
SF3B1 induced by overexpression of DYRK1A was reduced at a concentration of 
5 µM harmine. Treatment with DMAT (5 µM) failed to reduce the level of phospho-
Thr434 in overexpressed GFP-SF3B1-NT (Fig. 18, lane 1+2, 5+6), but showed a 
slight effect on endogenous SF3B1-phosphorylation on Thr434 (lane 5+6). 
These results indicate that harmine can be used to inhibit DYRK1A in cultured 
cells and contributed to the publication of Göckler et al. (2009) where harmine has 
been shown to be a specific inhibitor of DYRK1A. 
 
 
Figure 18: Effect of harmine on phosphorylation of SF3B1 by DYRK1A in vivo. 
HEK_GFP-DYRK1A cells were transiently transfected with GFP-SF3B1-NT and 2 h post-
transfection indicated inhibitors were added as indicated. After 15 min, GFP-DYRK1A 
expression was induced with doxycycline (2 µg/ml, +Dox) or not. Phosphorylation of 
GFP-SF3B1-NT and endogenous SF3B1 was determined by immunoblotting with 
phospho-specific anti-pThr434 antibody. Untransfected cells were used as background 
control.  
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4.2.1.2 Harmine inhibits the phosphorylation of Septin4 
In a two-hybrid screen for DYRK1A-interacting proteins, Jan Sitz identified a cDNA 
for Septin4 as a positive clone (2003, Dissertation, LMU München). He has shown 
that Septin4, a member of the group III septin family of guanosine triphosphate 
hydrolases (GTPases), specifically interacted with DYRK1A. In collaboration with this 
group, we wanted to assess whether Septin4 was phosphorylated by DYRK1A in 
living cells.  
When both proteins were co-expressed in cells, Septin4 exhibited a mobility 
shift in SDS gels. To verify that the mobility shift is due to phosphorylation by 
DYRK1A and to further characterize the inhibitory effect of harmine on DYRK1A in 
cell culture, stable HEK293_GFP-DYRK1A ´cells were transiently transfected with 
FLAG-Septin4. When GFP-DYRK1A expression was induced by doxycycline, FLAG-
Septin4 was detected as a double band, where the relative amount of the faster 
migrating band (black arrowhead) was reduced in comparison to non-induced GFP-
DYRK1A overexpression (Fig. 19A, lane1+5). Harmine prevented the DYRK1A-
dependent mobility shift of FLAG-Septin4 and recovered the intensity of the faster 
migrating band (Fig. 19A, lane 3+4). In contrast, DMAT failed to exhibit an effect on 
the double band of FLAG-Septin4 (lane 2), suggesting that harmine is a more potent 
inhibitor of DYRK1A than DMAT. This effect of harmine verified that Septin4 is a 
substrate of DYRK1A and has been published in a collaborative paper of our groups 
(Sitz et al. 2008).  
Taken together, these results demonstrate that harmine is highly cell-
permeant and that it can be used as a specific and potent inhibitor of DYRK1A in vivo 
to verify phosphorylation of presumed DYRK1A substrates. 
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Figure 19: Phosphorylation of Septin4 by DYRK1A. 
A. HEK_GFP-DYRK1A cells were transiently transfected with FLAG-Septin4, 2 h post-
transfection indicated inhibitors were added and GFP-DYRK1A expression was induced 
with doxycycline (2 µg/ml, +Dox) additional 15 min later or left untreated and/or non-
induced. Effect of harmine on mobility shift due to DYRK1A-dependent phosphorylation of 
FLAG-Septin4 was analyzed by immunoblotting with anti-FLAG and anti-GFP antibodies. 
White arrowhead marks the hyperphosphorylated and black arrowhead the 
hypophosphorylated or unphosphorylated variant of FLAG-Septin4. Untransfected cells 
were used as background control. B. Sequence and position of the presumed DYRK1A 
phosphorylation site of Septin4, compared to the consensus sequence for DYRK1A 
substrates. The putative phosphorylated Ser residues are marked in bold. 
 
 
4.2.2 Phosphorylation of DYRK1A on Serine 748 
 
4.2.2.1 Endogenous DYRK1A is not fully autophosphorylated in cells 
To investigate if DYRK1A is completely phosphorylated on its serine, threonine and 
tyrosine residues in living cells or if DYRK1A is able to autophosphorylate on so far 
unphosphorylated sites in vitro, endogenous DYRK1A from HeLa and PC12 cells 
was immunoprecipitated. The DYRK1A-specific antibody (anti-D1A), which 
recognizes a C-terminal epitope of DYRK1A, was able to immunoprecipitate three 
variants of endogenous DYRK1A (Fig. 20A, lane1). Incubation of the 
immunoprecipitates with ATP revealed slower migrating variants of DYRK1A 
compared with immunoprecipitates incubated under the same conditions without ATP 
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(Fig. 20A and B, lane 1+2, indicated by arrowheads). This demonstrates that 
DYRK1A is able to incorporate phosphate residues and thereby to cause a mobility 
shift clearly detectable in SDS gels. These shifted bands show a diffuse pattern, 
suggesting a heterogeneous phosphorylation on multiple phosphorylation sites 
during the assay. The three bands of endogenous DYRK1A have also been found 
with a different C-terminal antibody against DYRK1A (Okui et al. 1999), but to date 
the origin of the three bands is still unknown. Under the phosphorylation conditions 
used in this assay, even the fastest-migrating band (Fig. 20A and B, black 
arrowhead), which represents either an N-terminal truncated product of DYRK1A 
(because the anti-D1A antibody recognizes a C-terminal epitope) or an isoform 
derived from an internal splicing event, is shifted in the gel, suggesting that indeed it 
is a catalytically active form.  
To further examine whether inhibition of DYRK1A autophosphorylation during 
expression leads to an altered pattern in SDS gels, HeLa cells were treated with two 
different concentrations of harmine. Harmine treatment did not alter the 
electrophoretic mobility of DYRK1A (Fig. 20A, lane 1+3+5). This suggests that the 
three variants of DYRK1A are not derived from harmine-inhibitable 
autophosphorylation events of DYRK1A, but could be due to alternative splicing or 
phosphorylation by harmine-independent events. Moreover, DYRK1A expressed in 
the presence of harmine was able to incorporate phosphate residues when incubated 
with ATP, causing the same band shift detectable in SDS gels like DYRK1A 
expressed in non-treated cells (Fig. 20A, lane 2+4+5 and Fig. 13B, lane 2+4). This is 
consistent with the result that harmine is not an irreversible inhibitor of DYRK1A. 
The observation that inhibition of DYRK1A activity does not affect the pattern 
of bands in SDS gels shows that the autophosphorylation which causes the mobility 
shift after in vitro phosphorylation must either be prevented by unknown mechanisms 
or counteracted by phosphatases in living cells. 
 
4.2.2.2 Autophosphorylation of exogenous DYRK1A is inducible by Calyculin A  
Similar results as for endogenous DYRK1A were obtained with overexpressed 
DYRK1A fused to GFP (Fig. 21A). GFP-DYRK1A was shifted after incubation with 
ATP (Fig. 21A, lane 1+2). Neither treatment with harmine during expression nor 
presence of harmine in a high concentration (4 µM) during the kinase assay 
interfered with the autophosphorylation in vitro and the resulting mobility shift of 
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DYRK1A (Fig. 21A, lane 2+3 and 5+6). These two approaches, applying harmine 
during expression or during the assay, strongly support that a) the mature DYRK1A 
kinase, expressed in the presence of harmine, maintains its ability to 
autophosphorylate and b) the autophosphorylation on further residues is not inhibited 
by harmine under the conditions of the in vitro assay (see Discussion 5.2.2). 
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Figure 20: Endogenous DYRK1A is further autophosphorylated in vitro. 
HeLa cells (A) or PC12_GFP-DYRK1A cells induced with doxycycline (2 µg/ml) (B) were 
treated with indicated concentrations of harmine for 2 d or left untreated, lysed and 
DYRK1A was immunoprecipitated (IP) with anti-DYRK1A antibody. Harmine was washed 
out and immuno-complexes were split and subjected to a phosphorylation assay in the 
presence of ATP (+) or mock incubation without ATP (-) (see Material and Methods). 
Proteins were eluted from immuno-complexes by boiling and analyzed by immunoblotting 
with indicated antibodies. Arrowheads indicate the three variants of endogenous DYRK1A. 
 
Another approach to determine whether the phosphorylation sites within 
DYRK1A are permanently saturated or are targets of cellular phosphatases, and 
therefore can be modulated, is the use of Calyculin A, an inhibitor of phosphoprotein 
phosphatase 1A and 2A (PP1A and PP2A). HeLa cells overexpressing GFP-tagged 
DYRK1A were treated with Calyculin A for 1 h or left untreated and whole cell lysates 
were analyzed. GFP-DYRK1A from Calyculin A-treated cells showed a lower 
electrophoretic mobility compared to GFP-DYRK1A from untreated cells (Fig. 21B). 
This mobility shift is most likely caused by prevention of dephosphorylation of 
DYRK1A. In parallel, HeLa cells were transfected with the kinase mutants GFP-
DYRK1A K188R and GFP-DYRK1A Y321F (see Introduction 1.2.3). The K188R 
mutant failed to exhibit a mobility shift due to Calyculin A treatment (Fig. 21B), 
showing that the hyperphosphorylation of the DYRK1A protein is an 
autophosphorylation event and is not mediated by an upstream kinase. In contrast, 
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the Y321F mutant showed a slight mobility shift, thereby suggesting this mutant 
retains a low activity, what has been previously described (Himpel et al. 2001).  
The results indicate that DYRK1A is not fully autophosphorylated in living cells 
due to activity of phosphatases and/or interaction with other cellular proteins that 
inhibit autophosphorylation. 
 
A 
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Figure 21: GFP-DYRK1A autophosphorylates in vitro and is targeted by 
phosphatases in vivo. 
A. HEK_GFP-DYRK1A cells induced with doxycycline (2 µg/ml) were treated with 
4 µM harmine for 2 d or left untreated, lysed and immunoprecipitated with a-GFPmag 
(GFP-Trap coupled to magnetic particles). Harmine was washed out or was present 
during the assay as indicated. Immunoprecipitates were split and subjected to a 
phosphorylation assay in the presence of ATP (+) or not (-) (see Material and Methods). 
Immunoprecipitated proteins were analyzed in Western blot. GFP-DYRK1A is marked 
by a black arrow. B. HeLa cells overexpressing wild-type GFP-DYRK1A (WT) or 
kinase inactive mutants (K188R, Y321F) were treated with 100 nM Calyculin A for 1 h 
or left untreated. Whole cell lysates were analyzed in Western blot. 
 
 
4.2.2.3 Generation of a phospho-specific anti-pSer748 antibody  
The result that DYRK1A is not fully phosphorylated on its serine, threonine or 
tyrosine residues and an upregulation of Ser748 phosphorylation in mitotic cells was 
found by Daub et al. (2008) (see Introduction 1.3), suggest that Ser748 
phosphorylation levels are regulated . 
To characterize the phosphorylation level of Ser748 in asynchronous cells and 
during the cell cycle, an antibody recognizing the phosphorylated state of this residue 
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(pSer748) was generated. Further, a GFP-tagged version of DYRK1A in which the 
Ser748 is mutated to alanine (GFP-D1A S748A) was generated. Two methods were 
used to test the specificity of the antibody. First we examined the reactivity of 
overexpressed wild-type GFP-DYRK1A (WT) and GFP-DYRK1A S748A by 
immunoblotting of whole cell lysates. The anti-pS748 antibody recognized GFP-
DYRK1A WT, but not the point mutation version (Fig. 22A). Second, GFP-
DYRK1A WT was partially purified by IMAC (immobilized-metal affinity 
chromatography) and incubated with phosphatase. The phospho-specific antibody 
failed to recognize wild-type GFP-DYRK1A (Fig. 22B) after dephosphorylation, 
demonstrating that the phosphorylation state of the protein is required for detection 
with this antibody.  
Summarized, the generated antibody is specific to detect the phosphorylation 
on Ser748 and can be used as a valuable tool to examine the phosphorylation state 
of Ser748.  
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Figure 22: Specificity of the phospho-specific anti-pS748 antibody. 
A. Whole cell extracts from HeLa cells overexpressing wild-type GFP-DYRK1A (WT) or 
GFP-DYRK1A S748A were analyzed in Western blot with anti-pS748 and anti-GFP 
antibodies. B. HEK_GFP-DYRK1A cells were induced with doxycycline (2 µg/ml) for 
2 d and GFP-DYRK1A was partially purified by IMAC. Samples were then split and 
incubated in phosphatase buffer in the absence or presence of calf intestinal phosphatase 
(CIP). Then samples were analyzed in Western blot with anti-pS748 and anti-DYRK1A 
antibodies. 
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4.2.2.4 Phosphorylation on Ser748 is an autophosphorylation event 
First, to determine whether DYRK1A autophosphorylates on Ser748, the 
phosphorylation state of wild-type DYRK1A and the kinase-dead mutant 
DYRK1A K188R fused to GST and expressed in bacteria was examined. Wild-type 
DYRK1A (WT) was phosphorylated on Ser748 (Fig. 23A). The kinase inactive mutant 
(KR) showed a very faint reactivity with the phospho-specific anti-pSer748 antibody, 
consistent with earlier reports that this mutant retains a very low activity (Himpel et al. 
2001). Because E. coli lacks Ser/Thr phosphatase activity, even a very low degree of 
autophosphorylation is detectable. Since E. coli also lacks endogenous protein 
kinase, this result indicates that phosphorylation on Ser748 occurs independently of 
upstream kinases and requires DYRK1A activity.  
Next, the ability of DYRK1A to autophosphorylate on Ser748 in living cells was 
examined. GFP-tagged DYRK1A expressed in HeLa cells was recognized by the 
phospho-specific anti-pSer748 antibody (Fig. 23B), whereas the catalytic inactive 
mutant (GFP-DYRK1A K188R) was not, what demonstrates that kinase activity of 
DYRK1A is essential for phosphorylation on Ser748 in mammalian cells. Notably, 
phosphorylation on Ser748 was not detectable in endogenous DYRK1A (Fig. 23B, 
arrowheads). 
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Figure 23: DYRK1A expressed in bacteria and in cells autophosphorylates on Ser748. 
A. Wild-type GST-DYRK1A (WT) or kinase-inactive GST-DYRK1A KR were expressed 
in E. coli and analyzed by immunoblotting with indicated antibodies. Full-length protein is 
marked by an arrow. B. HeLa cells were transiently transfected with wild-type GFP-
DYRK1A (WT) or the kinase-inactive mutant GFP-DYRK1A KR and whole cell lysates 
were analyzed by immunoblotting with indicated antibodies. Recombinant GFP-DYRK1A 
WT and mutant are marked by an arrow and the three variants of endogenous DYRK1A by 
arrowheads. 
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The results in bacteria and mammalian cells indicate that DYRK1A Ser748 
phosphorylation is mediated by DYRK1A itself and not by upstream kinases and thus 
is an autophosphorylation event. 
 
4.2.2.5 DYRK1A autophosphorylation on Ser748 is inhibited by harmine 
Recombinant GFP-tagged DYRK1A is autophosphorylated on Ser748, but Ser748 
phosphorylation of endogenous DYRK1A could not be detected in whole cell lysates. 
Therefore endogenous DYRK1A was partially purified from HeLa cells by IMAC.   
This method is used for purification of histidine-tagged proteins. DYRK1A contains an 
endogenous histidine repeat (His13-sequence) in the C-terminal region and thus can 
be partially purified from cell lysates by IMAC.  
Endogenous DYRK1A partially purified by IMAC from HeLa or PC12 cells was 
detected by the phospho-specific anti-pSer748 antibody (Fig. 24A and B, 
arrowheads).  Treatment of the cells with harmine, an inhibitor of DYRK1A, reduced 
the detection by the phospho-specific anti-pSer748 antibody compared to the signal 
of endogenous DYRK1A isolated from non-treated cells (Fig. 24A and B, 
arrowheads), suggesting that Ser748 phosphorylation of endogenous DYRK1A is an 
autophosphorylation event that can be inhibited by harmine. 
Next, to elucidate whether phosphorylation of Ser748 interferes with the 
precipitation method and whether IMAC biased for either the phosphorylated or the 
non-phosphorylated DYRK1A protein, HeLa cells overexpressing GFP-tagged 
DYRK1A were lysed and subjected to IMAC. Thereby endogenous and recombinant 
DYRK1A were partially purified simultaneously from the same cell lysate. This direct 
comparison showed that endogenous DYRK1A is isolated as efficiently as 
recombinant GFP-tagged DYRK1A, and that both proteins showed phosphorylation 
on Ser748 (Fig. 24A). In addition, the efficiency of partial purification of DYRK1A by 
IMAC is not affected by the phosphorylation state of Ser748 (Fig. 24A, +/- harmine) 
and this method can be used as a tool to compare phosphorylation levels of DYRK1A 
under different conditions.  
These results showed that the autophosphorylation on Ser748 in living cells 
can be inhibited by harmine and most importantly they confirmed the third in vivo 
phosphorylation site in endogenous DYRK1A, in addition to the previously described 
Tyr321 and Ser529 (Himpel et al. 2001; Alvarez et al. 2007). 
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Figure 24: Endogenous DYRK1A is autophosphorylated on Ser748 in living cells. 
A. HeLa cells were transiently transfected with GFP-DYRK1A or left untransfected and 
treated for 1 d with 1 µM harmine (Ha) as indicated. Endogenous DYRK1A and 
recombinant GFP-DYRK1A were partially purified by IMAC. Samples were analyzed by 
immunoblotting with anti-pS748 and anti-DYRK1A antibodies. B. PC12 cells were treated 
for 1 d with 1 µM harmine and endogenous DYRK1A was partially purified and subjected 
to Western blot analysis like in A. The arrow marks exogenous GFP-DYRK1A and 
arrowheads the three variants of endogenous DYRK1A. 
 
 
4.2.2.6 DYRK1A autophosphorylates on Ser748 in vitro 
To test if Ser748 is completely phosphorylated in living cells and if DYRK1A is able to 
autophosphorylate on Ser748 in vitro, the two membranes shown in Fig. 20A and 
Fig. 21A were also immunodetected with the phospho-specific anti-pSer748 antibody 
(anti-pSer748). Endogenous and recombinant DYRK1A purified and subjected to      
a phosphorylation assay in the presence of ATP showed a stronger signal with anti-
pSer748 antibody (Fig. 25A and B), demonstrating that in untreated cells the 
phosphorylation on Ser748 is not saturated.  
These results provide further evidence that phosphorylation on Ser748 is an 
autophosphorylation event. Furthermore, the phosphorylation on Ser748 of DYRK1A 
isolated from untreated cells is elevated when incubated with ATP (Fig. 25B, 
lane1+2+3), indicating that Ser748 is not fully autophosphorylated in living cells. 
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Next the question was addressed whether phosphorylation on Ser748 is an 
one-off reaction that is only catalyzed by a DYRK translational intermediate only 
present during maturation, as reported for the second tyrosine of the Tyr-X-Tyr motif 
in the activation loop (Lochhead et al., 2005; see Introduction 1.2.3). To prevent 
autophosphorylation, HeLa cells overexpressing wild-type GFP-DYRK1A were 
treated with harmine during translation. GFP-DYRK1A was isolated by 
immunoprecipitation and harmine was removed by washing. Then immuno-
complexes were subjected to a phosphorylation assay in the presence or absence of 
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Figure 25: DYRK1A autophosphorylates on Ser748 in vitro. 
A. HeLa cells were treated with indicated concentrations of harmine for 2 d or left 
untreated, lysed and DYRK1A was immunoprecipitated (IP) with anti-DYRK1A 
antibody. Harmine was washed out and immuno-complexes were split and subjected to a 
phosphorylation assay in the presence of ATP or mock incubation without ATP 
(see Material and Methods). Proteins were eluted from immuno-complexes by boiling and 
analyzed by immunoblotting with indicated antibodies. Arrowheads indicate the three 
variants of endogenous DYRK1A. B. HEK_GFP-DYRK1A cells induced with 
doxycycline (2 µg/ml) were treated with 4 µM harmine for two days or left untreated, 
lysed and immunoprecipitated with a-GFPmag (GFP-Trap coupled to magnetic particles). 
Harmine was washed out or was present during the assay as indicated. 
Immunoprecipitates were split and subjected to a phosphorylation assay in the presence of 
ATP (+) or not (-) (see Material and Methods). Immunoprecipitated proteins were 
analyzed in Western blot. GFP-DYRK1A is marked by a black arrow. The ratio of anti-
pSer748 to anti-DYRK1A antibody signal is shown below the respective lanes and was 
determined using the AIDA software. 
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ATP. Ser748 phosphorylation of GFP-DYRK1A was not detectable in harmine treated 
cells, but incubation of GFP-DYRK1A, isolated from the same cells, in the presence 
of ATP during the assay, showed a clearly phosphorylation of Ser748 (Fig. 25B, 
lane 5). Furthermore, recombinant GFP-DYRK1A protein was able to 
rephosphorylate even when harmine was present in the assay (Fig. 25B, lane6), 
supporting the notion that harmine differentially affects autophosphorylation of 
Ser748 in vivo (in living cells) and in vitro (see Discussion 5.2.2).  
This ability of the mature protein to rephosphorylate in vitro demonstrates that 
the phosphorylation on Ser748 is not an one-off event. In addition, the 
phosphorylation on Ser748 of DYRK1A isolated from untreated cells is elevated in 
the presence of ATP (Fig. 25B, lane1+2+3), indicating that Ser748 is not fully 
phosphorylated in asynchronous cells. 
 
4.2.2.7 Calyculin A does not elevate DYRK1A phosphorylation on Ser748  
Calyculin A elevates autophosphorylation of DYRK1A (Fig. 21B) and DYRK1A is not 
fully phosphorylated on Ser748 when isolated from cells. Therefore we tested if 
Calyculin A treatment leads to enhanced level of Ser748 phosphorylation.  
HeLa cells overexpressing wild-type GFP-DYRK1A (WT), the mutants with 
impaired kinase activity (K188R, Y321F) or the point mutant GFP-DYRK1A S748A 
were treated with Calyculin A. As shown above, treatment with Calyculin A caused a 
mobility shift of wild-type GFP-DYRK1A due to inhibition of protein phosphatases 
(Fig. 21B and Fig. 26). As expected, the phospho-specific anti-pSer748 antibody 
failed to recognize the kinase inactive mutant K188R of DYRK1A in cells treated with 
Calyculin A, supporting once more that Ser748 phosphorylation occurs due to 
autophosphorylation and is not mediated by upstream kinases. The kinase deficient 
mutant Y321F is weakly phosphorylated on Ser748, consistent with the reported low 
activity of this DYRK1A variant. Finally, the point mutant S748A exhibited the same 
pattern as the wild-type GFP-DYRK1A protein, indicating that the mobility shift is not 
caused only by enhanced phosphorylation level on this residue. Furthermore, the 
quantification of several independent experiments (n= 5) revealed that the 
phosphorylation level of Ser748 is not upregulated by Calyculin A (ratio of phospho-
specific pSer748 antibody to total amount of protein anti-GFP in Calyculin A-treated 
and untreated cells; 1.092 ± 0.1446). 
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Taken together, exposure of cells to Calyculin A induces a mobility shift of 
catalytically active DYRK1A, but had no effect on phosphorylation level on Ser748. 
This suggests that exogenous GFP-tagged DYRK1A either a) is a target of 
phosphatases other than PP1A or PP2A or b) interacts with yet unknown cellular 
proteins that regulate the phosphorylation level of Ser748. 
 
 
 
4.2.2.8 Ser748 autophosphorylation occurs via an intermolecular mechanism 
A closer look on the sequence of DYRK1A around Ser748 reveals the presence of a 
proline in the P+1 position and an arginine at P-3 and therefore this sequence 
matches perfectly the consensus target sequence (RXXp(S/T)P) for DYRK1A 
substrates (Fig. 27A) defined based on intermolecular phosphorylation of peptides 
(Himpel et al. 2000).  
 
 
Figure 26: Effect of Calyculin A on DYRK1A Ser748 phosphorylation. 
HeLa cells transiently transfected with  wild-type GFP-DYRK1A (WT), the kinase 
deficient mutants (K188R, Y321F) or the point mutant S748A were treated with 100 nM 
Calyculin A for 1 h before lysis and whole cell extracts were analyzed by immunoblotting 
with anti-pSer748 antibody. Total amount of protein was verified using anti-GFP 
antibody. Whole cell extracts from cells overexpressing GFP-DYRK1A WT and the 
kinase deficient mutants (K188R, Y321F) were used also in the experiment shown in 
Fig. 21B. 
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To test whether the autophosphorylation on Ser748 is an intermolecular event, 
wild-type GFP-DYRK1A  (WT) and the kinase inactive HA-tagged DYRK1A KR were 
co-expressed in HeLa cells. Due to the tags the proteins have different molecular 
masses and can be easily distinguished on SDS gels. As shown above, the kinase 
inactive mutant (HA-DYRK1A KR) is not phosphorylated on Ser748 when expressed 
alone in HeLa cells (Fig. 27B, lane2). When co-expressed with active wild-type GFP-
DYRK1A, the kinase inactive mutant is detected by the phospho-specific anti-pS748 
antibody (Fig. 27B, lane3). Activity of endogenous DYRK1A was apparently to low to 
generate detectable levels of intermolecular phosphorylation when HA-DYRK1A KR 
was expressed alone.  
This result demonstrates that phosphorylation of Ser748 can be an 
intermolecular (trans) autophosphorylation event, where the C-terminal tail 
harbouring Ser748 is recognized by the catalytic domain as a substrate, but 
phosphorylation in cis can not be excluded (see Discussion 5.2.3). 
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Figure 27: DYRK1A autophosphorylates on Ser748 via an intermolecular 
mechanism. 
A. Alignment of the sequence surrounding Ser748 is compared to the known Ser529 
autophosphorylation site of DYRK1A (Alvarez et al. 2007) and the consensus sequence for 
DYRK1A substrates. The phosphorylated Ser residues are marked in bold. B. HeLa cells 
were transiently transfected with wild-type GFP-DYRK1A (WT), the kinase-inactive 
mutant HA-DYRK1A K188R (KR) or both as indicated. Whole cell extracts were 
analyzed by immunoblotting with indicated antibodies. 
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4.2.2.9 Ser748 phosphorylation alters DYRK1A activity 
The phosphorylation of a kinase can modulate its activity e.g. by conformational 
changes or by altering its interaction with other proteins. A dynamic phosphorylation 
can thereby regulate the activity of a kinase. Up to date, it has been reported for 
DYRK1A that the autophosphorylation on Ser529 regulates the interaction with a 
protein which enhances DYRK1A activity (Alvarez et al. 2007) (see Discussion 5.2.4).  
       To analyze if phosphorylation on Ser748 alters DYRK1A activity, we generated a 
point mutant of GFP-DYRK1A by glutamic acid substitution of Ser748 (GFP-
DYRK1A S748E). Furthermore, the residue Thr751 located close to the Ser748 
(Fig. 28C) could, in principle, also be phosphorylated and thereby interfere with 
Ser748 phosphorylation. In addition, Ser758, which has been found to be 
upregulated in mitotic cells like Ser748 (Daub et al. 2008), could interfere with Ser748 
phosphorylation or detection by anti-pS748 antibody. To exclude involvement of 
Thr751 and Ser758 phosphorylation the double mutants GFP-DYRK1A 
T751A/S758A (TA/SA), GFP-DYRK1A S748E/S758E (EE) and S748E/S758A (EA) 
have been also generated. The substitution of serine residues by glutamic acid 
generates a phosphorylation-mimetic mutant, and the substitution by alanine             
a phosphorylation-deficient one. Additionally, a C-terminal truncated mutant of 
DYRK1A lacking the last 19 amino acids was generated (GFP-DYRK1A ∆C19) 
(Fig. 28C). HeLa cells were transiently transfected with the GFP-DYRK1A constructs. 
GFP-tagged proteins were immunoprecipitated either using an agarose-coupled 
(Fig. 28A) or a magnetic-coupled anti-GFP antibody (Fig. 28B) and subjected to an  
in vitro kinase assay with DYRKtide as exogenous peptide substrate.  
Substitution of Ser748 with alanine (S748A) and thereby prevention of its 
phosphorylation reduced the phosphorylation of DYRKtide in two independent 
experiments (Fig. 28A, Pi (norm)= 0.66; data not shown, Pi (norm)= 0.5). The 
phosphorylation-mimetic mutants, GFP-DYRK1A S748E/S758E (EE) and S748E/ 
S758A (EA), showed an increase of activity (Fig. 28A and B). The EA mutant 
phosphorylated DYRKtide stronger than the EE indicating that the phosphorylation of 
Ser758 is not the one mediating this increment. Even the GFP-DYRK1A 
T751A/S758A (TA/SA) mutant showed an increased activity in comparison with wild-
type GFP-DYRK1A, suggesting that these residues could influence Ser748 
phosphorylation when they are available for phosphorylation, and indicating that the 
increased activity of DYRK1A is mediated independently of these residues.              
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In contrast, deletion of the last 19 amino acids of DYRK1A (GFP-D1A ∆C19) resulted 
in an increase of activity (Fig. 28A, and two further independent experiments, data 
not shown), suggesting the involvement of an inhibitory protein (see Discussion 
5.2.4) 
Taken together, these results suggest that Ser748 phosphorylation leads to an 
increase of DYRK1A activity.  
 
A 
 
            B 
  
C                 748      751                     758   
WT - D R E E S P M T G V C V Q Q S P V A S S - - 
S748A - D R E E A P M T G V C V Q Q S P V A S S - - 
EE - D R E E E P M T G V C V Q Q E P V A S S - - 
EA - D R E E E P M T G V C V Q Q A P V A S S - - 
TA/SA - D R E E S P M A G V C V Q Q A P V A S S - - 
∆C19 - D  - - 
 
Figure 28: Influence of Ser748 phosphorylation on catalytic activity of DYRK1A. 
Extracts of HeLa cells transiently transfected with indicated wild-type GFP-DYRK1A 
or mutants were immunoprecipitated with GFP-mag (A) or anti-GFP antibody (B) and 
subjected to an IVK assay with DYRKtide. Subsequently, bound proteins were eluted 
and analyzed by immunoblotting with anti-GFP (A, B). Incorporation of labeled 
phosphate into DYRKtide normalized to densitometric evaluation of expression levels 
is indicated below the respective lanes. The phosphorylation of DYRKtide by wild-
type GFP-DYRK1A (WT) was arbitrarily set as 1. C. The sequence of the last 20 
amino acids of DYRK1A is shown. Residues considered as putative phosphosites are 
marked in bold and numbered. Mutated residues are marked in grey, bold and 
underlined. 
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4.2.2.10 Ser748 phosphorylation of DYRK1A in mitotic cells 
As DYRK1A isolated from asynchronous cells is not fully phosphorylated, we tested if 
DYRK1A immunoprecipitated from mitotic cells is also able to further phosphorylate 
on its serine, threonine or tyrosine residues in vitro.  
Therefore GFP-DYRK1A protein isolated from asynchronous HeLa cells and 
from cells synchronized with nocodazole, a specific inhibitor of microtubule formation 
that reversibly arrests cells at metaphase (Zieve et al. 1980; Hamilton and Snyder, 
1982), was analyzed in an in vitro phosphorylation assay as described before 
(Fig. 29). GFP-DYRK1A expressed in the presence of harmine in asynchronous 
HeLa cells was used as a control. Surprisingly, DYRK1A from mitotic cells exhibited 
retarded bands on SDS gel similar to these of DYRK1A expressed in harmine treated 
cells when incubated in the presence of ATP (Fig. 29). At least two clear bands of 
GFP-DYRK1A were detectable by immunoblotting, when ATP was added to the 
phosphorylation assay. Unfortunately, in this particular experiment GFP-DYRK1A 
isolated from untreated asynchronous cells failed to show a mobility shift (in contrast 
to a series of experiments performed the same way; as in Fig. 25B).  
Nevertheless, this experiment shows that DYRK1A is not completely 
phosphorylated on its serine, threonine or tyrosine residues in mitotic arrested cells. 
 
 
Figure 29: DYRK1A is not fully phosphorylated in mitotic cells. 
HEK_GFP-DYRK1A cells induced with doxycycline (2 µg/ml) were treated with 4 µM 
harmine (Ha) for two days or with nocodazole (50 ng/ml; Noco) for 16 h or left untreated  
(-). GFP-DYRK1A was immunoprecipitated with anti-GFP antibody, split and subjected to 
a kinase assay in the presence of ATP (+) or not (-) (see Material and Methods). After the 
reaction, GFP-DYRK1A was eluted by boiling and analyzed in Western blot with the 
indicated antibody.  
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       To analyze if phosphorylation on Ser748 is upregulated during mitosis we 
transfected HeLa cells with wild-type GFP- DYRK1A (WT) and treated the cells with 
nocodazole. GFP-DYRK1A WT showed no detectable increased phosphorylation 
level of Ser748 in mitotic cells (Fig. 30A, lane 2+3). To confirm the effect of 
nocodazole on the cell cycle, the same membrane was incubated with an anti-
pThr434 antibody, which recognizes the phosphorylated Thr434 residue of SF3B1 
(Fig. 30A, pSF3B1). Treatment with nocodazole increased the reactivity of the anti-
pThr434 antibody with endogenous SF3B1, consistent with the reports that SF3B1 is 
hyperphosphorylated in mitotic cells (Boudrez et al. 2002).   
Next, to determine whether nocodazole treatment a) induces Ser748 
phosphorylation of DYRK1A in a cell type specific manner and b) generates variants 
of DYRK1A with different electrophoretic mobility, GFP-DYRK1A was partially 
purified by IMAC from HEK_GFP-DYRK1A cells that were treated with nocodazole or 
left untreated. Three different migrating bands were detected for GFP-DYRK1A, with 
the middle one giving the strongest signal with the anti-DYRK1A antibody (Fig. 30B, 
indicated by the grey arrow). We suggest that this represents the main variant of 
GFP-DYRK1A in cells. As the mRNA of GFP-DYRK1A is not spliced, these variants 
derive from posttranslational modifications. Quantification of the Ser748 
phosphorylation level of all three variants together, by determination of the ratio 
signal of phospho-specific anti-pSer748 antibody to signal of total DYRK1A, showed 
that Ser748 phosphorylation is not upregulated in mitotic cells compared to 
asynchronous cells (Fig. 30B). However, the slowest migrating band (white arrow) 
appeared to show a stronger phosphorylation on Ser748 in mitotic cells.  
These results show that upregulation of Ser748 phosphorylation took place 
only in a minor part of overexpressed GFP-DYRK1A and thereby suggest that our 
experimental settings are not suitable to detect mitosis-dependent changes in 
phosphorylation (see Discussion 5.2.1).  
Finally, to investigate if fast dephosphorylation during mitosis is the reason 
why no upregulation on Ser748 phosphorylation can be observed, asynchronous and 
mitotic HeLa cells overexpressing GFP-DYRK1A were treated with increasing 
amounts of Calyculin A. As shown above, nocodazole treatment showed neither an 
affect on Ser748 phosphorylation (Fig. 31, lane 1+2) nor generated a mobility shift of 
GFP-DYRK1A in total cell lysates. GFP-DYRK1A from Calyculin A-treated 
asynchronous cells showed a clear shift with all three concentrations of Calyculin A. 
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A shift appeared also for unspecific bands, but taken this shift as a baseline the shift 
for GFP-DYRK1A is still noticeable. The same pattern was received for GFP-
DYRK1A from Calyculin A-treated mitotic cells. As expected from the results shown 
above (see Results 4.2.2.7), Calyculin A-treatment failed to enhance Ser748 
phosphorylation in asynchronous and in mitotic cells (Fig. 31, ratio indicated below 
respective lane). 
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Figure 30: Effect of nocodazole on DYRK1A Ser748 phosphorylation. 
A. HeLa cells were transiently transfected with wild-type GFP-DYRK1A (WT) or GFP-
DYRK1A S748A and cells were treated with nocodazole (50 ng/ml; Noc) for 16 h or left 
untreated as indicated. Whole cell extracts were analyzed by immunoblotting with 
phospho-specific anti-pSer748 and anti-DYRK1A antibodies. Mitotic arrest by nocodazole 
treatment was determined by detecting the highly phosphorylated endogenous SF3B1 
protein (pSF3B1) using anti-pThr434 antibody. Black arrow marks GFP-DYRK1A, 
arrowheads mark the three variants of endogenous DYRK1A and # the background signal 
of anti-pSer748 due to the use of the same secondary antibody. B. HEK_GFP-DYRK1A 
cells induced with doxycycline (2 µg/ml) for 2 d were treated with nocodazole (100 ng/ml; 
Noc) for 16 h or left untreated. GFP-DYRK1A was partially purified by IMAC and 
analyzed by immunoblotting with anti-pS748 and anti-DYRK1A antibodies. The ratio of 
anti-pSer748 to anti-DYRK1A antibody is shown below the respective lanes and was 
determined by densitometry using the AIDA software. The position of marker proteins (in 
kilodaltons) is indicated. Arrows mark the three variants of GFP-DYRK1A.  
                                                                                                                                                                         Results 
 
 69 
In the experiments shown above, endogenous DYRK1A was not recognized at 
detectable levels by the phospho-specific anti-pSer748 antibody 
(Fig. 31, arrowheads). However, detecting endogenous DYRK1A with the anti-
DYRK1A antibody revealed a shift of the bands when treated with 20 nM of 
Calyculin A (Fig. 31, lane 3+6). With higher concentrations of Calyculin A, the 
recognition by the anti-DYRK1A antibody was lower, suggesting that the endogenous 
protein is phosphorylated on different sites and thereby many different variants of 
DYRK1A are generated with different phosphorylation levels and different molecular 
masses. This would lead to a diffuse and weak signal. 
In summary, GFP-DYRK1A from mitotic cells behaves like in asynchronous 
cells. Prevention of dephosphorylation also results in a mobility shift of GFP-DYRK1A 
in mitotic cells. However, upregulation of Ser748 phosphorylation was not detectable 
in mitotic cells treated with Calyculin A, suggesting that fast dephosphorylation by 
PP1A and PP2A is not responsible for this event.  
 
 
 
Figure 31: Effect of Calyculin A on DYRK1A Ser748 phosphorylation in mitotic cells. 
HeLa cells transiently transfected with wild-type GFP-DYRK1A (WT) were treated with 
nocodazole (50 ng/ml; Noc) for 16 h or left untreated as indicated. Different concentrations 
of Calyculin A were added 1 h before lysis and whole cell extracts were analyzed by 
immunoblotting with anti-pSer748 and anti-DYRK1A antibodies. The ratio of anti-
pSer748 to anti-DYRK1A antibody signal is shown below the respective lanes and was 
determined by densitometry using the AIDA software. Black arrow marks GFP-DYRK1A, 
arrowheads mark the three variants of endogenous DYRK1A and # an unspecific signal.  
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4.2.3 Posttranslational modifications of DYRK1A during mitotic exit 
 
4.2.3.1 Establishment of cell cycle synchronization 
To investigate posttranslational modifications of DYRK1A during the cell cycle,         a 
protocol for synchronization had to be established and verified. Two methods for 
synchronization were chosen a) the double thymidine block (early S phase block) and 
b) the thymidine-nocodazole block (mitotic block) (ref: www.sbcellcycle.org; State-of-
the-art in human cell synchronization; DIAMONDS Deliverable 1-D1.1.3). For cell 
cycle analysis, two cell lines were examined:  
a) The HeLa cell line which is a well-characterized cell line in cell cycle research and 
is simple to transfect even during synchronization. Furthermore, the Ser748 
phosphorylation was originally identified in HeLa cells (Daub et al. 2008).  
b) The PC12_GFP-DYRK1A cell line which overexpresses GFP-DYRK1A under the 
control of a doxycycline-inducible promoter at endogenous level and thereby 
transfection of the cells can be avoided. In addition, PC12 is a neuronal cell line and 
serves to determine if findings in HeLa are cell type specific. Further, neuronal cells 
are able to exit the cell cycle and differentiate, and a role of DYRK1A in premature 
neuronal differentiation has been reported (Yabut et al. 2010). 
Cells were released from cell cycle arrest by washing out of thymidine or 
nocodazole respectively and then collected at indicated time points. To verify cell 
cycle transition and to assign the time points to the phases of cell cycle,                 
cell synchrony was monitored by flow cytometry (FACS) of propidium iodide-stained 
cells (Fig. 32A and C). 56.6 % of thymidine-released cells reached G2/M phase after 
6 h and 9 h after thymidine release 61.8 % of the cells exit mitosis while still 28.3 % 
remained in G2/M phase, as estimated from the flow cytometry data (Fig. 32A and B). 
Nocodazole-induced arrest in G2/M phase is more efficient (Fig. 32C and D). 
Synchronization was also monitored by immunoblotting with antibodies against        
a) Cyclin D1, which is downregulated in S phase (see Introduction 1.3.1.2), b) histone 
H3 phosphorylation on Ser10 as marker of mitosis (Hendzel et al. 1997) and            
c) retinoblastoma protein (RB) phosphorylation on Ser807/Ser811, which is 
dephosphorylated at mitotic exit up to early G1 phase (see Introduction 1.3.1.1). 
Arrest by double thymidine or nocodazole block efficiently synchronizes cells 
in early S phase or M phase, respectively (Fig. 32B and D) and release from such an 
arrest is an adequate method to analyze cell cycle dependent events. 
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A         Double thymidine block release 
                              HeLa cells 
C      Thymidine nocodazole block release 
                  PC12_GFP-DYRK1A cells 
B             Double thymidine block release 
                                 HeLa cells 
D         Thymidine nocodazole block release 
                         PC12_GFP-DYRK1A 
 
E F 
 
Figure 32: Cell cycle synchronization. 
A. Synchronization at the G1/S transition by a double thymidine block. HeLa cells were 
treated with 2 mM thymidine for 19 h, released in fresh medium for 9 h and then treated 
again with 2 mM thymidine for 17 h. Cells were collected at the indicated time points     
(0, 6, 7.5, 9, 9.5, 10, 10.5, 11 h) after release from the second thymidine block. Cells were 
fixed and stained with propidium iodide and the DNA content (2n, diploid; 4n, tetraploid) 
was analyzed by flow cytometry (FACS). B. FACS profile of the double thymidine block-
released cells shown in A. C. G2/M arrest by thymidine nocodazole treatment. PC12_GFP-
DYRK1A cells were treated with 2 mM thymidine for 24 h, released in fresh medium for 
3 h and treated with nocodazole (100 ng/ml) for 16 h. Cells were collected at the indicated 
time points (0, 0.5, 1, 2, 3, 4, 5, 9.5, 11.5 h) after release from the nocodazole block. Cells 
were fixed, stained and analyzed like in A. D. FACS profile of the thymidine nocodazole 
block-released cells shown in C. E and F. Scheme of treatment. Thy, thymidine; Noco, 
nocodazole. 
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4.2.3.2 Ser748 phosphorylation of DYRK1A during the cell cycle 
As no upregulation on Ser748 phosphorylation of DYRK1A was observed in cells 
arrested in G2/M phase, the phosphorylation on Ser748 was further analyzed during 
the cell cycle. Previous results (Fig. 30A) showed that endogenous DYRK1A Ser748 
phosphorylation was not detectable in whole cell lysates, therefore the stable cell line 
PC12_GFP-DYRK1A which expresses GFP-DYRK1A under the control of a 
doxycycline-inducible promoter, was used to avoid transient transfection or 
purification of endogenous DYRK1A.  
PC12_GFP-DYRK1A cells induced with doxycycline and synchronized by 
double thymidine block were released and harvested at indicated time points for 
Western blot analysis. By monitoring the phosphorylation state of histone H3, the     
M phase was revealed to take place around 7.5 to 10.5 h after thymidine block 
release (Fig. 33A and C). The phosphorylation of Ser748 in GFP-DYRK1A 
(Fig. 33B and D, arrow) did not change significantly during progressing through the 
cell cycle. Strikingly, the protein levels of GFP-DYRK1A and endogenous DYRK1A 
were quite similar, but the phospho-specific anti-pSer748 antibody failed to detect the 
endogenous DYRK1A. Nevertheless, the phospho-specific anti-pSer748 antibody 
was used in the following experiments. 
Together with the previous results, these data indicate that Ser748 
phosphorylation of GFP-DYRK1A does not alter during the cell cycle. 
 
4.2.3.3 Degradation of DYRK1A during mitotic exit 
Unexpectedly, the cell cycle experiments revealed a variability of DYRK1A protein 
level at different stages of the cell cycle (Fig. 33B, time points 0, 9.5, 10 and 11 h). 
Therefore all independent experiments have been compared and it has been decided 
to focus on the time points where downregulation of DYRK1A protein level was 
consistently observed (Fig. 33B and D, time points 9, 9.5, 10 h). These time points 
correspond to late M phase or mitotic exit (see Results 4.2.3.1 and 4.2.3.2).  
Notably, GFP-DYRK1A was degraded at the same time points as endogenous 
DYRK1A (Fig. 33B and D, arrow and arrowheads). As expression of exogenous 
GFP-DYRK1A is not modulated by the endogenous DYRK1A promoter, the 
downregulation of DYRK1A protein level does not take place at a transcriptional 
level, but rather indicates degradation of the DYRK1A protein during mitotic exit. 
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A      
 PC12_GFP-DYRK1A+Dox 
 
Time (h) thymidine release 
 
C     
             PC12_GFP-DYRK1A+Dox 
 
             Time (h) thymidine release 
 
B  
            PC12_GFP-DYRK1A+Dox 
                 Time (h) thymidine release 
 
 
 
D 
              PC12_GFP-DYRK1A+Dox 
                 Time (h) thymidine release 
 
 
 
 
 
Figure 33: DYRK1A is degraded during M/G1 transition. 
PC12_GFP-DYRK1A cells were induced with doxycycline (2 µg/ml, +Dox) and 
synchronized at the G1/S transition by a double thymidine block or left untreated            
(as, asynchronous). Cells were collected at the indicated time points after release from the 
second thymidine block. Whole cell lysates were subjected to a 15% (A and C) or 10%    
(B and D) SDS gel and analyzed in Western blot with indicated antibodies (with β-Actin as 
a loading control). Arrow marks exogenous GFP-DYRK1A and arrowheads mark 
endogenous DYRK1A. Two independent experiments are shown, were A + B and C + D 
show samples from the same whole cell lysates. 
 
 
To confirm that the degradation of DYRK1A in late mitosis is not an artifact 
caused by the thymidine treatment and is not a PC12 cell specific event, HeLa cells 
were synchronized in parallel with PC12_GFP-DYRK1A at G2/M using nocodazole. 
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Synchronization was verified by the phospho-specific anti-pRB antibody (see 
Introduction 1.3.1.1). RB was dephosphorylated 2 h after release from nocodazole 
block and rephosphorylated after 5 h, indicating that cells exit mitosis between these 
time points (Fig. 34). This is consistent with a previous report that Ser807 of RB is 
dephosphorylated at mitotic exit (Rubin et al. 2001). Further, SF3B1 exhibits a slower 
migrating variant on SDS gels during mitosis (Fig. 34, upper arrow) what supports the 
determination of the mitotic exit between 2 and 5 h after nocodazole-release. 
Degradation of DYRK1A was detectable in both cell lines and at the same time points 
(Fig. 34, arrowhead), and again exogenous GFP-DYRK1A (asterisk) shows the same 
pattern as endogenous DYRK1A. As described above, GFP-DYRK1A in PC12 cells 
show much higher levels of Ser748 phosphorylation than the endogenous DYRK1A, 
but no change of phosphorylation level was observed during the cell cycle. 
As a conclusion, these results support that downregulation of DYRK1A occurs 
by degradation specifically during late mitosis and is cell type independent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
     
                                       HeLa                        PC12_GFP-DYRK1A+Dox 
 
                                                   Time (h) nocodazole release 
 
Figure 34: DYRK1A degradation during mitotic exit. 
HeLa or PC12_GFP-DYRK1A cells induced with doxycycline (2 µg/ml, +Dox) were 
synchronized at the G2/M phase by nocodazole block. Cells were collected at the indicated 
time points after release from the cell cycle block. Whole cell lysates were analyzed in 
Western blot with indicated antibodies (with β-Actin as a loading control). Asterisk marks 
exogenous GFP-DYRK1A, arrowhead endogenous DYRK1A and arrows the two variants 
of SF3B1.  
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4.2.3.4 Degradation of DYRK1A during mitotic exit is inhibited by MG132 
The anaphase-promoting complex or cyclosome (APC/C) is an E3 ubiquitin ligase 
which targets substrate proteins for destruction by the 26S proteasome and is active 
during mitosis and in the G1 phase (Peters et al. 2006). As protein levels of DYRK1A 
were decreased at mitotic exit, we addressed the question if the APC/C-26S 
proteasome system is involved in DYRK1A degradation. 
PC12_GFP-DYRK1A induced with doxycycline were synchronized at G2/M 
with nocodazole and released into fresh medium containing MG132, a specific 
proteasome inhibitor, or left untreated. As expected, cells released from nocodazole 
block in the absence of MG132 showed decreased levels of DYRK1A at mitotic exit 
(Fig. 35A, 0.5, 1, 2 h), but cells treated with MG132 failed to show DYRK1A 
degradation (Fig. 35A). Strikingly, MG132-treatment also affected dephosphorylation 
of RB (Fig. 35A, grey arrow), dephosphorylation of histone H3 (Fig. 35B) and the 
disappearance of the slow migrating variant of SF3B1 (Fig. 35A, black arrows), 
indicating that exit from mitosis is retarded or partially inhibited. 
This experiment suggests that DYRK1A degradation could be mediated by the 
proteasome and the time points imply the involvement of the ubiquitin ligase APC/C 
(see Discussion 5.2.6). 
 
4.2.3.5 Degradation of overexpressed DYRK1A is independent of its kinase 
activity 
To analyze if kinase activity of DYRK1A is required for its degradation at mitotic exit, 
HeLa cells overexpressing wild-type GFP-DYRK1A or the kinase deficient DYRK1A 
K188R mutant were synchronized by double thymidine block. Both GFP-DYRK1A 
variants showed a decrease of protein level 10 h after release from thymidine block 
(Fig. 36A and C). The same is observed for endogenous DYRK1A (Fig. 36A and C, 
arrowhead). Again, no changes in Ser748 phosphorylation levels for wild-type GFP-
DYRK1A was detectable (Fig. 36A). Antibodies against Cyclin D1, downregulated 
during S phase, and histone H3 phosphorylation determine the time point of 
degradation to the late mitosis (Fig. 36B and D). Detection with the anti-GFP 
antibody, which recognizes the N-terminal GFP-tag of DYRK1A, revealed a stepwise 
C-terminal degradation of the protein (Fig. 36A and C, dots). These fragments are not 
detectable with the anti-DYRK1A antibody that is directed against the last 90 amino 
acids in the C-terminal region of DYRK1A. As the anti-DYRK1A antibody is able to 
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detect the GFP-DYRK1A ∆C19 mutant (Fig. 37A) the longest fragment must be 
truncated in the C-terminal region between amino acid 674 and 744. 
 
 
A                                  PC12_GFP-DYRK1A+Dox 
 
                                                Time (h) nocodazole release 
 
B                                   PC12_GFP-DYRK1A+Dox 
 
                                                Time (h) nocodazole release 
 
Figure 35: DYRK1A degradation is inhibited by MG132. 
A. and B. PC12_GFP-DYRK1A cells induced with doxycycline (2 µg/ml, +Dox) were 
arrested at the G2/M by nocodazole treatment and then released into fresh medium in the 
presence or absence of 20 µM MG132, a 26S proteasome inhibitor. At the indicated time 
points after release from the cell cycle block cells were collected and whole cell lysates 
were subjected to a 10% (A) or 15% (B) SDS gel and analyzed in Western blot with 
indicated antibodies. Asterisk marks exogenous GFP-DYRK1A, arrowhead endogenous 
DYRK1A, black arrows the two variants of SF3B1 and grey arrow phosphorylated 
retinoblastoma protein (RB). 
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A          HeLa, GFP-D1A WT 
            Time (h) thymidine release 
 
 
C            HeLa, GFP-D1A KR 
                            Time (h) thymidine release 
B      
            HeLa, GFP-D1A WT 
           
                   Time (h) thymidine release 
D  
               HeLa, GFP-D1A KR 
 
                     Time (h) thymidine release 
    
Figure 36: DYRK1A is degraded at mitotic exit independently of its kinase activity. 
HeLa cells were transiently transfected with plasmids expressing wild-type GFP-DYRK1A 
(WT) or the kinase dead mutant GFP-DYRK1A K188R (KR) 2 h after release from the 
first thymidine block. 2 h post-transfection cells were washed and 5 h later the second 
thymidine block was performed (see Fig. 32E). G1/S synchronized cells were collected at 
the indicated time points after release from the second thymidine block. Whole cell lysates 
were subjected to a 10% (A and C) or 15% (B and D) SDS gel and analyzed in Western 
blot with indicated antibodies (with β-Actin as a loading control). Arrowhead marks 
endogenous DYRK1A, dots the truncated variants of GFP-DYRK1A WT or KR and 
arrows mark the two variants of SF3B1. A + B and C + D show samples from the same 
whole cell lysates. 
 
Notably, the degradation of β-Actin, which was thought to serve as a loading 
control (Fig. 36A-D), suggests that all proteins undergo degradation 9.5 h after 
thymidine block release. But Cyclin D1 protein levels remained stable (Fig. 36B 
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and D). In addition, Coomassie staining of an independent gel, using the protein 
lysates of wild-type GFP-DYRK1A overexpressing cells, confirmed that not all 
proteins were degraded unspecifically (data not shown).  
As β-Actin is a target of caspases (Mashima et al. 1995), the C-terminal 
truncation pattern of DYRK1A is similar to patterns obtained by caspase cleavage 
and the point that Cyclin D1 levels (degradation via ubiquitinylation) are not affected 
suggest that degradation observed in this overexpression experiments may rather be 
triggered by caspase cleavage than proteasomal destruction (see Discussion 5.2.6). 
These data demonstrate a C-terminal degradation of overexpressed GFP-
DYRK1A during mitotic exit, which is independent of its kinase activity. 
 
4.2.3.6 Catalytically active DYRK1A interferes with RB dephosphorylation 
The phosphorylation status of RB is a crucial regulation mechanism for cell cycle 
control (see Introduction 1.3.1.1). As RB is sequentially phosphorylated at multiple 
Ser/Thr residues, dephosphorylation occurs also sequentially and is temporally 
regulated (Rubin et al. 2001). Phosphoprotein phosphatase 1 (PP1) 
dephosphorylates RB at mitotic exit. In our study we used a phospho-specific anti-
pRB antibody that recognizes the phosphorylated residues Ser807/811. As reported, 
Ser807 is dephosphorylated 30 min after mitotic release (Rubin et al. 2001).  
The pattern of phosphorylated RB differed markedly between HeLa cells 
overexpressing wild-type GFP-DYRK1A or kinase inactive GFP-DYRK1A KR after 
release from double thymidine block. The phosphorylation level of RB declined 
rapidly 7.5 h after thymidine release and remained at low level (Fig. 36C, 7.5-9.5 h) 
when the cells overexpressed the kinase dead mutant of DYRK1A (KR). In contrast, 
this dephosphorylation was not observed in cells overexpressing wild-type GFP-
DYRK1A (Fig. 36A, 7.5-9.5 h). Following the histone H3 phosphorylation, which 
reached its maximum around 7.5 h after thymidine release, cells can be considered 
to be in M phase (Fig. 36B and D). Furthermore, phosphorylation level of histone H3 
after 10 h of thymidine block release did not decrease obviously in HeLa cells 
overexpressing wild-type GFP-DYRK1A, compared to cells overexpressing GFP-
DYRK1A KR (Fig. 36B and D, 10-11.5 h).  
The experiment was also performed with HeLa cells overexpressing GFP-
DYRK1A ∆C19 or unfused GFP. GFP-DYRK1A ∆C19 (Fig. 30A) showed the same 
degradation pattern as wild-type and the kinase dead mutant of GFP-DYRK1A 
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(Fig. 36A and C). Unfused GFP was not degraded at mitotic exit, confirming that not 
all proteins were degraded unspecifically. Consistent with the results for wild-type 
GFP-DYRK1A, the catalytically active GFP-DYRK1A ∆C19 mutant prevented the 
dephosphorylation of RB (Fig. 37A, 7.5-9.5 h). But, the effect on histone H3 
dephosphorylation was not as strong for GFP-DYRK1A ∆C19 (Fig. 37B) as for wild-
type GFP-DYRK1A (Fig. 36B). Overexpression of unfused GFP did not affect 
dephosphorylation of RB (Fig. 37C, 10-11.5 h) or histone H3 (Fig. 37C, 10-11.5 h).  
To summarize this data, it appears that RB dephosphorylation is prevented at 
mitotic exit when catalytic active GFP-DYRK1A is overexpressed.  
 
4.2.3.7 The C-terminus of DYRK1A is essential for interference with RB and 
histone H3 dephosphorylation 
Considering that GFP-DYRK1A underwent cleavage at sites in the C-terminal domain 
at mitotic exit and that the GFP-DYRK1A ∆C19 mutant lacking the Ser748 showed 
similar behavior towards the dephosphorylation of RB like wild-type GFP-DYRK1A, 
the question was addressed whether the regions outside the catalytic domain are 
crucial for the interference with RB dephosphorylation. 
Therefore deletion mutants of GFP-DYRK1A were generated (Fig. 38A). As 
catalytic activity of DYRK1A is necessary for interference with RB dephosphorylation 
(see Results 4.2.3.6), the catalytic activity of the three deletion mutants was 
investigated. First, the three deletion mutants, immunoprecipitated with anti-GFP 
antibody, phosphorylated the peptide substrate DYRKtide in an IVK assay (data not 
shown). Second, GFP-SF3B1 ∆256-382 was phosphorylated on Thr434 by all three 
deletion mutants when co-expressed in HeLa cells (data not shown).  
Summarized, GFP-DYRK1A ∆C, GFP-DYRK1A ∆N and GFP-DYRK1A ∆C∆N 
are enzymatically active kinases in vitro and in living cells. 
In order to study the impact of the C-terminal region of DYRK1A on RB 
dephosphorylation at mitotic exit, HeLa cells overexpressing wild-type GFP-DYRK1A, 
the deletion mutants or unfused GFP were released from double thymidine block and 
harvested at indicated time points (Fig. 38B-F) similar to the experiment shown in 
Fig. 35 and Fig. 36. 
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A            HeLa, GFP-D1A ∆C19aa 
                            Time (h) thymidine release 
 
C           HeLa, GFP 
                            Time (h) thymidine release 
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                               Time (h) thymidine release 
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                             Time (h) thymidine release 
 
 
 
 
Figure 37: DYRK1A interferes with RB dephosphorylation. 
HeLa cells were transiently transfected with plasmids expressing GFP-DYRK1A ∆C19aa 
or unfused GFP 2 h after release from the first thymidine block. 2 h post-transfection cells 
were washed and 5 h later the second thymidine block was performed (see Fig. 32E). G1/S 
synchronized cells were collected at the indicated time points after release from the second 
thymidine block. Whole cell lysates were subjected to a 10% (A and C) or 15% (B and D) 
SDS gel and analyzed in Western blot with indicated antibodies (with β-Actin as a loading 
control). Arrowhead marks endogenous DYRK1A, dots the truncated variants of GFP-
DYRK1A ∆C19 and arrows mark the two variants of SF3B1. A + B and C + D show 
samples from the same whole cell lysates. 
 
In contrast to the previous experiment, dephosphorylation of RB occurred 3 h 
after thymidine release (Fig. 38C and E-F) and not 7.5 h (Fig. 36C and Fig. 37C). 
Analysis using the histone H3 phosphorylation antibody revealed that this time point 
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corresponds to mitosis (Fig. 39A-E). Histone H3 phosphorylation was upregulated 6 h 
after thymidine release and Cyclin D1 was downregulated at time point 0 h and 
present at time point 3 h. Therefore cells harvested at time point 3 h after thymidine 
release, correspond to G2 phase. RB dephosphorylation 3 h after thymidine release 
did not occur in HeLa cells overexpressing wild-type GFP-DYRK1A (Fig. 38B, time 
point 3 h), whereas in cells expressing unfused GFP, RB is dephosphorylated 
(Fig. 38F). Overexpressing the catalytic domain of DYRK1A, as represented in GFP-
DYRK1A ∆C∆N, did not interfere with dephosphorylation of RB (Fig. 38C, time point 
3 h). The N-terminal deleted fusion protein (Fig. 38D, time point 3 h) showed the 
same RB phosphorylation state as wild-type GFP-DYRK1A suggesting that the 
deletion of this region is not essential for the interference. In contrast, deletion of the 
C-terminal region of DYRK1A eliminated the ability of DYRK1A to affect RB 
dephosphorylation (Fig. 38E). 
These results suggest that the C-terminal region is required for the effect of 
DYRK1A on RB phosphorylation level in G2 phase. 
Following the phosphorylation of RB in HeLa cells expressing unfused GFP 
and released from thymidine block, the expected dephosphorylation of RB occurred 
at time point 11 h (Fig. 38F). Compared to the histone H3 phosphorylation (Fig. 39E), 
this time point can be determined to mitotic exit or early G1 phase. Consistent with 
the pattern obtained at time point 3 h, N-terminally deleted fusion protein of DYRK1A 
behaved like wild-type GFP-DYRK1A and showed a dephosphorylation of RB 
(Fig. 38B and D) and of Histone H3 (Fig. 39A and C), suggesting exit from mitosis. In 
contrast, in cells expressing the catalytic domain or the C-terminal deletion mutant of 
DYRK1A the dephosphorylation of RB (Fig. 38C and E), the dephosphorylation of 
histone H3 (Fig. 39B and D) and thus exit from mitosis was prevented. 
In summary, these experiments suggest that DYRK1A might interfere with 
crucial mechanisms of cell cycle control, such as the dephosphorylation of RB 
(directly or indirectly) and that DYRK1A degradation at mitotic exit could be an 
essential event to enter the next stage of the cell cycle. However, more experiments 
are required to elucidate the role of DYRK1A and the role of the C-terminal region of 
DYRK1A in cell cycle and above all at mitotic exit. 
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A B                            HeLa, GFP-D1A WT  
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C                              HeLa, GFP-D1A ∆C∆N 
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                                Time (h) thymidine release 
F                                   HeLa, GFP 
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Figure 38: C-terminal deletion of DYRK1A interferes with RB dephosphorylation. 
A. Schematic illustration of the deletion constructs of GFP-DYRK1A. B.-F. HeLa cells 
were transiently transfected with plasmids expressing wild-type GFP-DYRK1A (B), 
indicated GFP-DYRK1A deletion mutants (C-E) or unfused GFP (F) during double 
thymidine block (see Fig. 32E). G1/S synchronized cells were collected at the indicated 
time points after release from the second thymidine block. Whole cell lysates were 
analyzed in Western blot with indicated antibodies (with β-Actin as a loading control). 
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Figure 39: C-terminal deletion of DYRK1A alters dephosphorylation of Histone H3. 
A-E. HeLa cells were transiently transfected with plasmids expressing wild-type GFP-
DYRK1A (A), indicated GFP-DYRK1A deletion mutants (B-D) or unfused GFP (E) 
during double thymidine block (see Fig. 32E). G1/S synchronized cells were collected at 
the indicated time points after release from the second thymidine block. Whole cell lysates 
were analyzed in Western blot with indicated antibodies (with β-Actin as a loading 
control).  
Discussion 
 
84  
5. Discussion 
 
5.1 DYRK4 
The mammalian DYRK family consists of 5 members, of which DYRK1A, DYRK1B, 
DYRK2 and DYRK3 have been extensively studied due to their roles in cell 
differentiation and survival, and their critical participation in processes such as 
neurogenesis or cancer (Aranda et al. 2010). By contrast, very little is known about 
the fifth member of the family, DYRK4. This study revealed several features of 
mammalian DYRK4 that are common to DYRK kinases, such as the mode of 
activation or the subcellular distribution as a regulatory mechanism. Furthermore, 
different substrate specificity characterized during this work could be important for 
establishing functional differences between DYRK family members. 
 
5.1.1 Alternative promoter use and alternative splicing of DYRK4  
Several different transcripts of human and mouse DYRK4 are expressed, each 
encoding distinct protein products, due to alternative promoter use and first exon 
choice, as evident for other mammalian DYRK genes (reviewed in Aranda et al. 
2010). 
In this study, the genomic structure of human DYRK4 was defined and a new 
isoform (hDYRK4644) was identified which has a different 5’-terminal sequence 
containing at least one motif (Fig. 7B) which is not present in the short variant 
previously described (hDYRK4520). The new splicing variant of DYRK4 is present in 
mouse and human (Fig. 7A-C). Tissue distribution of the long isoform differs from   
the short one, with the long isoform present in several human tissues and the short 
isoform predominantly expressed in testis (Fig. 8A). Further, as the additional          
N-terminal sequence is conserved in mammals (Fig. 7C) the longer isoform can be 
considered as the reference sequence for DYRK4. Use of alternative promoters 
probably underlies the differential expression pattern of the two DYRK4 5’ variants in 
human tissues. 
By distinct alternative splicing events, further variants are generated, some of 
which lead to small in-frame deletions/insertions while others give rise to aberrant 
protein products. Exon 6 can be alternatively spliced out in-frame, generating            
a deletion of 9 amino acids in the N-terminal domain similar to a variant of DYRK1A 
(reviewed in Aranda et al. 2010). The ratio of these two splice variants, with or 
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without exon 6, differs in tissues and in cell lines (Fig. 8A and B). This suggests the 
existence of a regulatory mechanism for this alternative splicing event and the 
possibility that each protein isoform fulfils a distinct functional role. The presence of 
exon 7 differs also in tissues and in cell lines (Fig. 8A and B). Insertion of exon 7 
leads to the appearance of an in-frame stop codon and the generation of a short 
truncated protein. However, if the ATG in exon 8 is used as the initiator codon,          
a 571 amino acid protein may be produced. These upstream open reading frames 
(uORFs) are not unusual in human genes and can cause a reduction of protein 
expression (Calvo et al. 2009).  
 
5.1.2 DYRK4 gene expression 
DYRK4 gene expression has been reported to be restricted to the testis in rodents 
(Becker and Joost, 1999; Sacher et al. 2007), but the expression of human DYRK4 
mRNA was detected in all the tissues analyzed (Fig. 8A). Further, it should be noted 
that human DYRK4 has also been described to be expressed in NTera, a human 
neuronal precursor cell line, where it is upregulated during retinoic acid induced 
differentiation (Leypoldt et al. 2001), in SH-SY5Y neuroblastoma cells, where DYRK4 
is upregulated by tunicamycin-induced ER stress (Reimertz et al. 2003), in MCF-7 
breast cancer cells, where it is upregulated by XBP1 (X-box binding protein-1) 
overexpression (Gomez et al. 2007), but downregulated by tanshinone IIa (Wang et 
al. 2005) and in Jurkat cells (T cell lymphoblast-like cells) (Gwack et al. 2006).  
Bringing these findings together with the results of this study, human DYRK4 
shows a broad pattern of expression in various tissues and cell lines (Fig. 8A and B) 
that suggests a functional discrepancy between mouse and humans, and which 
severely limits the value of mouse models for the functional analysis of human 
DYRK4. The unusually low degree of sequence conservation between human and 
mouse DYRK4 (93% of amino acid identity in the catalytic domain; 63% in the         
N-terminal and 47% in the C-terminal region) when compared with other orthologous 
DYRK pairs (e.g. human and rat DYRK1A: 3 of 763 amino acids differ) propose that 
DYRK4 has acquired different functions during evolution. Therefore the described 
Dyrk4 deficient mice which are vital and fertile (Sacher et al. 2007) may not display   
a valid model to elucidate the role of DYRK4 in humans. 
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5.1.3 A putative role of DYRK4 in the unfolded protein response 
In this study, the mRNA of the newly identified long DYRK4 isoform (hDYRK4644) has 
been observed to be strongly upregulated by tunicamycin treatment in SH-SY5Y 
cells, but in contrast DYRK4 in general (using oligonucleotides matching the catalytic 
domain) showed only a twofold induction (Table 7).  
Tunicamycin induces unfolded protein response (UPR), a cellular stress 
response conserved between all mammalian species, including yeast and worm. 
Inhibition of protein glycosylation by tunicamycin leads to accumulation of unfolded 
proteins in the ER lumen. This so-called ER stress has been suggested to play a role 
in the pathogenesis of neurodegenerative disorders such as Alzheimer’s disease 
(Sherman and Goldberg, 2001). Proteins upregulated by ER stress have been 
classified with respect to their expression kinetics. Early response proteins include 
molecular chaperones aiming to alleviate ER stress and late response proteins 
trigger an evolutionary conserved caspase-dependent apoptosis (Perez-Sala and 
Mollinedo, 1995). DYRK4 has been found to be an intermediate tunicamycin-induced 
response gene (Reimertz et al. 2003). Using the same cell line and conditions, the 
effect of tunicamycin on DYRK4 has been verified in this study. A second hint that 
DYRK4 may play a role in the UPR is the report that it is upregulated by XBP1 
overexpression (Gomez et al. 2007). Human XBP1 is a transcription factor that 
participates in the UPR and is persistently activated due to tunicamycin treatment 
(Reimertz et al. 2003).  
Taken together, these findings strongly suggest a role of DYRK4 in the UPR, 
but further studies are required to elucidate whether DYRK4 is involved in the early 
response pathway, supporting survival of the cell, or in the late response pathway, 
initiating apoptosis. 
 
5.1.4 The subcellular localization of DYRK4 could represent a 
regulatory mechanism 
Several mechanisms including active nuclear import, active nuclear export, and 
nuclear or cytosolic retention regulate the subcellular localization of proteins larger 
than 45 kDa (exclusion size of the nuclear pore), such as DYRK4. The results of this 
study show that all these mechanisms could act on DYRK4 and they might indeed 
modulate the biological activity of DYRK4 by altering the accessibility of substrates or 
modulators in particular subcellular compartments.  
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The short isoform of human DYRK4, GFP-DYRK4520, was localized in the 
cytosol of COS-7 cells (Sacher et al. 2007). Subcellular localization of the newly 
identified long DYRK4 isoform (hDYRK4644 or mDYRK4642) is different. Its extended 
N-terminal region, which is highly conserved (Fig. 7C), accounts for this difference. 
Our collaborators showed that the N-terminal extension harbours a classic NLS 
based on the binding to importin α, and on the nuclear import of a heterologous 
protein when fused to it (Papadopoulos et al. 2011). In addition, the extended          
N-terminal region mediates the nuclear retention of the long isoform (hDYRK4644 or 
mDYRK4642), as suggested by the lack of nucleocytoplasmic shuttling in FLIP 
experiments (Fig. 10A and B). Detectable amounts of hDYRK4520 and mDYRK4594, 
which lack the conserved N-terminal NLS, were found in the nucleus, which suggests 
that a second NLS could exist in DYRK4, such as that described between the kinase 
subdomains X and XI in DYRK1A (Alvarez et al. 2003). The DYRK4 long isoform was 
only partially localized in the nucleus suggesting that full nuclear accumulation      
was prevented by mechanisms such as strong CRM1-independent nuclear export, 
NLS masking or an interaction with cytosolic proteins. Further research will help 
uncovering the signals that modulate the subcellular localization of DYRK4. 
Regulated nuclear translocation has been demonstrated for DYRK2 or yeast Yak1p 
in response to extracellular signals (Moriya et al. 2001; Taira et al. 2007) 
(see Introduction 1.2.5). This could be a common feature of the DYRK family of 
kinases.  
Summarized, and given that NLSs have been identified in DYRK4 (this study) 
and DYRK2 (Taira et al. 2007), and that DYRK3 is also at least partially localized in 
the nucleus (Lord et al. 2000; Guo et al. 2010), the distinction of “cytosolic” class II 
DYRKs from the “nuclear” class I DYRKs must be regarded as an oversimplification 
of the complex behaviour of these kinases.  
 
5.1.5 DYRK4 is phosphorylated by cellular kinases 
The characteristic migration of DYRK4 as a doublet in SDS gels, where the slower 
migrating band disappeared after phosphatase treatment (Fig. 11), show similarity to 
the fly orthologue of DYRK4, dDYRK2, which is the only DYRK protein migrating as  
a doublet due to phosphorylation in non-treated cells reported so far (Lochhead et al. 
2003). Strikingly, for dDYRK2 the appearance of the doublet depends on 
autophosphorylation, but in case of DYRK4 catalytic activity is not required as the 
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kinase inactive version shows the same doublet as wild-type DYRK4 (Fig. 11). 
Furthermore, our collaborators identified phosphorylated residues outside the 
catalytic domain in both wild-type and kinase inactive hDYRK4520 using mass 
spectrometry analysis (Papadopoulos et al. 2011).  
Phosphorylation of the second tyrosine residue within the activation loop   
(Tyr-X-Tyr motif) appears to be necessary for full activity of DYRK4, like in other 
DYRK kinases (reviewed in Aranda et al. 2010). Once expressed, DYRK kinases are 
constitutively active, but the activity of some DYRKs can be modulated post-
translationally by phosphorylation on serine/threonine residues. 
Regulatory phosphorylation of other DYRK kinases by upstream kinases has 
been reported recently, as in the case of yeast Yak1 by PKA (protein kinase A), worm 
MBK-2 by CDK-1 (cyclin-dependent kinase 1), mammalian DYRK2 by MAP3K10 
(mitogen-activated protein kinase kinase kinase 10) or ATM (ataxia telangiectasia 
mutated) (Lee et al. 2011; Cheng et al. 2009; Varjosalo et al. 2008; Taira et al. 2010).  
In conclusion, human DYRK4 is phosphorylated by cellular kinases and this 
phosphorylation could affect its subcellular localization, kinase activity or interaction 
with other proteins. 
 
5.1.6 Substrate specificity of DYRK4  
The new identified peptide substrate Pep285 is significantly phosphorylated by 
DYRK4 but not by DYRK1A (Fig. 14B and C). As no substrate for DYRK4 is known, 
this peptide can be used to analyze the specificity of DYRK inhibitors in vitro and their 
effect on their family members.  
Up to now, substrate specificity of DYRK kinases has been little explored, 
although DYRK1A, DYRK2 and DYRK3 have previously been reported to differ in 
their specificities towards protein and peptide substrates (Becker et al. 1998; 
Campbell and Proud et al. 2002). However, only a few substrates were compared in 
these studies since the experiments were directed towards systematically analyzing 
the importance of specific residues in a given peptide on substrate recognition.  
The experimental set-up employed by our collaborators offers a broader view 
by using an array with peptides that reflect known human phosphorylation sites 
(Papadopoulos et al. 2011). The validity of the assay was not only supported by     
the identification of two known DYRK1A phosphorylation sites but also, by the fact 
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that the majority of the peptides phosphorylated by DYRK1A match its consensus 
target sequence, with a proline at P+1 and an arginine at P-3 (Himpel et al. 2000).  
The new identified peptide substrate Pep285 does not contain an arginine     
at P-3 or P-2 (Fig. 14A). However, the relatively high number of DYRK substrates 
that do not contain an arginine residue at P-3 or P-2 contrasts with the almost 
absolute requirement for the arginine observed elsewhere (Campbell and Proud       
et al. 2002), where DYRKs were considered as arginine-directed protein kinases.          
This difference is most likely due to the fact that in the previous study, the importance 
of the arginine was only tested in the context of one specific DYRK target site 
(Ser539 in eukaryotic initiation factor 2Bε), whereas the phosphosite array contains   
a large selection of diverse peptides. One example of an arginine-independent target 
site of DYRK1A is Thr434 in SF3B1 (de Graaf et al. 2006), which is mimicked by    
the peptide SAPtide, a peptide that is phosphorylated with a similar efficiency as 
DYRKtide by both DYRK1A and DYRK4 (Fig. 14B and C).  
Given that human DYRKs appear to be co-expressed in some tissues and that 
they could be localized in the same subcellular compartments, substrate specificity 
may represent a critical factor that governs biological specificity among this family of 
protein kinases. Further research will be necessary to exactly define the structural 
determinants that distinguish target site recognition by DYRK4 from that of the other 
members of the DYRK family. Finally, Pep285 sequence could help to identify 
possible target sequences and substrates of DYRK4.   
 
 
5.2 DYRK1A 
As DYRK1A is a constitutively active protein kinase, which do not require an 
activating kinase, other control mechanisms may regulate the biological activity of 
DYRK1A. Posttranslational modification of DYRK1A can be such a mechanism     
that modulates its activity. Thus, targeting posttranslational modification of DYRK1A 
could be a tool to decrease the activity of DYRK1A.  
This study revealed Ser748 as an autophosphorylation site in DYRK1A which 
phosphorylation increases DYRK1A activity. The inhibitor harmine is able to block 
Ser748 autophosphorylation. Another mechanism to downregulate DYRK1A activity 
is its degradation. This is the first study showing regulated degradation of DYRK1A 
and suggesting its involvement in mitotic exit. Understanding the regulation of Ser748 
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autophosphorylation and the mechanism which prime DYRK1A for degradation could 
be important for the development of drug targets which could then interfere with 
these mechanisms to decrease DYRK1A activity.   
 
5.2.1 Different phosphorylation level of endogenous DYRK1A and 
GFP-DYRK1A 
Partially purified endogenous and exogenous (GFP-tagged) DYRK1A are both 
phosphorylated on Ser748 (Fig. 24). However, Ser748 phosphorylation of 
endogenous DYRK1A could not be detected in whole cell lysates. A reason for this 
might be that protein level of endogenous DYRK1A is not sufficient to allow detection 
by the phospho-specific antibody. The stable PC12_GFP-DYRK1A cell line shows  
an expression level of GFP-DYRK1A similar to endogenous DYRK1A, but still        
the phospho-specific antibody only recognizes exogenous DYRK1A in whole cell 
lysates (Fig. 34).  
A possible explanation would be that the GFP protein fused N-terminally 
directly interfere with Ser748 phosphorylation of DYRK1A by altering the 
conformation of DYRK1A and thereby indirectly changing its subcellular localization 
or interaction with cellular proteins.  
Differential subcellular localization of endogenous DYRK1A and GFP-
DYRK1A could display different phosphorylation levels. This could be due to either  
a) increased autophosphorylation activity of DYRK1A when localized in the nucleus 
or b) interaction with nuclear or cytosolic proteins, which block or promote Ser748 
phosphorylation or c) the presence of nuclear or cytosolic phosphatases. 
Overexpressed GFP-DYRK1A accumulates in the nucleus of HeLa and in neuronal 
cells, but endogenous DYRK1A is detected in both the nucleus and the cytosol 
(Aranda et al. 2010; see Introduction 1.2.5). Similar localization has been observed 
with exogenous GFP-DYRK1A when expressed at low levels in the stable 
PC12_GFP-DYRK1A cell line (Fig. 4). Distribution between both compartments 
seems to be different for endogenous DYRK1A and GFP-DYRK1A and even from 
cell to cell as observed for exogenous GFP-DYRK1A (Fig. 4).  
As a conclusion, differences on Ser748 phosphorylation levels of endogenous 
DYRK1A and GFP-DYRK1A observed in this study, suggest that GFP affects         
the function of DYRK1A in living cells.  
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5.2.2 Harmine and the Ser748 autophosphorylation of DYRK1A 
Harmine does not inhibit tyrosine autophosphorylation of GFP-DYRK1A in HEK293 
cells, and GFP-DYRK1A isolated from harmine-treated cells has similar catalytic 
activity as that purified from untreated cells (Göckler et al. 2009). Otherwise, harmine 
inhibits substrate phosphorylation potently (Fig. 18 and Fig. 19). It has therefore been 
postulated that harmine differentially affects tyrosine autophosphorylation by the 
translational intermediate of DYRK1A and substrate phosphorylation by the mature 
DYRK1A.  
The autophosphorylation at Ser748 is inhibited by harmine in cells (Fig. 24A, B 
and Fig. 25A, B). Strikingly, harmine was not capable to inhibit autophosphorylation 
of Ser748 in vitro (Fig. 25B), at least not at a detectable level. In vitro, DYRK1A        
is able to autophosphorylate Ser748 even in the presence of high concentrations of 
harmine (Fig. 25B). In living cells harmine inhibits Ser748 autophosphorylation almost 
completely, which could be explained by the presence of cellular phosphatases. 
Ser748 autophosphorylation could reflect a balance between autophosphorylation 
and dephosphorylation in living cells (Fig. 40). Harmine inhibits the 
autophosphorylation and thereby would shift this balance. Even if DYRK1A 
autophosphorylation occurs in the presence of harmine at low levels, the strong 
dephosphorylation by phosphatases predominates (Fig. 40) and therefore 
phosphorylated Ser748 is not detectable. In vitro, phosphatases are missing and   
the balance is not given. Even low levels of rephosphorylation on Ser748 would lead 
to a measurable signal.  
 
 
Figure 40: Autophosphorylation balance of DYRK1A.  
Schematic presentation of reversible serine autophosphorylation of DYRK1A. In untreated 
cells there is a balance between autophosphorylation and dephosphorylation by 
phosphatases. Treatment with harmine inhibits autophosphorylation and thereby shifts the 
balance to unphosphorylated Ser748. 
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Taken together, the finding that harmine inhibits autophosphorylation at 
Ser529 in HEK293 cells (Alvarez et al. 2007) and at Ser748 in HeLa, PC12 and 
HEK_GFP-DYRK1A cells (this study) lead to the hypothesis that harmine inhibits 
both substrate phosphorylation and serine autophosphorylation of mature DYRK1A, 
but not tyrosine autophosphorylation of the translational intermediate.  
 
5.2.3 Inter- and intramolecular autophosphorylation of DYRK1A 
In general, phosphorylation in cis (intramolecular) occurs if phosphorylation of           
a protein kinase by itself can be validated, and the active kinase is not capable to 
phosphorylate its kinase inactive version. Phosphorylation in trans (intermolecular, 
phosphorylation of one protein kinase molecule by another one) takes place when 
the kinase inactive mutant is phosphorylated by its wild-type active version.  
The third Ser/Thr autophosphorylation site for DYRKs which is characterized 
in this study, Ser748 of mammalian DYRK1A, shows both features of 
autophosphorylation (Fig. 23A, B and Fig. 27B). The kinase active DYRK1A version 
is phosphorylated on Ser748 and the kinase inactive is not when expressed in E. coli. 
Ser748 phosphorylation is an autophosphorylation event and kinase activity is 
essential. The kinase inactive DYRK1A expressed in living cells does not show any 
Ser748 phosphorylation, therefore no upstream kinase is capable to phosphorylate 
Ser748. Co-expression of both (the active and the inactive version) in living cells 
leads to Ser748 phosphorylation of the kinase inactive version by the active version 
of DYRK1A (Fig. 27B) and thus phosphorylation of Ser748 in trans is validated.  
Further methods to distinguish cis and trans are either a) using a peptide, 
which contains the Ser/Thr or Tyr residue of interest, or a truncated domain of the 
protein containing the Ser/Thr or Tyr residue of interest, as an exogenous substrate 
(trans) in an IVK assay or immunoblotting with the phospho-specific antibody at the 
corresponding residue, respectively or b) measuring if the rate of phosphorylation 
increases as the concentration of protein kinase molecules increases (titration),   
what would provide evidence for trans and not cis phosphorylation. 
Up to date two Ser/Thr autophosphorylation sites for DYRKs are known, 
Thr335 of yeast Yak1 and Ser529 of mammalian DYRK1A. Both 
autophosphorylations occur via an intramolecular phosphorylation event as the 
kinase inactive mutants of Yak1 or DYRK1A cannot be phosphorylated by their   
equivalent wild-type kinases (Lee et al. 2011; Alvarez et al. 2007). In principle, Yak1 
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is able to recognize this residue as a substrate phosphorylation site and to 
phosphorylate Thr335 in trans, when the truncated N-terminal domain of Yak1, 
containing Thr335, serves as exogenous substrate (Lee et al. 2011). It seems that 
Thr335 is only accessible for phosphorylation in cis in full-length Yak1, probably due 
to its conformation. It has not been tested, if mammalian DYRK1A is able to 
phosphorylate a peptide or the truncated C-terminal domain containing Ser529.       
In contrast to Ser748 which sequence matches perfectly the consensus target 
sequence (RX1-2p(S/T)P) for DYRK1A substrates, Ser 529 does not contain a proline 
at P+1 (Fig. 27A).   
Summarizing, the three Ser/Thr autophosphorylation sites for DYRK identified 
so far show different mechanisms of autophosphorylation. The two 
autophosphorylation sites published to date are intramolecular events and this study 
reports an autophosphorylation that can occur by an intermolecular mechanism. 
 
5.2.4 Ser748 phosphorylation of DYRK1A may modulate its activity 
Tyrosine autophosphorylation of the YXY-motif is essential for kinase activity of 
DYRKs (Himpel et al. 2001). Once expressed DYRK1A is a constitutively active 
kinase. 
The autophosphorylation of DYRK1A on Ser748 seems to be involved in 
increasing of DYRK1A kinase activity. Substitution of Ser748 with alanine (S748A) 
showed a reduction in kinase activity. GFP-DYRK1A S748A maintained only ~60% of 
the activity of wild-type GFP-DYRK1A (Fig. 28A). As the GFP-DYRK1A ∆C19 mutant 
showed an increase of activity similar to the phosphorylation-mimetic mutants, GFP-
DYRK1A S748E/S758E (EE) and S748E/S758A (EA) (Fig. 28A and B), 
autophosphorylation on Ser748 seems not to be directly involved, but rather 
suggests that an inhibitory protein is implicated. As the IVK assays have been 
performed with GFP-DYRK1A immunoprecipitated from cells, it is possible that 
regulatory proteins have been co-immunoprecipitated and were present in the 
reaction. One possible mechanism (Fig. 41) would be that DYRK1A binds to an 
inhibitory protein, when Ser748 is unphosphorylated and thus kinase activity of 
DYRK1A is reduced. Phosphorylation on Ser748 would disrupt this binding and 
increase the kinase activity. Binding of the inhibitory protein could be mediated by the 
last 19 amino acids, because they seem to be essential as their deletion leads to an 
increase of kinase activity.  
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Figure 41: Model for regulation of DYRK1A kinase activity via Ser748 
phosphorylation.  
A. Substitution of Ser748 by Ala and thereby prevention of autophosphorylation on Ser748 
leads to a reduced activity of DYRK1A (Fig. 28A) by binding of an yet unidentified 
inhibitory protein (Inh). B. Deletion of the 19 C-terminal amino acids leads to an increase 
of DYRK1A activity (Fig. 28A). C. Autophosphorylation on Ser748 of wild-type 
DYRK1A would disrupt the binding of an inhibitory protein (Inh) and enhance DYRK1A 
kinase activity. Dephosphorylation by phosphatases would keep a balance. A putative 
enhanced phosphorylation on Ser748 induced by an unknown mechanism or a putative 
downregulation of the specific phosphatases would regulate DYRK1A kinase activity. 
 
 
 
Another possible explanation could be that no inhibitory protein is involved,  
but that the last 19 amino acids directly interact with a yet unknown binding site within 
DYRK1A itself and thereby alter its conformation or prevent the access to the ATP-
binding pocket or the catalytic center, as Ser748 is also phosphorylated in trans.  
The known autophosphorylation site of DYRK1A, Ser529, is involved in the 
regulation of kinase activity. The DYRK1A S529A mutant maintained only ~50% of 
wild-type DYRK1A activity when immunoprecipitated from living cells and subjected 
to IVK assay with DYRKtide peptide as substrate (Alvarez et al. 2007).  
Autophosphorylation on Ser529 of DYRK1A seems not to be directly affecting kinase 
activity, but rather regulates the binding of 14-3-3 to this autophosphorylated Ser529 
residue. Binding of 14-3-3 increases DYRK1A kinase activity (Alvarez et al. 2007). 
Thus, autophosphorylation on Ser/Thr residues and thereby modulation of kinase 
activity could be a general mechanism for DYRKs. A recent study showed that yeast 
Yak1 autophosphorylates on at least four Ser/Thr residues resulting in full kinase 
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activity (Lee et al. 2011). Further, Bmh1, a yeast 14-3-3 protein, binds to 
autophosphorylated sites of Yak1 (with Thr335 as primary binding site) and inhibits 
its kinase activity. Therefore 14-3-3 is a good example that protein interaction 
facilitated by autophosphorylation on Ser/Thr residues, can trigger opposite 
(increasing or inhibiting) effects on kinase activity of DYRK family members, even if 
the interaction is taking place with same protein (Alvarez et al. 2007; Lee et al. 2011). 
As a conclusion, the results suggest that Ser748 phosphorylation leads to     
an increase of DYRK1A activity. This is probably mediated by the interaction with      
a regulatory protein as this feature is already reported for other Ser/Thr 
autophosphorylation sites of DYRK kinases. As mutation of both Ser529 or Ser748 
leads to an ~50-60% reduction of catalytic activity of DYRK1A, targeting one of those 
or both sites could trigger important effects, as DYRK1A heterozygous mice exhibit 
clear phenotopic alterations (Fotaki et al. 2002).  
 
5.2.5 Ser748 phosphorylation of DYRK1A during mitosis 
A two-fold increase in Ser748 phosphorylation of DYRK1A has been reported in 
mitotic cells (Daub et al. 2008). 
In this study, the same cell line (HeLa cells) and the same synchronization 
protocols has been used. As Ser748 phosphorylation is present in both S phase and 
in M phase at least on a basal level (Fig. 33D and Fig. 36A), slight changes in 
phosphorylation levels can be difficult to distinguish. Ser748 phosphorylation during 
the release from S phase arrest did not reveal any differences in phosphorylation 
levels of GFP-DYRK1A in HeLa cells or PC12_GFP-DYRK1A cells. The 
synchronization was controlled by detecting changes in histone H3 phosphorylation 
levels (Fig. 36A and B) and by FACS analysis (Fig. 32A and B). A reason why slight 
changes cannot be detectable could be the resolution of GFP-DYRK1A on a SDS 
gel. In this study conventional one-dimensional gel electrophoresis has been used. 
Partially purified GFP-DYRK1A showed three different migrating bands which differed 
in their Ser748 phosphorylation level (Fig. 30B). Therefore, it is possible that 
alteration of the phosphorylation status of each band cannot be detected and two-
dimensional gel electrophoresis would be an option to make slight changes in 
phosphorylation levels between different GFP-DYRK1A variants detectable.  
Another reason why an upregulation of Ser748 phosphorylation during mitosis 
was not observed could be the different behaviour of endogenous and GFP-tagged 
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DYRK1A (see Discussion 5.2.1). The hypothesis that Ser748 phosphorylation of 
DYRK1A is regulated like in the model suggested in Fig. 41 could explain why 
overexpressed GFP-DYRK1A shows a stronger detectable phosphorylation 
compared to endogenous one. Either a) the amount of phosphatases 
dephosphorylating Ser748 of DYRK1A could be limited or b) the nuclear localization 
of GFP-DYRK1A prevents dephosphorylation by cytosolic phosphatases. 
Nevertheless, as in mitosis the nuclear membrane disappears and GFP-DYRK1A 
would be available to dephosphorylation by cytosolic phosphatases another 
hypothesis could be that phosphatases dephosphorylating Ser748 are slightly 
downregulated in mitosis. Thereby the two-fold upregulation of Ser748 
phosphorylation found by Daub et al. (2008) could be explained for endogenous 
DYRK1A which was probably located in the cytosol.  
 Finally, the mass spectrometry analysis from Daub et al. (2008) reports two  
M phase-induced phosphorylation sites for DYRK1A, Ser748 and Ser758. This serine 
also has a proline at P+1 position but not an arginine at P-3 and thus does not match 
as perfect as Ser748 the consensus target sequence for DYRK1A substrates. 
Therefore it is possible that Ser758 could be also an autophosphorylation site of 
DYRK1A and could be the one which shows a stronger regulation of phosphorylation 
level during mitosis. The Phosida database (http://www.phosida.com) assigns both 
Ser748 and Ser758 the same p-value score. However, the IVK assays using          
the GFP-DYRK1A S748E/S758A (EA) mutant suggests that phosphorylation of 
Ser748 could be the functional one. 
In summary, using a phospho-specific antibody against Ser748 did not reveal 
any modulation in phosphorylation of this residue in the stages of the cell cycle. 
  
5.2.6 Degradation of DYRK1A during mitotic exit 
Downregulation of DYRK1A activity cannot only be regulated by inhibiting kinase 
activity, but also by degradation of the protein. 
This is the first study showing that DYRK1A is degraded during mitotic exit. 
The simultaneous disappearance of endogenous DYRK1A and exogenous GFP- 
DYRK1A during mitotic exit (Fig. 33B and D) indicates that downregulation of 
DYRK1A is regulated on protein level and thus occurs via degradation, because    
the two proteins are expressed under the control of different promoters.                
This event is a) not cell type dependent as it has been observed in HeLa and 
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PC12_GFP-DYRK1A cells and b) not dependent on the synchronization methods    
as it occurs when cells were released from both S phase and M phase (Fig. 33B, D 
and Fig. 34).  
Treatment with the specific and potent proteasome inhibitor, MG132, prevents 
the degradation of DYRK1A (Fig. 35A) suggesting that the 26S proteasome system 
may mediate this degradation. Using MG132 is a common method to validate 
whether the 26S proteasome is involved in degradation during mitotic exit (e.g. Tang 
et al. 2009). The reappearance of DYRK1A after entry of G1 phase correlates with 
the anaphase promoting complex/cyclosome (APC/C) inactivation and thus suggests 
that DYRK1A is targeted by the APC/C. The APC/C is an E3 ubiquitin ligase,     
which is active during mitosis and in the G1 phase. The APC/C targets cell cycle 
proteins for degradation by the 26S proteasome by tagging them with ubiquitin 
(reviewed in Peters, 2006). Two known recognition amino acid sequences for APC/C 
recognition are the destruction-box (D-box; consensus RXXLXXXN) and the KEN-
Box (consensus KEN). Both are not present in DYRK1A. Thus, it might be also 
possible that MG132 is preventing the proteasomal degradation of a protein that 
protects DYRK1A against degradation. 
In contrast, the degradation pattern of overexpressed GFP-DYRK1A during 
mitotic exit might also suggest a caspase-mediated cleavage event (Fig. 36A, B 
and Fig. 37A). The finding that an antibody detecting the N-terminal part of GFP-
DYRK1A (anti-GFP) is recognizing different fragments and another antibody 
detecting the C-terminal part (anti-DYRK1A) strongly indicates that the degradation 
occurs in the C-terminal region domain. Sequence analysis of the C-terminal domain 
of DYRK1A did not reveal any known cleavage sites for caspases. It should be 
considered that cleavage by caspases does not necessarily lead to degradation of    
a protein in general, but can also give rise to a truncated variant which exhibits 
different properties than the full-length protein, such as higher or lower kinase 
activity. The finding that β-Actin is also degraded in this experiments (Fig. 36A-D 
and Fig. 37A-D) suggests that in this experiment a caspase-mediated pathway could 
have been induced. 
Taken together, the two different degradation patterns of a) endogenous 
DYRK1A and low level GFP-DYRK1A and b) overexpressed GFP-DYRK1A obtained 
during mitotic exit should be analyzed separately. Endogenous and lowly 
overexpressed GFP-DYRK1A degradation during mitotic exit might be regulated by 
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ubiquitinylation and subsequent proteasomal destruction and highly overexpressed 
DYRK1A may cause activation of and cleavage by caspases.  
 
5.2.7 The effect of overexpressed DYRK1A on cell cycle proteins  
 
5.2.7.1 The retinoblastoma protein (RB) 
As expected, dephosphorylation of RB occurs at mitotic exit (Fig. 35A, without 
MG132) (see Introduction 1.3.1.1) and phosphorylation returns about 3 h after 
nocodazole release. Degradation of DYRK1A correlates with dephosphorylation of 
RB in HeLa and PC12_GFP-DYRK1A cells (Fig. 32D, Fig. 33 and Fig. 34). It has not 
been analyzed if DYRK1A is able to phosphorylate RB directly on these residues 
which are followed by a proline. It is more likely that DYRK1A interferes indirectly  
with RB phosphorylation, as overexpression of DYRK1A altered Cyclin B protein level 
(Branchi et al. 2004) (see Introduction 1.3.2). High levels of Cyclin B in transgenic 
mice overexpressing DYRK1A suggest that DYRK1A might stabilize this protein.   
The degradation of DYRK1A observed in this work, may cause destabilization of 
Cyclin B and thereby could explain the dephosphorylation of RB, whose 
hyperphosphorylated state is maintained by Cyclin B during mitosis (see Introduction 
1.3.1.1). Vice versa, overexpression of active DYRK1A prevented dephosphorylation 
of RB at mitotic exit (Fig. 36A and Fig. 38B). This could be due to stabilization of 
Cyclin B by DYRK1A which then maintains RB phosphorylation. The kinase inactive 
version of DYRK1A did not interfere with RB phosphorylation and showed similar RB 
phosphorylation like in cells transiently transfected with unfused GFP 
(Fig. 36B and Fig. 37B). Human Cyclin B contains three serine and one threonine 
residues followed by a proline, but all lack an arginine at P-2 or P-3 position. 
Nevertheless, Cyclin L2 is reported to be a substrate of DYRK1A and three serine 
residues have been found to be phosphorylated by DYRK1A in vitro, all followed by a 
proline but without an arginine at P-2 or P-3 position (de Graaf et al. 2004).  
RB is dephosphorylated by phosphoprotein phosphatase 1 (PP1) during 
mitotic exit (see Introduction 1.3.1.1). The results of this study cannot exclude       
that the effect of DYRK1A on RB phosphorylation is caused by interference between 
DYRK1A and PP1.  
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Summing up, the effect of altering DYRK1A protein level on RB 
phosphorylation at Ser807/811 suggests that DYRK1A might play a role in the cell 
cycle specific phosphorylation of RB.   
  
5.2.7.2 Protein level of Cyclin D1 
The degradation of Cyclin D1 is regulated by phosphorylation (see Introduction 
1.3.1.2). It has been found that DYRK1B phosphorylates Cyclin D1 at Thr288 and 
thereby causes its degradation (Zou et al. 2004). In a recent publication was shown 
that overexpression of DYRK1A can also induce Cyclin D1 degradation (Yabut et al. 
2010) (Table 1).  
When cells were released from thymidine block, overexpression of DYRK1A  
in HeLa cells failed to cause a detectable effect on Cyclin D1 protein levels compared 
to cells overexpressing unfused GFP (Fig. 36B, Fig. 37D, Fig. 39A-E). Therefore this 
effect of DYRK1A on Cyclin D1 may occur in a cell type dependent manner. The 
constant protein levels of Cyclin D1 exclude the possibility that all proteins 
unspecifically undergo degradation 10 h after thymidine release under the used 
experimental conditions (Fig. 36B, D and Fig. 37B, D).  
 
5.2.7.3 Phosphorylation level of histone H3 
Dephosphorylation of histone H3 on Ser10 correlates with mitotic exit (see 
Introduction 1.3.1.3), similar to dephosphorylation of RB at Ser807/811. 
Overexpression of DYRK1A seems to influence both dephosphorylation levels, but 
the effect on histone H3 Ser10 phosphorylation is not as impressive as for RB 
(Fig. 38B-F and Fig. 39A-E). Considering the hypothesis that overexpression of 
DYRK1A stabilizes Cyclin B and thus dephosphorylation of RB is prevented, 
overexpressed DYRK1A would cause an altered mitotic exit. A delayed histone H3 
dephosphorylation can be observed when active GFP-DYRK1A is overexpressed 
(Fig. 36B and D). Anyway, in the second experiment the effect of full-length DYRK1A 
and its deletion mutants was not consistent regarding the correlation between RB 
and histone H3 phosphorylation (Fig. 38B-F and Fig. 39A-E).  
Nevertheless, an alteration on Ser10 dephosphorylation of histone H3 can be 
observed when active GFP-DYRK1A is overexpressed, thus further investigation has 
to be performed to elucidate if this alteration is caused directly by DYRK1A or is a 
side effect of cell cycle arrest.   
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6. Summary 
 
Members of the dual-specificity tyrosine(Y)-phosphorylation regulated kinase (DYRK) 
family play key roles in the regulation of cell differentiation, proliferation and survival 
with DYRK1A being the best characterized member due to its gene location within 
the Down syndrome critical region (DSCR) on chromosome 21 in humans. DYRK1A 
is a candidate target for drug development, as it is overexpressed in Down syndrome 
individuals. The roles of DYRK1A in cell differentiation and apoptosis have been 
extensively characterized, but recent reports have implicated DYRK1A also in cell 
cycle control. For example, an upregulation of DYRK1A Ser748 phosphorylation was 
observed in a screening of mitotic cells compared to asynchronous cells.  In contrast, 
investigation of DYRK4 has been neglected so far. This dissertation aims to address 
these open questions by providing a comprehensively molecular analysis of DYRK4 
and a characterization of DYRK1A during the cell cycle. 
This study revealed the subcellular localization, substrate specificity and tissue 
distribution of DYRK4. The here discovered long DYRK4 splice variant (human 
DYRK4644) showed a broader tissue distribution compared to the already described 
short isoform (human DYRK4520) and an induction of transcript levels in the human 
SH-SY5Y neuroblastoma cell line in response to endoplasmic reticulum stress. 
Moreover, the longer isoform contains a functional nuclear localization signal and 
displayed distinct nucleocytoplasmic mobility compared to the shorter isoform in live 
cell imaging experiments. A fusion protein of green fluorescent protein (GFP) and the 
long isoform did not exit the nucleus, whereas GFP fluorescence in the nucleus 
significantly decreased in the case of the short isoform in fluorescence loss in 
photobleaching experiments. Furthermore, it was shown here that DYRK4 is 
phosphorylated by other kinases independently of its kinase activity and can 
phosphorylate a known substrate of DYRK1A in living cells. Finally, it was confirmed 
that the substrate specificity of DYRK4 differed from that of DYRK1A and a peptide 
was identified which is specifically recognized by DYRK4. 
To elucidate the phosphorylation state of DYRK1A it was shown that DYRK1A 
autophosphorylation in living cells is inducible by a phosphatase inhibitor and that 
DYRK1A autophosphorylates in vitro. A phospho-specific antibody was generated to 
study the phosphorylation of DYRK1A at Ser748. Using a kinase inactive mutant of 
DYRK1A, Ser748 phosphorylation was found to be an autophosphorylation event 
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that can occur in trans (intermolecular event). Furthermore, mimicking Ser748 
phosphorylation by substitution of the serine with a glutamic acid residue enhanced 
DYRK1A activity towards a substrate peptide. However, no modulation of Ser748 
phosphorylation levels during the phases of cell cycle was detectable. 
In these cell cycle experiments, a degradation of endogenous DYRK1A and 
GFP-DYRK1A during mitotic exit was observed in two different cell lines (rat neuronal 
PC12 and human cervix carcinoma HeLa) and using two different synchronization 
methods. This degradation was inhibited in the presence of the proteasome inhibitor, 
MG132, suggesting a role of the anaphase-promoting complex or cyclosome 
(APC/C) that mediates proteasomal destruction of proteins during mitotic exit. 
Degradation of GFP-DYRK1A was also found in overexpression experiments 
independently of the kinase activity of DYRK1A. Furthermore, overexpression of wild-
type GFP-DYRK1A interfered with dephosphorylation of the retinoblastoma protein 
during mitotic exit whereas the kinase inactive mutant or a mutant lacking the C-
terminus of DYRK1A did not show this effect.  
In summary, this study 1) provides a characterization of the newly discovered 
long splice variant of DYRK4 as well as differences in substrate specificity of DYRK4 
towards DYRK1A and 2) characterizes the role of DYRK1A during the cell cycle and 
the autophosphorylation on Ser748. 
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7. Zusammenfassung 
 
Mitglieder der dual-specificity tyrosine(Y)-phosphorylation regulated kinase (DYRK) 
Familie haben Schlüsselfunktionen bei der Regulation von Differenzierung, 
Proliferation und des programmierten Zelltods. DYRK1A ist auf Grund seiner 
Genlokalisation innerhalb der Down syndrome critical region auf Chromosom 21 
beim Menschen die am Besten charakterisierte Proteinkinase dieser Familie. Da 
DYRK1A bei Down-Syndrom überexprimiert ist, stellt es ein mögliches Ziel für eine 
pharmakologische Therapie dar. Die Rolle von DYRK1A in Zelldifferenzierung und in 
der Apoptose wurde umfangreich charakterisiert, wohingegen neueste Publikationen 
zusätzlich einen Einfluss von DYRK1A auf den Zellzyklus implizieren. Kürzlich wurde 
zum Beispiel in einem Screening eine Hochregulation der Phosphorylierung von 
DYRK1A an Ser748 in mitotischen Zellen gefunden. Im Gegensatz zu DYRK1A 
wurde DYRK4 bisher kaum erforscht. Die vorliegende Dissertation geht diesen 
offenen Fragestellungen durch eine umfassende molekulare Analyse von DYRK4 
und der Charakterisierung von DYRK1A im Zellzyklus nach. 
In dieser Arbeit wurden die subzelluläre Lokalisation, die Substratspezifität 
und die Gewebsverteilung von DYRK4 aufgeklärt. Die hier entdeckte lange DYRK4 
Spleißvariante (human DYRK4644) zeigte verglichen mit der schon beschriebenen 
kurzen Variante (human DYRK4520) eine breitere Gewebsverteilung sowie eine 
Induktion als Stressantwort des endoplasmatische Reticulum in der menschlichen 
SH-SY5Y Neuroblastomazelllinie. Des Weiteren besitzt die lange Isoform ein 
funktionelles nukleäres Lokalisationssignal und verfügte in Lebendzell-Experimenten 
über eine unterschiedliche nukleozytoplasmatische Mobilität im Vergleich zur kurzen 
Isoform. In fluorescence-loss-in-photobleaching-Versuchen verblieb ein Fusions-
protein aus dem grün-fluoreszierenden Protein (GFP) und der langen Isoform im 
Zellkern, wohingegen im Falle der kurzen Isoform die GFP-Fluoreszenz im Zellkern 
signifikant sank. Außerdem wurde hier gezeigt, dass DYRK4 durch andere Kinasen 
unabhängig von seiner Kinaseaktivität phosphoryliert wurde und dass DYRK4 ein für 
DYRK1A bekanntes Substrat in Lebendzellen phosphorylieren konnte. Schließlich 
wurde bestätigt, dass die Substratspezifität von DYRK4 und DYRK1A unterschiedlich 
ist und ein Peptid identifiziert, welches spezifisch von DYRK4 erkannt wird. 
Durch die Behandlung mit einem Phosphataseinhibitor wurde belegt, dass die 
Autophosphorylierung von DYRK1A in HeLa-Zellen induzierbar ist und dass 
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DYRK1A sich auch in vitro autophosphorylierte. Um die Phosphorylierung von 
DYRK1A an Ser748 zu untersuchen, wurde ein phospho-spezifischer Antikörper 
gegen das Ser748 generiert. Mittels der kinase-inaktiven Mutanten von DYRK1A 
wurde gezeigt, dass an Ser748 eine Autophosphorylierung in trans (intermolekular) 
erfolgt. Die Imitation der Phosphorylierung an Ser748 durch Austausch des 
Serinrestes mit Glutaminsäure erhöhte die Aktivität von DYRK1A gegenüber einem 
Peptidsubstrat. Jedoch wurden keine Veränderungen des Ser748-
Phosphorylierungslevels während der Phasen des Zellzyklus detektiert.  
In den Zellzyklusversuchen wurde der Abbau von endogenem DYRK1A und 
GFP-DYRK1A  während des Austritts aus der Mitose in zwei verschiedenen Zelllinien 
(neuronale PC12-Zellen aus der Ratte und menschliche Zervixkarzinom HeLa-
Zellen) und mittels zwei unterschiedlicher Synchronisationsmethoden beobachtet. 
Dieser Abbau wurde bei Behandlung mit dem Proteasominhibitor MG132 inhibiert, 
was eine Rolle des Anaphase fördernden Komplexes (engl. Anaphase promoting 
complex/Cyclosome; APC/C) vermuten lässt, welcher den proteasomalen Abbau von 
Proteinen während des Austritts aus der Mitose vermittelt. Ein Abbau von GFP-
DYRK1A wurde auch in Überexpressions-versuchen gefunden, welcher unabhängig 
von der Kinaseaktivität von DYRK1A auftrat. Zusätzlich beeinträchtigte die 
Überexpression von Wildtyp GFP-DYRK1A die Dephosphorylierung des 
Retinoblastom-Proteins, eines Zellzyklus-Regulators, während des Austritts aus der 
Mitose, wobei die kinase-inaktive Mutante oder die C-terminale Deletionsmutante 
von DYRK1A diesen Effekt nicht aufwiesen. 
Zusammenfassend erfolgte in dieser Studie 1) eine Charakterisierung der neu 
entdeckten langen Spleißvariante von DYRK4 und zugleich eine Beschreibung der 
Unterschiede in der Substratspezifität von DYRK4 und DYRK1A sowie 2) eine 
Untersuchung der Rolle von DYRK1A während des Zellzyklus und die 
Autophosphorylierung an Ser748. 
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